Tolerance of normal brain tissue to boron neutron capture irradiation. by Philipp, K.H.I.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/58652
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
  
 
 
 
TOLERANCE 
OF NORMAL BRAIN TISSUE 
TO 
BORON NEUTRON CAPTURE 
IRRADIATION 
 
  
 
 
TOLERANCE OF NORMAL BRAIN TISSUE 
TO BORON NEUTRON CAPTURE 
IRRADIATION 
 
 
een wetenschappelijke proeve op het gebied van de 
Medische Wetenschappen 
 
 
 
 
Proefschrift 
 
 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen  
op gezag van de Rector Magnificus Prof. Dr. C. W. P. M. Blom 
volgens het besluit van het College van Decanen 
in het openbaar te verdedigen op maandag 14 juni 2004 
des namiddags om 1.30 uur precies 
 
 
door 
 
 
 
Katharina Hedwig Irmgard Philipp 
 
 
geboren op 1 maart 1965 
te Bonn 
 
 
 
 
Nuclear Research and Consultancy Group (NRG), Petten 2004 
 Promotor:  Prof. dr. A. J. van der Kogel 
Copromotor:  Dr. R. Huiskamp, NRG Radiation & Environment, Petten 
Manuscriptcommissie: Prof. dr. J. W. Leer 
Prof. dr. J. W. Hopewell, 
University of Oxford, United Kingdom  
Prof. dr. P. R. Gavin, 
Washington State University, USA 
Prof. dr. J. R. Fike, 
University of California San Francisco, USA 
Dr. B.J. Mijnheer, 
Netherlands Cancer Institute, Amsterdam 
 
 
 
 
 
 
 
 
 
The investigations presented in this thesis were performed at the Institute of Advanced 
Material Science of the Joint Research Center and the Department of Radiation & 
Environment of the Nuclear Research and Consultancy Group (NRG), Petten, The 
Netherlands. 
 
The study was financially supported by a grant (No.: S/MR4*-900322) of the European 
Commission, the Netherlands Energy Research Foundation ECN and the Nuclear Research 
and Consultancy Group (NRG). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Meinen Eltern 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tolerance of normal brain tissue to boron neutron capture irradiation. 
K.H.I. Philipp 
Thesis Katholieke Universiteit Nijmegen 
ISBN 90-9018104-0 
  
CONTENTS 
 
Chapter 1 General introduction        11 
  1.1 Ionizing radiation       12
   1.1.1 Directly and indirectly ionizing radiation   12 
1.1.2 Neutrons and their capture reactions    13 
1.1.3 Radiation damage      16 
1.1.4 Linear energy transfer (LET)     18 
1.1.5 Relative biological effectiveness (RBE)   18 
1.1.6 Dose rate       19 
1.2 The central nervous system      20 
1.2.1 Anatomic outline      20 
 1.2.1.1 Genesis      20 
 1.2.1.2 Cells of the nervous system    21 
 1.2.1.3 Functional divisions of the brain   23 
1.2.2 Radiation effects on CNS     24 
1.2.3 Brain tumors       30 
1.3 Boron neutron capture therapy     32 
1.3.1 Principle       32 
1.3.2 History and first clinical trials    35 
1.3.3 Capture agents and compounds    38 
1.3.4 Neutron sources      44 
 1.3.4.1 Irradiation facilities     45 
 1.3.4.2 Neutron beam characteristics    47 
 1.3.4.3 Computer Modeling     48 
1.4 References        51 
 
Chapter 2 Scope of the present study       63 
 
Chapter 3 Healthy tissue tolerance studies in normal beagle dogs using the Petten 
 epithermal neutron beam HB11 and borocaptate sodium as capture agent 69 
  3.1 Introduction        70 
  3.2 Materials and methods      71 
  3.2.1 Animals       71 
  3.2.2 Boron compound      71 
  3.2.3 Boron analysis      72 
  3.2.4 Irradiation       74 
  3.2.5 Neutron monitoring      75 
3.2.6 Gamma-ray monitoring     77 
  3.2.7 Beam monitoring      77 
  3.2.8 Monte Carlo calculations     78 
  3.2.9 Anesthesia       78 
  3.2.10 Recording skin reaction     78 
  3.2.11 Blood parameters      79 
  3.2.12 Recording brain response     80 
  3.2.13 Data processing      83
 3.3 Results        83 
  3.3.1 General observations      83 
  3.3.2 Boron        83 
   3.3.3 Neutron activation foils     85 
  3.3.4 Gamma-ray measurements     86 
  3.3.5 Skin reaction       86 
  3.3.6 Blood changes      87 
  3.3.7 Brain response      88 
  3.4 Discussion        93 
  3.5 Referenes        104 
 
Chapter 4 Dose fractionation effects in normal brain tissue with boron neutron  
capture irradiation using borocaptate sodium    109 
  4.1 Introduction        110 
  4.2 Materials and methods      112 
  4.3 Results        114 
  4.4 Discussion        115 
  4.5 References        120 
 
Chapter 5 RBE values and compound factors with BNCT using an epithermal  
neutron beam and borocaptate sodium deducted from skin effects in  
dogs          123 
  5.1 Introduction        124 
  5.2 Materials and methods      125 
  5.3 Results        126 
  5.3.1 BMRR irradiated animals     126 
  5.3.2 Fast neutron RBE (BMRR)     127 
  5.3.3 HFR irradiated animals     127 
  5.3.4 Compound factors and equivalent doses (HFR)  128 
  5.4 Discussion        131 
5.4.1 Fast neutron RBE in skin      131 
5.4.2 BSH compound factor in dog skin     131 
5.4.3 Fast neutron RBE in brain      131 
5.4.4 BSH compound factor in brain     134 
5.4.5 Equivalent Doses       136 
  5.5 References        137 
Chapter 6 The compound factor of the 10B(n,α)7Li reaction from borocaptate  
sodium and the relative biological effectiveness of recoil protons for  
induction of brain damage in boron neutron capture therapy  141 
  6.1 Introduction        143 
  6.2 Materials and methods      144 
6.2.1 The Healthy Tissue Tolerance Study    144 
6.2.2 Dose Rates and Dose Point      145 
6.2.3 Analysis of Data       148 
6.2.4 Statistical Analysis of Data      150 
  6.3 Results        151 
6.3.1 RBE for Recoil Protons from Fast Neutrons and the  
14n(N,P)14c Reaction       151 
6.3.2 Compound Factor for BSH      152 
6.3.3 Dose-Response Curves      153 
  6.4 Discussion        154 
  6.5 References        159 
 
  
Chapter 7 Canine brain tolerance of boron neutron capture irradiation  
using sodium borocaptate (BSH)      163 
  7.1 Introduction        164 
  7.2 Material and methods       165 
7.2.1 Beam only irradiation BMRR     166 
7.2.2 Brain tolerance study at the HFR Petten    166 
7.2.3 Biological endpoints       166 
7.2.4 Dose description       167 
7.2.5 Dose deposition in tissue      167 
7.2.6 RBE of beam components      168 
7.2.7 Boron dose Petten dogs      169 
  7.3 Results        171 
  7.4 Discussion        174 
  7.5 Acknowledgements       179 
7.6 References        181
 
Chapter 8 General discussion        187 
 8.1 Healthy tissue tolerance studies     188 
  8.2 Fractionation with BNCT      194 
  8.3 Dose description       196
 8.4 Clinical status of BNCT and future prospects   204 
  8.5 References        208 
 
Annex A           213 
Annex B           221 
Annex C           225 
Summary           229 
Samenvatting           233 
Zusammenfassung          237 
Nachwort           241 
Curriculum Vitae          245 
 
General introduction  11 
 
 
 
CHAPTER 1 
 
 
GENERAL INTRODUCTION 
 
12  Chapter 1 
The aim of this study is to estimate the tolerance of normal brain tissue to boron neutron 
capture irradiation as a prerequisite for boron neutron capture therapy (BNCT) in brain 
tumor patients. In the first part of this chapter the characteristics of ionizing radiation in 
general and of neutrons and their capture reactions in particular are described. The second 
part deals with the central nervous system (CNS) and gives a summary of the effects of 
radiation on nervous tissue. In the last part of the general introduction a brief outline of 
principles and a historical overview of boron neutron capture therapy (BNCT) will be 
given. 
1.1 IONIZING RADIATION 
The word radiation is most often used in the context of ionizing radiation. Ionizing 
radiation is energy that is propagated through space or material in the form of waves or 
particles. It has enough energy to directly or indirectly remove an electron from an atom 
creating ions, hence, the term ionizing radiation. The result of ionization is the production 
of negatively charged free electrons and positively charged ionized atoms. There are four 
types of ionizing radiation involved that can be classified in two groups: a) photons, such 
as gamma- and X-rays, and b) particles, such as beta particles (positrons or electrons), 
alpha particles (helium nuclei with 2 protons and 2 neutrons), and neutrons. Photons are 
electromagnetic radiation having energy but no mass or charge, whereas particles have 
typically both mass and charge as well as energy. Neutrons have mass and energy, but no 
charge. All types of ionizing radiation can remove electrons, but interact with matter in 
different ways. Particles are more highly ionizing; excitation and ionization are the primary 
interaction with matter, and potential for ionization increases as mass and charge increase. 
The range in tissue (depth to which the radiation may penetrate) for particles is energy 
dependent, but decreases as mass and charge increase, and increases with increasing 
energy of the respective particle. Photons, because they have no mass or charge, are less 
ionizing but more penetrating in matter. 
1.1.1 Directly and indirectly ionizing radiation 
Directly ionizing radiation are charged particles with a certain kinetic energy like 
alpha- and beta-radiation, protons and deuterons. They produce ionizations along their 
track as a result of energy imparted to orbital electrons via electrical forces. The indirectly 
ionizing types of radiation (X-rays, gamma-rays and neutrons) are electrically neutral. 
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Their energy is transferred in a different way: gamma- as well as X-rays ionize tissue by 
ejection of directly ionizing electrons from the orbits of the atoms. There are different 
ways of interaction with an atomic electron or an atomic nucleus, such as: 1. Photoelectric 
effect: in this interaction the energy of the X- or gamma-rays is completely transferred to 
an atomic electron that is ejected from its atom. The X-ray or gamma-ray no longer exists 
after the collision. 2. Compton effect: the X-ray or gamma-ray loses only part of its energy 
in its interaction with an atomic electron. The electron is ejected from its atom. The X-ray 
or gamma-ray of reduced energy and the electron fly off in different directions. 3. Pair 
production: gamma-rays with an energy greater than about 1.2 MeV may interact with an 
atomic nucleus to form an electron-positron pair. The gamma-ray energy is completely 
converted into mass and kinetic energy of the electron and positron with only a very small 
amount going into the nucleus in order to conserve momentum. 
Neutrons transfer their energy through collisions, mainly with atomic nuclei. With the fast 
component of degraded fission neutrons (mean energy around 10.4 keV) as used in this 
study, this results in ejection of recoil protons that are directly ionizing. The ionizing 
density along the track of recoil protons is much higher than that of fast electrons.  
1.1.2 Neutrons and their capture reactions 
Neutrons, discovered in 1932 (Chadwick 1932), are uncharged nuclear particles 
having an atomic mass of 1 and a free decay half life of about 13 min. The most important 
property of neutrons in the context of radiation biology is that they interact with atomic 
nuclei and not with electrons. The efficiency of this interaction depends on the neutron 
energy and the target. Neutrons are particles which have nearly the same mass as hydrogen 
atoms. Neutrons interact with atomic nuclei via two basic processes: scattering and 
absorption. The elastic scattering is the most important process for slowing down neutrons 
in material. Fast neutrons transfer energy to light nuclei by elastic collisions. The elastic 
interaction of neutrons with atomic nuclei is most important at neutron energies below the 
threshold for nuclear reactions at a few MeV. The amount of energy that a neutron loses in 
a collision with an atomic nucleus will be large only if the atomic nucleus is relatively 
light. In biological materials 85-95% of the energy of fast neutrons is transferred to 
hydrogen nuclei, which are abundant in the body as a constituent of water, leading to recoil 
protons. The recoiling atomic nuclei (i.e. recoil protons) cause ionization that damages 
living tissue. With inelastic neutron scattering, the nucleus initially absorbs energy and is 
14  Chapter 1 
left in an excited state. Thus, the nucleus emerges from the collision with a different 
amount of energy than before the collision. The excited nucleus subsequently decays by 
emitting ionizing radiation in the form of gamma-rays. Once neutrons have been slowed 
down so that they have on the average no more energy than the atoms in the surrounding 
material, they are called thermal neutrons. Such neutrons behave much like a gas and their 
propagation through matter is analogous to diffusion. Neutrons below 1 eV, the so-called 
thermal neutrons, have almost no effect on biological matter. They will continue to collide 
with nuclei, but cannot impart energy to them. However, these neutrons have a high 
probability of being captured by the atomic nuclei of a variety of atoms with which they 
collide. Such nuclear events liberate large amounts of energy. The probability of neutrons 
being captured by a given nucleus is usually given by its cross section σth expressed in 
barn (1 barn = 10-24 cm2). Several different reactions have been observed as the 
consequence of neutron capture in different nuclei. The neutron capture cross section and 
the subsequent reaction is different for each nuclide. Thus, chemically almost 
indistinguishably similar nuclides of one element, i.e. 10B and 11B show vastly different 
capture behaviors. Emission of gamma-rays is the most frequently found reaction (i.e. in 
1H). Here the chemical nature of the element is not changed. In some cases, radioactive 
nuclei are formed (e.g. 23Na). In fissile nuclides, such as 235U and 241Pu, fission products 
are formed. Some nuclides will emit a proton (e.g. 14N), whereas some will emit α-
particles (10B, 6Li). Table 1.1 compiles the thermal cross section σth in barns and the 
capture reaction of a selection of elements, which are normal constituents of tissue or 
theoretically could be used as capture agent for NCT. 
 
Neutrons can be classified according to their kinetic energies. In the context of this work, 
neutrons with energies below 1 eV will be called thermal neutrons. Neutrons with energies 
between 1 eV and 10 keV are epithermal, and those neutrons with energies exceeding 
10 keV will be called fast neutrons. Fast neutron effects are due mainly to recoil nuclei 
from elastic collisions in biological material. They are being utilized in radiotherapeutic 
modalities. These neutrons are produced in accelerators by bombarding beryllium or 
tritium targets with deuterons. The deuterons are stripped of their protons, and the 
tritium in the target is slowly used up and converted to helium. The energy of the resulting 
relatively monoenergetic neutron beams varies from around 5 to 20 MeV. Some nuclides, 
in particular 252Cf, undergo spontaneous fission under emission of neutrons and γ−rays. 
Neutrons with a wide range of energies (around 1 MeV) are obtained from fission reactions 
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of 235U in nuclear reactors. Such neutrons have been used for therapy of tumors such as 
head and neck cancers (Wagner and Köster, 1989). Innovation in the physics of neutron 
beam filtration resulted in beams of intermediate energy epithermal neutrons (Fairchild and 
Bond, 1985). In tissue, epithermal neutrons have a greater penetration than thermal 
neutrons. They are slowed down by collisions mainly with hydrogen into the thermal 
energy range at depth. Epithermal neutron beams have been developed at the Brookhaven 
Medical Research Reactor (BMRR) (Fairchild et al. 1990), the Massachusetts Institute of 
Technology Reactor (MITR) (Choi et al. 1990), the High Flux Reactor (HFR) at Petten, The 
Netherlands (Moss 1990), and the Finnish research reactor (FiR 1) at the Technical Research 
Center of Finland in Helsinki (Auterinen et al. 1993). They make it possible to treat brain 
tumors with boron neutron capture therapy (BNCT) without surgical removal of the scalp and 
the skull, as was the case with thermal neutron beams (see chapter 1.3). 
 
Table 1. 1: Cross section for thermal neutrons σth of selected nuclides (Karlsruher Nuklidkarte 1998) Upper 
part: normal tissue constituents; lower part: elements that could be considered for neutron capture therapy. 
Nuclide Natural abundance % Cross section [barn] Reaction 
1H 99.985 0.332 n,γ 
6Li 7.5 940 n,α 
12C 98.9 0.0034 n,γ 
14N 99.64 1.81 n,p 
16O 
17O 
99.762 
0.038 
0.000178 
0.235 
n,γ 
n,α 
23Na 
24Mg 
31P 
100 
78.99 
100 
0.4 
0.052 
0.18 
n,γ 
n,γ 
n,γ 
32S 95.02 0.004 n,α 
35Cl 
39K 
40Ca 
56Fe 
75.77 
93.25 
96.941 
91.7 
43.6 
0.0043 
0.4 
2.63 
n,γ 
n,α 
n,γ 
n,γ 
10B 20 3837 n,α 
11B 80 0.0055 n,γ 
40Ar 99.6 0.66 n,γ 
113Cd 
135Xe 
12.3 
unstable isotope 
20000 
2650000 
n,γ 
n,γ 
157Gd 15.7 255000 n,γ 
197Au 
199Hg 
235U 
241Pu 
100 
17 
radioactive 
radioactive 
98.7 
2000 
583.54 
1009 
n,γ 
n,γ 
n,f 
n,f 
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1.1.3 Radiation damage 
Ionizing radiation is a very potent cytotoxic agent, which exerts its effects by 
depositing energy in biological material. The amount of energy transferred to tissue by 
irradiation is described by the term-absorbed dose. Dose is a macroscopic concept 
describing the total energy deposited in tissue, and tissue-doses are expressed in energy 
units per unit tissue mass. The international unit (SI unit) for absorbed dose is gray (Gy). 
1 Gy corresponds to 1 joule (J) of absorbed radiation energy per kilogram of tissue. The 
biological potency of ionizing radiation is related to its spatial concentration along tracks, 
rather than to its meager addition of energy to cells. For example, a total body dose of 10 
Gy, which leads to death of an individual, is energetically equivalent to a maximal increase 
in body temperature of 0.002 °C (Tempel 1982). The primary cause of biological damage 
from ionizing radiation is the production of ions in living tissue. Energy from radiation is 
transferred via two major ways: ionization and excitation. The interaction of all types of 
radiation will ultimately have the same effect.  Ionizing radiation deposits energy discrete 
in tissues and cells, which can lead to a break in a chemical bond and initiate a chain of 
effects that eventually culminates in a biological effect. Most ionizations are not 
deleterious to the cell because of the redundancy and normal rate of replacement of most 
molecules. For deoxyribonucleic acid (DNA), which is a single copy molecule, enzyme 
repair mechanisms are responsible for the maintenance of the structural and functional 
integrity of the molecule. The DNA molecule contains the genetic information a cell needs 
to propagate itself. It is the most important molecule in living cells and is generally 
regarded as the critical target for radiation-induced lethality in rapidly proliferating cell 
populations. Only a small proportion of the initially induced lesions results in permanent 
damage. Simple lesions, such as single strand breaks (SSB) tend to correlate poorly with 
biological effectiveness. An equitoxic dose of H2O2 produces about 400 times more SSB 
than low LET radiation (Ward et al. 1985). For many years the DNA double strand break 
(DSB) has been considered to be the most important type of lesion caused by ionizing 
radiation in cells, which, if left unrepaired, leads to cell death. Recent data suggest that 
DSB as such are not the principle determinant of cell death. Initial clusters of ionization 
leading to clustered DNA damage are now considered to be the driving factor for the 
induction of reproductive cell death. These severe types of DNA damage are least likely to 
be correctly repaired and therefore most likely causing permanent effects (Goodhead 
1994). Damage to cells can take on various forms. If the DNA is damaged, a loss of control 
in daughter cells may result, or the ability to duplicate may be lost. Non-specific cell 
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damage can result in loss of important cellular functions, production of toxic waste 
products or cell death without further reproduction. If the DNA is damaged, effects 
manifest in morphological observable and functional disorders such as mutations, cell 
destruction, metabolic irregularities, malfunction of organs, tumor induction or even death 
of the individual organism. 
Injury induced by ionizing radiation in normal tissues is expressed as early or late 
impairment of the integrity and function of organs. The expression of injury varies from 
one tissue to another and conditional on their function, cellular composition, and cell 
proliferation kinetics. The radiosensitivity of a particular cell depends on a number of 
factors. An early observation of this is reflected in the Law of Bergonie and Tribondeau 
(1906), which states: the radiosensitivity of a tissue is directly proportional to the rate of 
cell division or the degree of mitotic activity and the length of time that cells within the 
tissue stay in proliferation. And it is inversely proportional to the degree of cell 
differentiation. Tissues consisting of rapidly dividing stem cells (like blood or intestine cell 
precursors) are quite sensitive to radiation whereas cells that do not divide or only rarely 
divide (like nerve or muscle cells) are considerably more resistant. It should be pointed out 
that most tissues depend on several cell types for their integrity and function. For instance, 
nerve cells, considered as a nonrenewable component of a system, depend in tissue on slow 
renewal of glial cells and slow renewal of the endothelial cells of blood vessels. Late 
effects in rapid renewal systems such as epidermis and intestine also depend on slow 
renewal endothelial cell systems. Other factors involved in the radiosensitivity of cells 
include metabolic rate, state of nourishment, and oxygen level. 
An important difference between shapes of dose-response curves for cellular effects and 
tissue effects can be explained in terms of quantitative differences. Reproductive cell death 
can be detected in cell culture at relatively low doses. By contrast, it is a general 
observation that most dose-response curves for tissue responses show a threshold dose, 
below which damage is not detectable (i. e. skin or CNS tissue). This can be ascribed to the 
fact that substantial numbers or relatively large proportions of cells in affected tissues must 
be lethally damaged before tissue responses become detectable and significant. Because of 
this characteristic, tissue responses have been called non-stochastic or deterministic effects. 
Stochastic effects are health effects that occur randomly and for which the probability of 
18  Chapter 1 
the effect occurring, rather than the severity, is assumed to be a function of dose without a 
threshold. Genetic defects and cancer induction are examples of stochastic effects. 
1.1.4 Linear energy transfer (LET) 
Differences in ionization density are described by the term mean track average 
linear energy transfer (LET). It is a measure of the number of ionizations which radiation 
causes per unit distance as it traverses the living cell or tissue. The energy loss per unit 
length of particle track is termed the stopping power in nuclear physics and linear energy 
transfer (LET) in radiation biology. The concept involves lateral damage along the path, in 
contrast to path length or penetration capability. Its value, usually expressed in keV µm-1, 
gives the rate of energy loss of an ionizing radiation per unit of track length in a material. 
A low LET value means that the described radiation is sparsely ionizing. Hence, a densely 
ionizing type of radiation has a high LET. The LET varies with mass, charge and energy: 
slow, highly charged heavy particle radiations have higher LET values. Low LET radiation 
transfers its energy so gradually that very little of its total energy is deposited in any one 
location of its track. Examples of low LET radiation are beta particles, X-rays and gamma-
rays. High LET radiation includes alpha particles, protons, and other heavy charged 
particles. Neutrons are usually considered high LET because they produce recoil protons 
along their track that deposit most of their energy in a small volume. To a considerable 
extent, the Relative Biological Effectiveness (RBE) of various radiation types depends on 
the rate of energy loss (LET) along the paths of the individual ionizing particles or 
photons. Radiation with low LET such as X- or gamma-rays produce diffuse ionizations 
throughout the medium. In contrast, the LET associated with neutrons or alpha particles is 
so high that the passage of a single track will, in all probability, put enough ionizations into 
a traversed cell to produce death. 
1.1.5 Relative biological effectiveness (RBE) 
In order to compare and predict the response of a biological system to different 
types of radiation the term relative biological effectiveness (RBE) has been established. 
RBE is the ratio of dose of a reference radiation quality (usually 250 kV X-rays) and dose 
of a test radiation that produce an equal effect in the same biological system.  
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Although RBE is conceptually very simple it is a very complex quantity that is dependent 
on a)  radiation quality (LET) b)  radiation dose c)  number of dose fractions d) fraction 
size e) dose rate and f)  biological system. Therefore it is not possible to assign a single 
RBE value to a given radiation quality, e. g. fast neutrons, low energy protons or α-
particles. Determinations of the RBE are always associated with an experimental 
uncertainty. High LET radiation has a higher relative biological effectiveness (RBE) up to 
a maximum of LET values between 100 and 300 keV µm-1. Beyond this plateau the RBE 
decreases with increasing LET. This decrease in RBE can be attributed to a surplus of 
energy deposition, which is not needed to produce the biological effect (overkill). 
The use of RBE is crude but effective in conventional therapy where radiation is of a single 
quality. For Boron Neutron Capture Therapy, the RBE concept is questionable as 
biological effects depend not only on the kind of radiation but also on the energy 
distribution of the radiation and microscopic distribution of the capture agent. Therefore, 
the concept of Compound Biological Effectiveness (CBE) or Compound Factor (CF) has 
been introduced. The concept of RBE is valid only when the quantity absorbed dose can 
be defined, i. e. when the averaging procedure implicit in the definition of absorbed dose is 
applicable. For the boron dose in BNCT the concept of absorbed dose cannot be applied 
because of the inhomogeneous distribution of the boron compounds and the short range of 
the α- and lithium particles. Therefore the RBE cannot be defined and the influence of an 
inhomogeneous distribution of the boron atoms cannot be determined. Only the product of 
these two components, RBE and boron distribution, can be assessed for a given tissue and 
experimental conditions. This product is referred to as CBE or CF. 
1.1.6 Dose rate 
One of the factors that influence the biological effect of a given dose of radiation is 
the rate at which exposure to radiation occurs. The term dose rate describes the dose 
absorbed per unit time. The SI unit for it is the gray per hour (Gy h-1). An acute exposure, 
which involves a high radiation dose over a short period of time, will produce more 
damage than a chronic exposure, which involves an accumulation of dose over a long 
period of time, hence, allowing time for repair and recovery to occur. Radiation tolerance 
of normal tissues is dose-rate dependent. In general, the effects of radiation decrease with a 
decrease in dose rate. Processes such as repair of sublethal and potentially lethal damage, 
cell cycle progression and redistribution, repopulation, and reoxygenation that are 
20  Chapter 1 
important for the biological effects of fractionated radiation therapy are also important for 
low-dose-rate therapy.  
In vitro, repair of sublethal damage is most important in the dose-rate range of 
0.05 Gy/min to ≥ 1.0 Gy/min. In the dose-rate range of 0.005-0.05 Gy/min, cell cycle 
progression and redistribution becomes important, and the dose needed for an effect and 
the dose rate becomes more complex (Fu 1991). In skin, a decrease in dose rate generally 
results in considerable sparing of the acute and late radiation injury. The dose rate factor 
for acute, medium and late skin reaction remains relatively constant at dose rates down to 
0.05 Gy/min. Below 0.05 Gy/min the dose rate factor increases rapidly with decrease of 
dose rate (Fu 1991). Radiation tolerance of the central nervous system shows a strong 
dose-rate dependence in addition to total dose and volume effects. The relation between 
dose rate factor and dose rate for spinal cord injury resembles the one for acute, medium 
term and late skin reaction (Fu 1991). 
1.2 THE CENTRAL NERVOUS SYSTEM 
1.2.1 Anatomic outline 
1.2.1.1 Genesis 
During early embryological development, the nervous system is formed by a 
longitudinal invagination of the ectoderm (neuroectoderm), the neural groove, which 
subsequently closes to form the hollow neural tube. The lining of the central canal forms a 
proliferative zone, giving rise to neurons and supporting glial cells. The neurons become 
arranged around the proliferative ependymal zone, while an outer layer contains the fibers 
arising from the nerve cells. Functionally similar groups of neurons are clustered together 
in so-called nuclei of the central nervous system (CNS). Groups of neurons organized in 
layers (laminae) on the outer surface of the brain, are called cortex, such as the cerebral 
cortex and cerebellar cortex. The long processes (axons) of neurons course in the CNS in 
functional groups and form tracts. Since many of the axons have a layer of shin fat 
(myelin) surrounding them, they appear white (white matter). The nuclei and cortex have 
little myelin in them, appear gray, and are therefore called the gray matter of the CNS. Of 
mesenchymal origin are the shrouds/covers of the nervous system (meninges), blood 
vessels and the mesoglia (Hortega-glia), mainly responsible for resorption of metabolic and 
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catabolic products within the CNS. The CNS itself contains no lymphatic vessels, but is 
connected to the cervical and abdomino-thoracic lymphatic system via the liquor space. 
The entire brain has a lumen filled with cerebrospinal fluid (liquor), and dilatations of the 
lumen are called ventricles.  
1.2.1.2 Cells of the nervous system  
Neurons essentially define the CNS. They are electrically active cells and 
responsible for the majority of the functional properties which we ascribe to the nervous 
system. 
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Figure 1.1: Schematic view of blood brain barrier, indicating the endothelial cell layer with tight junction, 
basal layer and surrounding astrocytes 
 
The main supportive tissue of the nervous system is composed of glial cells. Glial cells 
provide nutritive functions toward neurons, help maintain the blood-brain barrier and act as 
the primary cellular defense mechanism for the central nervous system. Tree types of glial 
cells can be identified: oligodendroglial, astrocytes, microglia and ependymal cells. The 
terminally differentiated oligodendroglial cells are the myelin producing cells in the 
nervous system. By wrapping the cell membranes around axonal processes, myelination is 
accomplished. A single oligodendroglial cell may myelinate several axonal processes 
within the CNS. Myelination of axons by oligodendroglial cells insulates axons and 
improves the speed of action potential propagation by neurons. Besides myelination, these 
cells provide local nutritional support for the axonal processes that they contact. They also 
help inactivate neurotransmitter substances. Astrocytes are the most prevalent phenotype in 
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the CNS, comprising more than half the brain volume and outnumbering neurons by 
approximately 9:1 (Montgomery 1994). They have numerous functions in the normal CNS, 
including effects on potassium homeostasis, calcium signaling, and neurotransmitter 
function (Juurlink et al. 1992). The astrocyte provides the scaffolding maintaining the 
structure of the nervous system. They play an important role in isolating the nervous 
system from the rest of the body by reinforcing the structural barrier and providing an 
enzymatic barrier which helps prevent entry of materials into the nervous system. 
Astrocytic end-feet surround the capillaries of the nervous system, supporting the tight 
junctions of the capillaries in the nervous system and are an important part of the blood-
brain barrier (Fig. 1.1). The structural parts of this barrier is based upon the fact that the 
endothelial cells of the capillaries in the central nervous system have tight junctions, that is 
the endothelial cell fenestrations, unlike most capillary beds, are exceedingly close 
together. This prevents all but extremely small particles from passing through the 
endothelial cells of the central nervous system. Besides the tight junctions of the 
endothelial cells, the blood vessels of the central nervous system are reinforced by the 
presence of astrocytic end-feet, projections of fibrous astrocytes that surround capillaries 
and provide extra structural support. The addition of endothelial and astrocytic membranes 
to the barrier increases the membrane phospholipid content in the barrier, preventing 
passage of materials that are not lypophilic. The phagocytotic microglial cells are the 
primary cellular defense mechanism in the nervous system. They are involved in local 
inflammatory responses in the brain and are characterized by a high degree of 
morphological and functional plasticity (Thomas 1992). In response to infection, 
inflammation or tissue damage, these cells proliferate and accumulate in the parenchyma 
of the nervous system (Giulian et al. 1989). Their levels will also increase in the cerebral 
spinal fluid. Ependymal cells line the ventricular surfaces and the central canal of the 
spinal cord. They help to provide part of the barrier between the nervous tissue and the 
cerebral spinal fluid. In the lateral, third and forth ventricles, the ependymal cells along 
with capillaries form the choroid plexus, producing most of the cerebrospinal fluid (CSF) 
that circulates in and around the nervous tissue. CSF serves as a waste sink, diluting extra-
cellular metabolic products as they are eliminated. It also functions to cushion the CNS, 
protecting the brain in a hydrodynamic system. 
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1.2.1.3 Functional divisions of the brain 
The brain is composed of the brain stem, or segmental portion of the brain, and the 
suprasegmental portion of the brain, and the suprasegmental apparatus, comprising a 
caudal cerebellum and frontal paired cerebral hemispheres (Fig. 1.2).  
The telencephalon is a part of the brain that includes the olfactory bulbs and cerebral 
hemispheres (neocortex). Whereas the olfactory bulbs are very similar in all vertebrates, 
the cerebral hemispheres manifest greater diversity of structure among vertebrates than any 
other part of the brain. The olfactory bulbs receive and process information from the 
chemosense organs of the nasal region and transmit this information to the cerebral 
hemispheres. The size of this portion of the telencephalon is proportional to the size and 
importance of these chemo-senses in a given animal. The cerebral hemispheres play an 
integrative role in all vertebrates. 
The diencephalon is the most anterior part of the brain stem. The diencephalon is made up 
of the thalamus dorsally and the hypothalamus ventrally. The thalamus is largest in 
vertebrates with the largest cerebral hemispheres. It is a complex of nuclei relaying all 
sensory information from the spinal cord and other parts of the brain to the cerebral 
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Figure 1. 2: Schematic structure of a dog brain (median view, anterior to left) 
(adapted from: Nickel, R., Schummer, A., Seiferle, E., 1984, Lehrbuch der Anatomie der Haustiere, Vol. IV, 
p. 61, Paul Parey, Hamburg, Germany) 
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hemispheres except for olfaction. The hypothalamus, to which the pituitary gland 
(hypophysis) attaches, is a major integrating center for endocrine and visceral activities. Its 
main function is to maintain internal homeostasis. Through connections with the 
parasympathic and sympathic nervous system, the hypothalamus regulates heart rate, blood 
pressure, digestion and elimination. 
The mesencephalon (midbrain) is divided into a dorsal tectum and a ventral tegmentum. 
The tectum contains the rostral and caudal colliculli, important in visual and auditory 
reflexes, respectively. The tegmentum contains nervous pathways going to and from the 
forebrain and important motor centers. 
The dorsal portion of the metencephalon forms the suprasegmental cerebellum. The 
cerebellum coordinates motor movement, ensures that commands initiated in the cerebral 
cortex are carried out smoothly and is a motor command area for learned, repetitive motor 
functions. The ventral portion of the metencephalon (pons) contains fiber tracts traveling 
through it, and the central nuclei of several cranial nerves (n. trigeminus). 
The myelencephalon contains the remainder of cranial nerve nuclei. Together with the 
ventral portion of the metencephalon, the myelencephalon is called the medulla oblongata. 
The cranial medulla is responsible for vestibular function and balance and facial 
movements and expression. The caudal medulla is responsible for swallowing, regulation 
of cardiac and visceral responses and tongue movement. 
1.2.2 Radiation effects on CNS 
The CNS is exposed to ionizing radiation in a number of clinical situations, 
predominately those involving cancer treatment. Radiotherapy remains a major treatment 
modality for primary and metastatic neoplasms in the CNS, and exposure of the brain and 
spinal cord is often unavoidable in the radiotherapeutic management of tumors located 
close to the CNS such as head and neck cancers. The key to successful radiation therapy is 
obviously not the dose that is required to sterilize the last clonogenic cell in a given tumor, 
but the dose that can be tolerated by the surrounding and unavoidably irradiated normal 
tissue vital to the patient's survival and normal functioning. Whereas any type of normal 
tissue damage is undesirable, the CNS injury that can occur after radiotherapy is associated 
with a high rate of morbidity and mortality and is especially devastating. The probability of 
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developing side effects and their severity depends on parameters such as total dose, dose 
distribution, and fractionation scheme. Because there is a clear relationship between the 
prognosis and the time of onset, the radiation-induced syndromes are divided according to 
the elapsed time after treatment. The nervous system is generally regarded as relatively 
radiation resistant.  
Although the choice of terms differs, most authors divide the processes in each tissue into 
the initial events, the phase of repair and stabilization, and the period of slow progression 
of delayed or late effects. The onset of the different phases is strongly dependent on the 
type of tissue. Classically, based on time of expression, radiation-induced CNS injury has 
been divided into three reactions: acute, early delayed and late delayed (Hopewell and 
Wright 1970, Sheline et al. 1980, van der Kogel 1991, Schultheiss and Stephens 1992).  
Acute injury develops for the CNS during or immediately after irradiation. It is expressed 
in days to weeks after irradiation and is fairly uncommon under current radiotherapy 
protocols. If the brain is irradiated to high doses (>30 Gy), non-specific clinical symptoms 
may occur mediated by radiation induced hemorrhages or edema leading to an increased 
intracranial pressure and in the worst case to death. Symptoms related to the acute 
radiation effects after lower doses are temporary and disappear completely within several 
weeks. Patients may benefit from corticosteroid therapy. 
Early delayed injury typically occurs from one to six months and can involve transient 
demyelination with somnolence and Lhermittes syndrome after brain and spinal cord 
irradiation, respectively. Although acute and early delayed injuries can result in severe 
reactions, they are normally reversible and resolve spontaneously (Tofilon and Fike 2000). 
Occasionally, however, this affliction does not resolve and leads to death of the patient. 
In contrast, late delayed injury, which can be observed approximately six months after 
irradiation, is usually irreversible and progressive and has been casually associated with 
the morbidity and mortality of radiation-induced CNS damage. The CNS stays prone to the 
development of late side effects for years. The onset of symptoms can be acute as well as 
over several weeks. The clinical picture depends on the anatomical location of the induced 
damage and is therefore variable. Late delayed injury is characterized by demyelination, 
vascular abnormalities and ultimately necrosis (both focal and diffuse), which is generally 
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restricted to the white matter (Tofilon and Fike 2000). Another irreversible reaction of the 
brain after radiotherapy is characterized by brain atrophy with mental and neurological 
deterioration. Although this is seen relatively short after radiation treatment (within a few 
months), it is categorized under late delayed reactions because of its irreversibility and 
progressiveness. 
The major events leading to acute, immediate, and delayed radiation changes that are 
clinically evident are under debate for several years now (van der Kogel 1986, Hopewell et 
al. 1978, Tofilon and Fike 2000). Theories about the pathogenesis of radiation-induced 
syndromes are mainly based on histological examinations of irradiated human and animal 
CNS tissue. Several cellular mechanisms have been proposed to explain the different 
pathological findings. There is not a single target cell type and a single pathway of 
radiation induced damage of the CNS. Oligodendrocytes and endothelial cells are usually 
emphasized as the potential target cells. The general view is that these cells have both 
independent and overlapping roles in the pathogenesis.  
Acute disruption of the blood brain barrier (BBB) by radiation and the subsequent 
development of edema is thought to be responsible for the acute symptoms seen after 
irradiation of the human CNS. Improvement of clinical symptoms after administration of 
corticosteroids supports this theory, although it is realized that corticosteroids may have 
many other effects (Gutin 1991). 
The early delayed syndrome is probably due to degenerative changes such as break down 
of myelin and swelling of axons. Histopathologic examination reveals in plaques of 
demyelination similar to multiple sclerosis (Burger and Boyko 1991). Van der Kogel 
described a predominately dose driven dependency for lesions of the early delayed 
syndrome (Van der Kogel 1991). In the most basic form, the lesion presents as a small 
punched out area in the white matter with swollen axons and loss of myelin. Within the 
low dose range, lesions may remain as scattered foci and usually become mineralized in 
time. After slightly higher effective doses, foci rapidly expand and coalesce into larger 
necrotic areas. With increasing dose, severe neurological impairment and death occur 
before significant inflammatory reactions can be observed. The occurrence of 
remyelination at the time that the clinical symptoms disappear fits into the pathogenetic 
model. Advocates of this theory assume that the degeneration of fibers is a precursor of 
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white matter necrosis. The relatively short period between irradiation and the observed 
morphological changes supports the hypothesis that functional glial cells are directly 
damaged by radiation. 
Van der Kogel (1979) subdivided the late complications after irradiation of the rat spinal 
cord. The first part occurred after a latent period of about four to six months. It was mainly 
restricted to white matter and was characterized by demyelination, followed by loss of 
axons, focal necrosis and ultimately colliquation necrosis. If this syndrome did not 
develop, the spinal cord remained prone to the later development of vascular changes 
consistent of hyaline thickening of the vessel walls, various degrees of teleangiectasia, 
fibrinoid necrosis, vascular occlusion, focal hemorrhage, and hemorrhagic necrosis. 
Symptoms developed gradually. But sometimes severe neurological side effects were seen 
within hours due to the sudden onset of bleeding. Vascular changes in the rat spinal cord 
occurred later than white matter necrosis and were most of the time seen from one year 
postirradiation on. Asai et al. (1989) observed a glial atrophy that was characterized by a 
generalized atrophy of nervous tissue probably caused by glial cell depletion without clear 
signs of vascular injury or tissue necrosis. In later experiments van der Kogel found that an 
increased dose to the endothelium relative to the parenchymal tissue causes an effect 
similar to that produced by homogeneous irradiation of the whole tissue. In these 
experiments, all performed at dose levels isoeffective for induction of white matter 
necrosis, large differences in glial progenitor cell survival were observed (Van der Kogel et 
al. 1995, Hopewell and Van der Kogel 1999). Thus, although it seems unlikely that 
radiation injury can be attributed to a singular target, there is little doubt that vascular 
damage, and, presumably, endothelial cell loss plays a significant role in the expression of 
white matter necrosis. 
Of the consequences of vascular damage, white matter necrosis is considered to be a 
secondary response to ischemia. Substantial data are available describing radiation-induced 
vascular abnormalities including vessel wall thickening, vessel dilatation, and nuclear 
enlargement in endothelial cells, which are presumed to be the result of endothelial cell 
damage. Time- and dose-related reductions in blood vessel density and a slight loss of 
endothelial cells, which is extremely variable between individual vessels, have been 
reported prior to the development of necrosis in white matter (Schultheiss and Stephens 
1992, Calvo et al. 1988, Reinhold et al. 1990). 
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Tofilon and Fike suggest that other phenotypes as well as critical cellular interactions may 
also be involved in determining the radio-response of the CNS. In addition to acute cell 
death, the induction of an intrinsic recovery/repair response to radiation in the form of 
specific cytokines and the initiation of secondary reactive processes that result in the 
generation of a persistant oxidative stress could be involved in CNS damage (Tofilon and 
Fike 2000). 
Large animal models, particularly primates and dogs, have been used extensively in 
experimental studies of radiation brain damage and will be outlined on the basis of a 
review article by Fike and Gobbel (Fike and Gobbel 1991). Technologies such as 
computed tomography (CT), magnetic resonance imaging (MR), and positron emission 
tomography (PET) have facilitated serial noninvasive examinations of certain morphologic 
and physiologic parameters within the brain after irradiation. Fike quoted the work of Zook 
et al. who irradiated adult beagle dogs with fractionated doses of X-rays or fast neutrons. 
Zook et al. (1980) observed that a dose of  90 Gy delivered in 3.2 Gy fractions over a 7 
weeks period produced lethal radiation injury 17-28 weeks postirradiation. Fractionated 
photon doses of 40 and 60 Gy caused no neurologic or gross pathologic changes. Neutron 
irradiated dogs died at lower doses and relative biological effectiveness (RBE) values for 
neurologic impairment of greater than 4.5 were reported. Fike himself irradiated beagle 
dogs with X-rays delivered as single doses to one hemisphere. He showed that the dose 
response curves for normal brain were very steep and found ED50 values (the dose required 
to produce a given effect in 50 % of the animals irradiated) of 12.8 Gy for CT changes 
without clinical manifestation, and 14.9 Gy for lethal brain necrosis. These findings were 
consistent with both retrospective and prospective clinical data in patients expressed as 
equivalent single doses. Because of this similarity it is tempting to assume that the 
pathophysiology would also be based on the same mechanisms. Fike stated that the latent 
period between irradiation and expression of damage in dogs is usually in the order of 0.5 - 
1 year depending on the dose, while radiation damage in humans generally develops over a 
2 years period or longer. A possible explanation for these differences might be that with 
patients always a pathologic tissue with possible abnormal physiology is involved whereas 
the experimental animal studies deal with normal brain tissue. 
As with the small animals there is no general agreement about the primary cellular site or 
"target" of radiation damage in the brain. On one hand a vascular deficiency is favored and 
General introduction  29 
 
on the other hand it might be a direct degeneration of the neuroglial/myelin components. 
Both have, according to Fike, merit and are supported by considerable experimental and 
clinical data. The resolution of this apparent conflict is complicated by the observation that 
the histological changes reported in virtually every investigation of radiation induced brain 
injury include both vascular and parenchymal elements. However, there usually is a 
predominance of one over the other in terms of magnitude of damage or time of 
expression. Damage occurs after a relatively silent (latent) period, the duration of which is 
described as being dose dependent. Another aspect of the pathophysiology of radiation 
damage is the relatively abrupt and rapid progression of damage that is generally observed 
after the latent period. Fike et al. concluded that, in the dog at least, two different processes 
may be involved. One has a rapid onset and is consistent with classic radiation brain 
damage. It includes foci of coagulation necrosis, fibrinoid necrosis of vessel walls, edema, 
and variable degrees of demyelination. The other type of late radiation damage evolves 
more slowly and perhaps is a more degenerative process. Whether the latter will ultimately 
progress into more severe damage after longer times (> 12 months) or whether the two 
types of damage represent two different cellular or tissue targets remains yet to be 
determined. In large animals as well as in humans there is a characteristic selectivity of 
damage to the white matter. The vascular basis for radiation induced injury assumes that 
ischemia is ultimately responsible for the precipitation of the necrosis. However, the CNS 
cell system that is by far the most sensitive to oxygen deprivation is the neuron (Lutz 
1992), which is located in the gray not in the white matter. Consequently, although 
differences in blood flow between gray and white mater might be involved, the 
predilection of radiation induced necrosis for white matter is inconsistent with a solely 
vascular basis. On the other hand, the above mentioned BNCT studies (van der Kogel et al. 
1995) clearly indicated that delivery of a high radiation dose almost entirely to the 
vasculature results in white matter necrosis. Thus, although it seems unlikely that radiation 
injury can be attributed to a single target, there is little doubt that vascular damage and, 
presumably, endothelial cell loss play significant roles in the expression of white matter 
necrosis. In addition to vascular abnormalities, the histological presentation of radiation 
induced CNS damage is typically dominated by demyelination, which implicates an 
affection of oligodendrocytes. These cells provide the myelin sheet for neurons, and their 
loss results in demyelination. The strength of the glial hypothesis is that it accounts for the 
white matter selectivity of radiation induced CNS damage. However, demyelination is 
detected after relatively low radiation doses that are not associated with a significant risk of 
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necrosis. Thus, it appears that additional factors are required to result in white matter 
necrosis and late delayed injury. Tofilon and Fike (2000) suggest in their review that other 
phenotypes as well as critical cellular interactions may be involved in determining the 
radioresponse of the CNS. The general injury response of the CNS involves acute cell 
death, initiation of secondary reactive (oxidative) processes, and a competing process 
involving the induction of genes coding for protective cytokines. The level of tissue 
injury expressed after irradiation of the CNS then reflects the balance between these three 
reactions (Tofilon and Fike 2000). 
In their review article Fike and Gobbel (1991) draw the conclusion that changes induced in 
(large) animals as a function of dose, time, volume, and other factors closely resemble the 
types of changes that occur in human patients. The fact that more meticulous observations 
are possible with larger animals by using noninvasive means such as MR, CT, SPECT and 
PET studies will be helpful in understanding the response of normal brain after radiation. 
Observed changes should support the understanding of the response of normal brain in 
human clinical studies compromised by existing pathology. 
1.2.3 Brain tumors 
Brain tumors are either arising from the brain and its coverings (primary tumors) or 
metastatic tumors that have their origin elsewhere in the body. Primary tumors of the 
nervous system arise from intrinsic neural cellular elements, but even those that are 
biologically quite aggressive rarely metastasize outside the nervous system. Secondary 
tumors originate outside the nervous system and reach neural tissue either by growth from 
contiguous structures or spread by the blood stream from primary tumors in distant tissues. 
The metastatic tumors are thus a heterogeneous group, the vast majority of which is of non 
neural origin. 
Classification of tumors is generally based on a) cell of origin, b) degree of differentiation 
(anaplasia), and c) anatomical location. Tumors that originate from glial cells are grouped 
together as gliomas. Within this group are tumors of astrocytes (astrocytoma), 
oligodendrocytes (oligodendrogliomas) and ependymal cells (ependymomas). Mixed 
gliomas contain more than one type of neuroblastic cells. Most primary CNS tumors are of 
glial origin. Tumors of neural origin, which are poorly differentiated, are referred to as 
primitive neuroectodermal tumors. In terms of prognosis and adequate treatment, tumors 
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are further graded histologically by their degree of anaplasia. In the case of astrocytoma 
the presence or absence of abnormal appearance (atypia) of nuclei, endothelial 
proliferation, mitotic figures, and necrosis are examined. Astrocytomas with none of these 
features are grade 1. Astrocytomas in which one of these features is present are grade 2. 
Grade 3 astrocytomas have two, and grade four has three or all four of these abnormalities. 
There is a fairly good inverse correlation between the grade of tumor and survival: patients 
with higher-grade tumors have shorter survivals following diagnosis. The grading 
suggested by the World Health Organization (WHO) was to indicate the expected survival 
of a patient with such a tumor: grade 1: 5 or more years, grade 2: 3-5 years, grade 3: 2-3 
years, and grade 4: 6-15 months survival (Zülch 1979). 
Tumors that are derived from astrocytes have a variety of cytological and histopathological 
appearances, as well as biological behaviors. Astrocytomas with anaplastic histological 
appearance are called anaplastic astrocytoma, and those with the most pronounced 
anaplastic changes, including necrosis, are called glioblastoma multiforme. The 
glioblastoma multiforme is a primitive and highly malignant form of glioma whose cell of 
origin is uncertain. Astrocytomas of all grades can occur anywhere within the CNS, but the 
majority originate in the white matter. The location of the tumor may have important 
implications for treatment, since tumors in the optic chiasma or brain stem may be difficult 
to treat despite their histologically benign character. Astrocytomas tend to infiltrate 
surrounding CNS structures and can invade the arachnoid space. Astrocytomas are quite 
common in children with relatively favorable clinical outcome. But with increasing age the 
survival rate for these tumors is progressively worse. Astrocytomas of the brain stem have 
usually a fairly rapid clinical course resulting in death regardless of their histological 
grading. Glioblastoma multiforme is characterized by rapid clinical progression. The 
border at which an anaplastic astrocytoma becomes a glioblastoma multiforme is not 
precisely defined. 
Surgery is part of the initial management of virtually all brain tumors. It confirms the 
diagnosis and relieves the mass effect almost immediately. For benign tumors complete 
resection may be curative, and even for malignant tumors there is increasing evidence that 
extensive resection prolongs survival. However, complete surgical removal of malignant 
gliomas is difficult because of the typical arachnoid growth of these tumors. 
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Radiation therapy plays a central role in the management of malignant tumors of the CNS. 
For malignant gliomas the usual treatment regime is 50 - 60 Gy of X-rays delivered over a 
period of five to six weeks to a defined target volume.  
1.3 BORON NEUTRON CAPTURE THERAPY 
1.3.1 Principle 
As described above in chapter 1.1.2 thermal neutrons exert their effect in tissue 
through ionizations produced by transmutations of elements composing the body and, to a 
lesser extent, through neutron-induced radioactivity. Localized effects may be artificially 
produced if one deposits in the body or selected organ some element, the cross section of 
which is relatively high for a suitable neutron capture-induced transmutation. If the region 
of interest is then bombarded with slow neutrons, the action of the disintegration products 
and of induced radioactivity resulting from the interaction of the neutrons and atoms of this 
element will be superimposed on the general effects of the neutrons. Several elements with 
suitable properties for such use are known (see table 1.1). Among them is boron, where the 
10B(n,α)7Li reaction has a high neutron cross section of 3800 barn. The lithium nucleus 
and the alpha particle emitted in this reaction produce dense ionizations in tissue. 
It was Locher who first suggested the use of neutron capture reactions for therapeutical 
application: “... the possibility of destroying or weakening cancerous cells, by the general 
or selective absorption of neutrons by these cells. In particular, there exist the possibilities 
of introducing small quantities of strong neutron absorbers into the regions where it is 
desired to liberate ionizing energy (a simple illustration would be the injection of a 
soluble, non-toxic compound of boron, lithium, gadolinium, or gold into a superficial 
cancer, followed by bombardment with slow neutrons)“ (Locher 1936). 
One of the first elements regarded for neutron capture therapy (NCT) was uranium-235 
because of its high cross section and the high-energy fission products (Tobias et al. 1948, 
Liu et al. 1992).  
235U + nth = 2 ff + 2.4 n + γ Q = 200 MeV 
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The fission fragments (ff) have a high linear energy transfer (LET) and therefore a high 
biological effectiveness within a very short range in tissue. But 235U is radioactive with a 
biological half-life of 100 days. And 235U has a high affinity to bone thus endangering a 
very radiosensitive tissue, the blood-forming bone marrow. A slightly better profile for the 
use in NCT shows the lithium-6 reaction: 
6Li + nth = 4He + 3H      Q = 4.783 MeV 
The cross section of 6Li is relatively high and the capture reaction results in high (α-
particle) and low (the β-emitter tritium) LET products. 6Li has a low toxicity and is not 
radioactive. But compared to boron-10 its cross section is low and the emerging tritium has 
a very long half-life. There is another nuclide, which because of its high cross section is 
suitable for NCT: gadolinium-137 has a cross section of 254 000 barn, 66 times higher 
than that of 10B. The capture reaction of 157Gd results in a gamma quantum and high LET 
Auger or conversion electrons with very short track lengths:  
157Gd + nth (0.025 eV)
158Gd + γ (99.2%)
158Gd + internal conversion electron (0.592%)
Auger electron (0.041%) + characteristic X-rays (0.153%)
Q = 7.938 MeV
 
Most of the energy arising from the capture reaction chain is released in the form of 
photons with relatively low LET. 
Boron neutron capture therapy (BNCT) is a bimodal treatment that is based upon the 
nuclear reaction of low energy (thermal) neutrons with 10B, a nontoxic, stable isotope with 
a natural abundance of 20 %. The 10B nucleus has a large cross-section for capturing 
thermal neutrons compared to the nucleus of any element present in tissue. After capturing 
a thermal neutron, the 10B nucleus disintegrates into two charged particles with ranges in 
tissue comparable to the diameter of a cell. The boron neutron capture reaction is 
schematically given by:  
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10B + nth (0.025 eV) [11B]
4He + 7Li + 2.79 MeV (6%)
4He + 7Li + 0.48 MeV γ + 2.31 MeV (94%)  
The recoiling alpha and lithium particles have an initial kinetic energy totaling 2.35 MeV 
and have ranges in tissue of approximately 9 µm and 5 µm, respectively. The dose from 
the 478 keV capture gamma-ray, emitted in 94 % of the cases, does not significantly add to 
the dose from the heavy particles and can be neglected for dosimetric purposes. Alpha-
particles give rise to closely spaced ionizing events that consist of tracks of sharply defined 
columns. They have a short path length, are high LET, and damage a wide variety of 
biologically active molecules including DNA, RNA and proteins. For these reasons there is 
little, if any, cellular repair from alpha particle induced radiation injury. The energy 
released is lower than with the gadolinium capture reaction, but because of the short range 
of resulting products strongly localized within about one cell diameter around the capture 
event. The short range of the particles implies that the macroscopic and microscopic 
distribution of 10B will have a significant impact on biological effectiveness (Wuu et al. 
1992).  
Although the possibilities offered by BNCT are auspicious, there is a set of problems to be 
solved on the irradiation part as well as with the selection of suitable boron compounds. 
Thermal neutron beams are poorly penetrating in tissue, requiring brain tumor patients 
being treated via an open craniotomy procedure. This has increased interest in using higher 
energy epithermal neutron beams that have greater penetration and develop a thermal 
neutron spectrum as they moderate in tissue. Moreover, certain nuclei commonly found in 
tissue interact with thermal neutrons via capture events of their own. Although the cross 
sections for these thermal neutron reactions are much lower than for interactions with 10B, 
there is a much higher concentration of these nuclei in tissue. So these events can deposit 
significant energy leading to cell damage. In addition, neutrons beams currently available 
for BNCT treatments are produced using nuclear reactors and often have a considerable 
contamination with gamma-rays and fast neutrons. These beam contaminants can cause 
considerable damage to normal tissue even if such tissues do not contain high 10B 
concentrations. Another problem is the boron-carrying agent. Because of the extremely 
short range of the fission products, almost every malignant cell must be loaded with a 
sufficient number of 10B atoms to ensure tumor sterilization. Therefore, the tumor to 
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normal tissue ratio and the concentration in blood during irradiation are important 
parameters. The first set of human clinical trials carried out at Brookhaven National 
Laboratory used 10B-enriched boric acid derivatives. These led to high concentrations of 
boron in the blood at the time of treatment and also resulted in relatively low absolute 10B 
levels in tumor tissue. There was considerable blood vessel damage and little therapeutic 
benefit from treatment (Slatkin 1991). Japanese investigators used 10B-enriched sodium-
mercaptoundecahydrododecaborate (BSH) as a boron carrier and reported more favorable 
results. There are researchers all over the world investigating suitable boron carriers for 
BNCT but only two compounds (i.e. borocaptate sodium and boronophenylalanine) are 
presently used in clinical trials.  
Boron neutron capture therapy (BNCT) produces a complex mixed field of radiation in 
tissue, which consists of a wide spectrum of both low and high linear energy transfer 
(LET) radiation. The total absorbed dose in tissue irradiated with an epithermal neutron 
beam originates from thermal neutrons, intermediate and fast neutrons and gamma-rays. 
The dose resulting from the boron neutron capture reaction is the major contributor to dose 
in tissue when high boron concentrations are present. Other interactions that contribute to 
the dose during BNCT are hydrogen capture (1H(n,γ)2H) and nitrogen capture 
(14N(n,p)14C). Neutron capture by nitrogen produces protons with energy of 580 keV. The 
particles from the boron and nitrogen capture reaction dissipate their energy locally. The 
macroscopic dose from these reactions can therefore be calculated from the local thermal 
neutron fluence and the local concentrations of the respective nucleus. Gamma-rays are 
unavoidably present in the beam but are also generated by neutron capture of hydrogen 
through the 1H(n,γ)2H reaction. The gamma-rays from this reaction have energy of 
2.23 MeV. The low-LET γ-radiation, in the incident beam and from hydrogen capture in 
the tissue, results in significant total body irradiation severely limiting the use of small 
animals in normal tissue tolerance studies using an epithermal field (Gavin et al. 1994, 
Gavin et al. 1992). Fast neutrons interact in tissue mainly through the proton recoil process 
(1H(n,n')1H). 
 
1.3.2 History and first clinical trials 
Rutherford postulated the existence of neutrons in 1920 (Rutherford 1920), and 
Chadwick subsequently demonstrated its existence (Chadwick 1932). A few years later 
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Goldhaber described charged particles after bombarding boron with thermal neutrons. 
These particles were identified as 7Li nuclei and alpha particles (Chadwick and Goldhaber 
1935, Taylor and Goldhaber 1935). In 1936, Locher suggested the use of neutrons and 
their capture reactions for radiation therapy (Locher 1936). The first radiobiological studies 
using the stable isotope 10B were performed at the University of Illinois. Kruger suspended 
tumor slices in boric acid solution and irradiated them with slow neutrons. With neutron 
doses above a certain level these tumors would no longer grow after transplantation into 
mice. On the other hand, control tumor slices not suspended in boric acid were not affected 
by neutron doses up to a much higher level. Likewise, boric acid without neutrons was 
without effect (Kruger 1940). Zahl and coworkers infiltrated sarcoma in vivo with lithium 
and boron compounds. 6Li splits into an alpha particle and tritium on slow neutron 
bombardment. These disintegration products caused regression of some of the sarcoma 
(Zahl et al. 1940 and 1941). Zahl also suggested the use of epithermal neutrons for clinical 
applications in human cancer patients (Zahl 1941). 
BNCT was tried as a therapeutic modality for malignant glioma in the 1950s at 
Brookhaven National Laboratory (BNL) and in the early 1960s using a reactor at the 
Massachusetts Institute of Technology (MIT). The first clinical trial of BNCT was carried 
out by Farr and his coworkers (Farr et al. 1954) on ten patients with glioblastoma 
multiforme using the 20 MW reactor at BNL. 10B-enriched borax solution was given 
intravenously prior to irradiation. Five patients were treated with a single fraction and five 
patients treated with two to four doses at five to six weeks intervals. The study 
demonstrated the feasibility of reactor-based BNCT but showed no real advantage of 
BNCT over conventional therapy (median survival time: 97 days (range: 43 to 185 days)). 
Problems included severe scalp reactions, normal brain injury, and clear regions of viable 
tumor tissue on postmortem examination. The second clinical trial involved 18 patients 
treated at the MIT reactor in cooperation with the Massachusetts General Hospital. These 
patients were treated with scalp, bone and dura surgically reflected, and as a boron carrier 
10B-enriched paracarboxybenzene boronic acid (16 patients) or sodium perhydrodecaborate 
was used. The results were unsatisfactory and BNCT trials were halted in 1961. The 
disappointing results were attributed to inadequate penetration of the incident, low-energy 
neutrons, and poor localization of the boron in the tumor (Sweet 1986). Efforts to deliver 
therapeutic neutron fluences to a tumor at depth resulted in excessive damage to the skin 
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(Slatkin 1991). There was also a problem to satisfactory handle cerebral edema, which 
later could better be controlled with the application of dexamethasone. 
Despite the disappointing outcome of first clinical trials, boronated substances were further 
investigated (see also section 1.3.3), leading to the development of Na-Mercapto-
undecahydrododecaborat (BSH) (Miller et al. 1963, Knoth et al. 1964). The usefulness of 
this compound for BNCT was first evaluated in animal experiments by Soloway et al. 
(Soloway et al. 1967). Since 1968 BNCT clinical trials have been underway in Japan using 
five different reactors. Patients with glioblastoma have been treated using the more tumor-
selective boron delivery agent sulfhydryl borane Na2B12H11SH (BSH), followed by thermal 
neutron irradiation (Aizawa 1990, Hatanaka and Nakagawa 1994, Oda et al. 1993). The 
use of thermal neutrons necessitated reflection of the scalp and removal of the skull. Over 
120 patients with intracerebral malignancies have been entered into this treatment program 
and some have apparently survived for a long term (Hatanaka 1983, Hatanaka and 
Nakagawa 1994, Nakagawa et al. 1997). BSH shows a small degree of selective binding to 
tumors; tumor to blood ratios are in the 1.1 to 1.5 range. Nevertheless, Hatanaka reported 
that the median survival of these patients has been extended relative to patients having 
conventional radiotherapy (Hatanaka and Nakagawa 1994, Nakagawa et al. 1997). 
Japanese workers are also conducting a clinical trial using the amino acid analogue p-
boronophenylalanine (BPA) for BNCT of malignant melanoma in a thermal neutron beam 
(Aizawa 1990).  
This work has served as the impetus for a considerable body of work on boron carrier agent 
development, optimization of reactor beams, and even preliminary work on the development 
of non-reactor based, epithermal neutron sources like accelerators. A therapeutic BNCT 
treatment program for high-grade brain tumors has been initiated in the United States at the 
Brookhaven National Laboratory in 1994 (Lawler 1995 and Elowitz et al. 1996). Patients 
were irradiated at the BMRR epithermal neutron beam after a two-hour infusion of BPA-
fructose. Irradiation time is based on actual blood boron concentration and individual 
pharmacokinetics obtained from the tumor debulking procedure (Coderre et al. 1996). First 
results were reported on the Seventh and Eighth International Symposium on Neutron 
Capture Therapy for Cancer 1996 in Zürich, Switzerland and 1998 in La Jolla, California, 
USA. The Massachusetts Institute of Technology (MIT) started BNCT first on cutaneous 
melanoma and in 1996 also for intracerebral melanoma or glioblastoma. Clinical trials on 
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glioma patients were started in Petten in 1997. In 1999, the first glioblastoma patient was 
BNC-treated in Finland. In 2002 the Studsvic group reported 27 glioblastoma patients been 
irradiated at the Swedish BNCT facility (Capala et al., 2002). 
BSH pharmacokinetics and biodistribution have been studied in patients with malignant 
gliomas in Germany (Haritz et al. 1994), Switzerland (Fankhauser et al. 1992, Stragliotto 
et al. 1993 and 1995), Austria (Haselsberger et al. 1994) and Japan (Fankhauser et al. 1992, 
Nakagawa and Hatanaka 1996). The European studies were performed with the intent of 
applying BSH-based BNCT with epithermal neutron irradiation to human brain tumors. 
High boron concentrations were found in tumor tissue and blood whereas normal brain 
tissue has shown no significant uptake. Oda and his coworkers (Oda et al. 1993) treated 
glioblastoma patients with BNCT using BSH at the Kyoto University Reactor. Just prior to 
operation tumor boron concentrations and tumor-to-blood boron ratios were measured, 
which were unexpectedly low.  
1.3.3 Capture agents and compounds 
As shown in table 1.1 many nuclides capture thermal neutrons. To date only two of 
them have been seriously investigated because of their availability and low toxicity. 157Gd 
has the highest cross section for thermal neutrons of all stable isotopes and is routinely 
used in the form of Gd-DTPA complexes for the staging and delineation of mainly 
intracranial malignancies by magnetic resonance imaging (MR). Due to the seven unpaired 
electrons the paramagnetic Gd3+ ion exhibits the strongest effect of all elements on 
T1-relaxation times. The use of Gd3+ ion in the form of its chloride, sulfate or acetate is 
prohibited because of its poor tolerance by the body. Like many other metallic salts, these 
compounds form acid solutions in water, and insoluble hydroxides or phosphates arise in 
the neutral pH range, which accumulate in the reticuloendothelial system after intravenous 
administration. Since tolerance of the ion is insufficient, the gadolinium was detoxified by 
chelation with various ligands. Chelation of the lanthanide drastically changes not only its 
water solubility but also the tolerance profile and pharmacological behavior (Weinmann et 
al. 1996). The best-known gadolinium chelate is the aqueous formulation of Gd-DTPA 
(Gd-diethylentriaminpentaacetat, Magnevist®). Gd-DTPA leaves the organism in unaltered 
form by renal excretion with a half-life of about 1-2 hours. The extra-renal excretion is 
negligible. Gd-DTPA does not diffuse through plasma membranes, and is therefore unable 
to pass the intact blood-brain barrier. This leads to very low gadolinium concentrations in 
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normal brain tissue, whereas, due to the fast elimination from the blood pool, very 
favorable brain tumor to blood ratios are archived. In Japan Gd-DTPA has been used as 
capture agent for NCT in vitro and in vivo studies showing cytotoxic effects in cell culture 
and different animal tumor models (Akine et al. 1990, 1992, 1993). Beside Gd-DTPA there 
are other Gd-chelates available, such as the open chain complex gadodiamid 
(Omniscan®), macrocyclic gadolinium complexes like gadoterate meglumine (GdDOTA, 
Dotarem®), and gadoteridol (ProHance®). 
The fission reaction following neutron capture of 10B results in short range particles with a 
high destructive potential. There are several reasons for 10B being the most attractive 
capture agent for NCT at the moment: it is a stable isotope and readily available, 
comprising approximately 20 % of naturally occurring boron. The capture reaction results 
in largely high LET fission products with a short track length of about one cell diameter. 
Provided that 10B can be selectively localized in tumor cells, the potential lethal reaction 
would therefore be restricted to these cells. The extensive chemistry of boron is such, that 
it can be incorporated into a multitude of different chemical structures. Also, the gamma-
ray emitted after capture of a thermal neutron by 10B can be used for analytical purposes in 
the so-called prompt-gamma-ray spectroscopy.  
Boron is an ubiquitous element in rocks, soil and water. Most of the earths soils have less 
than 10 µg -1 boron. Highly concentrated, economically sized deposits of boron minerals, 
always in the form of compounds with boron bonded to oxygen, are rare and generally are 
found in arid areas with a history of volcanic or hydrothermal activity. Borate-mineral 
concentrates and refined products are used in many ways: in glass and related vitreous 
applications, in laundry bleaches, in fire retardants, as micronutrients in fertilizers and for 
many other purposes as well. The varied chemistry and importance of boron is dominated 
by the ability of borates to form trigonal as well as tetrahedral bonding patterns and to 
create complexes with organic functional groups, many of biological importance.  
 
Ideally, boron compounds to be used for BNCT should have a high specificity for 
malignant cells with concomitantly low concentrations in adjacent normal tissue cells and 
blood. Since it is desirable to confine the radiation solely to these cells, an intracellular and 
optimally intranuclear localization of boron would be preferred. Initially, boron 
compounds were not specifically designed for use in BNCT but, rather, were selected 
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because of their ready availability, known pharmacology, or lack of toxicity. This lead to 
the choice of sodium borate, boric acid and their derivatives for first in vivo investigations. 
These so-called boron compounds of the first generation depended on blood-brain barrier 
alterations to establish increased amounts of 10B in the tumor as compared to levels in the 
adjacent normal brain tissue. Differences in the concentration of boron in tumor and 
normal brain tissue were detected, but these were transient and not very large. They 
decreased within a time period of one to two hours to unity (Javid et al. 1952, Sweet and 
Javid 1952). Limitations of these first generation compounds included high levels of boron 
in the blood, lack of specificity for neoplastic tissue, low concentrations of boron in poorly 
vascularized regions of the tumor, and their inability to become incorporated into 
neoplastic cells infiltrating the adjacent brain parenchyma where the blood-brain barrier 
remained intact. The tumor to brain ratios were achieved by relative exclusion from areas 
with an intact blood-brain barrier. The radiation-induced complications seen in normal 
brain and brain vasculature may have been in part caused by elevated blood levels of the 
compound at the time irradiation was performed (Asbury et al. 1972). Prior to further 
clinical trials, major effort was put in compound development, resulting in the selection of 
paracarboxybenzene boronic acid and sodium decahydrodecaborate. These were 
synthesized at a high 10B enrichment level and used for another clinical trial, the results of 
which were disappointing (Sweet 1986). Following the cessation of clinical trials in 1961, 
new compounds were developed and screened. The observation that sulfhydryl containing 
boron hydride anions had more favorable tumor to blood ratios led to the development of 
mercaptoundecahydrododecaborate (BSH) (Soloway et al. 1967). It is a caged 
dodecahedron of twelve boron atoms with a sulfhydryl group (fig. 1.3) that can bind 
nonspecifically to neoplastic tissues.  
 
SH
2 -2 Na+
 
 
Figure 1. 3: Chemical structure of mercaptoundecahydrododecaborate (BSH). 
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This compound has been in clinical use for thermal neutron BNCT in Japan for more than 
thirty years (see chapter 1.3.2). The exact biochemical and pharmacological basis by which 
this compound is able to achieve elevated concentrations in brain tumors remains unclear. 
More recently, the dimer of BSH, Na2B24H22S2 (BSSB) has been shown to have greater 
potential of localizing in neoplastic tissue (Joel et al. 1989). 
But at the same time liver enzyme levels were elevated suggesting hepatotoxicity. The 
mechanism for the increased uptake of the dimer is also unknown.  
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Figure 1. 4: Chemical structure of the aromatic amino acid tyrosine (left) and the boronated derivative p-
boronophenyl-alanine (BPA) (right) 
An other important boron delivery substance of the so-called second generation is the 
amino acid analogue p-dihydroxyboryl phenylalanine (BPA) (fig. 1.4). BPA has a 
dihydroxyboryl group containing only a single boron atom per molecule. This results in a 
boron weight percentage of about 5%. BPA was first synthesized by Snyder in 1957. It is 
not very water soluble and must be complexed with fructose to permit infusion, further 
lowering the boron content of the formulation. This compound has been shown in animal 
models to accumulate in melanoma (Mishima et al. 1989, Coderre et al. 1988) and other 
tumors derived from the neural crest (Coderre et al. 1994). It is being used clinically in the 
treatment of malignant melanoma (Mishima et al. 1989) and recently also for BNCT on 
glioma patients at BNL (Coderre et al. 1996) and in Finland. The L-form of the compound 
is, as to be expected of an amino acid analogue, the preferred isomer (Yoshino et al. 1996). 
The o- and m-BPA isomers show significantly less uptake (p-BPA>>m-BPA>o-BPA) into 
malignant cells. Yoshino et al. (1996) attributed this phenomenon to possible intra-
molecular boron-nitrogen bonds. p-BPA is relatively insoluble in water (1.6 g/l water) at 
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physiological pH due to its lack of charge at neutral pH. But BPA forms an anionic 
complex with fructose via the boric acid group, thereby increasing solubility (Yoshino et 
al. 1989). BPA can pass the blood-brain barrier, accumulates selectively in melanomas 
(primary tumor as well as distant metastases), and is also taken up by other malignant cells, 
i.e. glioma (Bergland et al. 1996).  
It is not clear yet, how BPA is incorporated in cells. Mishima postulated an uptake because 
of molecular similarities of the melanin precursor tyrosin and BPA (Fig. 1.4). The amino 
acid analogue should fool the melanoma cells, which would use it as biochemical 
building block in place of or in addition to phenylalanine. He and his coworkers found that 
BPA is selectively taken up into melanoma cells by an active membrane transport system. 
It probably binds to DOPA and is transported with melanin monomers, together with active 
tyrosinase, into premelanosomes and melanosomes where melanin polymer formation 
occurs (Mishima 1996). This would not explain the uptake of BPA in amelanotic 
melanomas (Coderre et al. 1987) or in brain tumors (Coderre et al. 1994). Coderre et al. 
observed an accumulation of BPA in different kinds of dividing cells. The highest 
concentration was seen about six hours post application. If BPA was internalized in 
melanin its concentration in melanotic cells should not decrease after six hours. Coderre 
concluded that the selective accumulation probably stems from being taken up by the 
aromatic amino acid transport system (Coderre et al. 1987). 
A number of third generation compounds being developed, may have significant potential 
alone or in combination to meet the above-mentioned criteria. Polyhedral boranes, 
including carboranes, are important as building blocks in the design and synthesis of more 
tumor specific targeting molecules. Numerous compounds are under development for 
treatment of various tumor types, and some are now being tested experimentally for their 
potential effectiveness in BNCT.  
Low molecular weight structures, having known tumor affinity, and into which boron 
clusters can be inserted include porphyrines and phthalocyanines. Both have been 
synthesized with carborane cages attached to their molecular structure. The biochemical 
basis by which these compounds achieve elevated concentrations in tumors is unknown, 
but this observation has served as the rationale for the use of hematoporphyrin derivatives 
in photodynamic therapy. In a study by Hill et al. (1992) the boronated metalloporphyrin 
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BOPP was shown to selectively accumulate in a murine cerebral glioma. The molecule 
synthesized by Kahl and his coworkers is the disodium salt of the tetrakis-carborane ester 
of 2,4-bis(1,2-dihydroxyethyl)-6,7-bis(2-(hydroxycarbonyl)-ethyl)-1,3,5,8-tetrametylporp-
hyrin and contains 40 boron atoms (about 30% boron by weight). It has a molecular weight 
of 1341 and is, despite the hydrophobic carborane clusters highly water soluble. Peak 
levels in brain tumor were found around twenty four hours post intravenous application 
and the plasma half-life was about ten hours. Tumor to blood ratios exceeding 8:1 could be 
achieved. BOPP was found not to pass through the intact blood-brain barrier, but was able 
to gain access to nests of malignant cells in the brain adjacent to tumor. BOPP was readily 
tolerated at doses as high as 200 mg kg-1 with no apparent signs of morbidity of animals 
(Hill et al. 1992). Kahl et al. found no significant toxic side effects to canines at an 
intravenous dose of 35 mg of BOPP per kg of body weight (Kahl et al. 1996). High levels 
of the compound found in liver and intestine would not limit the use of BOPP as a capture 
agent for the treatment of brain tumors with BNCT. 
Another category of low molecular weight boron compounds is boron containing purines 
and pyrimidines and their nucleosides. The rationale for their development is that such 
compounds may be selectively incorporated into rapidly proliferating tumor cells and 
trapped within the cell following their conversion to the corresponding nucleotide (Barth 
and Soloway 1994). Alternatively, these bases and their nucleosides may function as 
analogues of naturally occurring precursors of nucleic acids and become incorporated into 
DNA. Schinazi and Prusoff have synthesized the boron containing 5-dihydroxyboryl-2´-
deoxyuridine (Schinazi and Prusoff 1978). Unfortunately, these compounds were not very 
good substrates for nucleoside kinases, and the enzymatic conversion to corresponding 
nucleotides is a necessary precondition for the incorporation of such nucleotides into RNA 
or DNA. These findings lead to the development of 5-tethered boron containing pyrimidine 
nucleosides with more promising properties (Rong et al. 1996). 
An additional approach to the delivery of 10B seeks to use antibodies as targeting devices. 
Antibodies are proteins that have the potential to recognize specific structures, so-called 
antigens, on the surface of (tumor) cells. Unfortunately, loading boron on these molecules 
usually caused significant loss of antibody specifity, or boron concentrations achievable in 
tumor tissue were to low for BNCT to be effective.  
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One final category of macromolecular species that potentially may be useful for the 
delivery of 10B is the group of encapsulating structures, such as liposomes, microspheres 
and low density lipoproteins. Theoretically, high amounts of boron can be encapsulated 
and targeted to a tumor by e.g. antibodies. But as for other particles, the preferred 
localization might be in the reticuloendothelial system of the body. 
 
1.3.4 Neutron sources 
In order for a neutron source to be useful in BNCT, it must allow treatment of a 
patient in a reasonable time. Furthermore, it must ensure that the boron neutron capture 
reaction is the dominant dose to the tissue accumulating boron. The time necessary and 
sufficient for treatment will depend on the neutron fluence of this source. At the same time, 
any other component of the beam must not be so large as to contribute substantially to the 
dose to tissue exposed to this particular beam. If these components are large and uniformly 
effective with depth in tissue, they would minimize the dose differential obtainable by 
BNCT. If their effect varies with depth in the irradiated volume, tissues other than the 
boron-containing target tissue might be at risk. Therefore, neutrons of the appropriate 
energy are requested for the use in BNCT, which will be captured when they interact with 
a boron loaded cell. Although only neutrons in the thermal energy range are captured by 
10B, epithermal neutrons, which loose energy as they penetrate tissues, may be more useful 
clinically, since they have greater depth of penetration (fig. 1.5).  
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Figure 1. 5: Thermal neutron fluence along the central axis in tissue irradiated with a thermal neutron beam 
(solid line) and an epithermal neutron beam (dotted line) 
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Neutrons with energy of about 1-2 MeV are produced in the fission reaction within a 
nuclear reactor core. And thermal, epithermal, and fast neutrons may be extracted for use 
in radiation therapy by varying the amount of moderation with appropriate filter systems. 
Epithermal beams can be produced by using moderators to slow the fast neutrons to the 
appropriate energy range, and the residual thermal neutrons can be filtered out with 
absorbers such as cadmium or boron. The use of such an epithermal beam would obviate 
the poor depth of penetration associated with thermal neutron beams. Alternatively, 
epithermal neutrons of the required energy and fluence may be produced by low energy 
proton accelerators. Theoretical calculations and preliminary design studies suggest that a 
proton beam with currents in the range of 20 mA would be required with additional 
moderation by heavy water (Wang et al. 1989). 
 
1.3.4.1 Irradiation facilities 
At the present time only nuclear reactors are capable of generating neutron beams with a 
sufficient neutron fluence rate for NCT. In particular, the Brookhaven Medical Research 
Reactor (BMRR) (5 MW), the Massachusetts Institute of Technology (MIT) Research 
Reactor (5 MW), the Georgia Institute of Technology Research Reactor (5 MW), and 
finally the High Flux Reactor (HFR) (45 MW) of the Joint Research Center in Petten, The 
Netherlands, have irradiation facilities that were designed for medical and biological 
research purposes. The FIR-1 reactor (250 kW) in Helsinki, Finland, has been adapted for 
clinical use (Savolainen et al. 1997), large animal studies were performed (Benczik 2000) 
and clinical trials started (Joensuu et al. 2002).  
 
  
Figure 1. 6: Filter configuration for the BNCT epithermal neutron beam HB11 at the High Flux Reactor in 
Petten 
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The BNCT group of Czech Republic designed a clinical facility at the LVR reactor of NRI 
Rez. (10 MW) (Burian et al. 2001) and have started clinical trials on glioma patients 
(Burian et al. 2002). Clinical BNCT studies are also performed in Studsvik, Sweden, at the 
R2-o reactor (Giusti et al. 2002, Capala et al. 2002). Other BNCT facilities are planned or 
being developed in Russia (Gulidov et al. 2002), the Ukraine (Gritzay et al. 2002) and 
Poland (Golnik et al. 2002).  
Animals in this study were irradiated at the epithermal neutron beam of the High Flux 
Reactor (HFR) at Petten. The reactor operates at 45 MW and is cooled and moderated by 
light water. The standard core configuration consists of 33 fuel assemblies, 6 control rods, 
and 17 free positions for placing experimental facilities in a regular square construction 
surrounded on three sides by 16 beryllium reflector elements. The reactor is also equipped 
with 12 horizontal beam tubes (HB 1-12), used mainly for nuclear physics and solid state 
physics research. For the healthy tissue tolerance studies in dogs, one of these tubes, the 
HB11 at the North side of the reactor, was used. The HB11 represents a tube with a large 
aperture to the reactor core to provide sufficient neutron fluence rate.  
 
Figure 1. 7: Horizontal cross-section through the dog irradiation facility at the HB11, indicating treatment 
area and lay-out of shielding (dimensions are given in mm) 
A special filter configuration (Fig. 1.6) was installed to modify the beam, resulting in 
neutron energies ranging from 0 to 20 MeV. This filter configuration consists of a 1 mm 
thick cadmium shield (reducing the thermal fluence rate) followed by in total 150 mm 
aluminum, 10 mm titanium, 50 mm sulfur (all three reducing the fast neutron fluence rate) 
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and 1500 mm liquid argon (to reduce the photon contamination of the beam). The HFR 
epithermal beam (Moss 1990) is highly collimated with an angular spread of less than 5 
degrees. The circular beam opening for the dog irradiations was 8 cm in diameter. 
Dimensions and shielding of the irradiation room are given in (Fig. 1.7). 
1.3.4.2 Neutron beam characteristics 
Neutrons. Free beam measurements have been performed by collaborators from 
AEA Technology using gas filled proton recoil counters (Perks and Delafield 1992). These 
measurements have been undertaken at low reactor power to avoid saturation of the 
counters and provided spectral information from neutron energies of about 10 keV 
upwards. The stability of the beam as a function of time was shown to be very good. A 
neutron spectrum could be established and verified by measurements (Fig. 1.8). The total 
neutron fluence rate was equal to 4.9 x 108 n cm-2 s-1 with an average neutron energy of 
10.4 keV. The epithermal neutron fluence rate amounted to 3.8 x 108 n cm-2 s-1, the fast 
neutron component to 1.5 Gy h-1 (Moss 1993). 
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Figure 1. 8: HB11 neutron spectra calculated by MCNP Monte Carlo with (dotted line) and without (solid 
line) adjusting with the measured foil activation rates in air. 
 
Foil activation techniques have been used in a water and a polyethylene phantom in the HB 
11 epithermal beam. The thermal neutron fluence rate in water peaked at two centimeters 
depth and amounted to 6.54 x 108 n cm-2 s-1 in water and 8.1 x 108n cm-2 s-1 in 
polyethylene. The epithermal neutron dose rate at two centimeters depth was found to be 
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1.00 Gy h-1 and 0.75 Gy h-1 in water and polyethylene, respectively (estimated accuracy: 
15-20 %) (Raaijmakers et al. 1995, 1996 and 1997).  
 
Gamma-rays. The influence of argon activation, 40Ar(n,γ)41Ar, was investigated and led to 
the conclusion that part of the free beam incident gamma-ray radiation originates from the 
decay of the activated argon. For fresh, unirradiated argon the gamma-ray dose rate in the 
free beam was about 1 Gy h-1. However, after operation the argon becomes activated and 
the gamma-ray contamination of the free beam rises by about 25 %. The midline incident 
beam gamma-ray dose rate amounted to about 1.25 Gy h-1 with a slight decrease at the 
more lateral positions in the beam (Fig. 1.9). In a water and a polyethylene phantom 
gamma-ray dose rates of 2.01 Gy h-1 and 2.33 Gy h-1, respectively, were measured at 
thermal neutron peak (2.5 centimeters depth) (Raaijmakers et al. 1995, 1996, 1997). This 
increase in gamma-ray dose results from the higher hydrogen content of polyethylene 
compared to water. 
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Figure 1. 9: Gamma profile in air of the HB11 neutron beam. (2) at the beginning of argon exposure, (1) 
argon exposed for five hours 
 
1.3.4.3 Computer modeling 
A Monte Carlo based computer code (MCNP) has been used to simulate particle 
transport and to predict the different dose rate distributions in tissue. Calculation models were 
validated by measurements of various parameters of the free beam as well as within 
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phantoms. The calculated spectrum was found to be in good agreement with measured 
data. The dose rates generated by MCNP were manipulated with a processing code, 
TREAT, to give irradiation times, peak dose positions and to display required data in a 
graphical format. Apart from the MCNP dose rates for the different components, TREAT 
was also used to correct for the actual boron concentration. 
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Figure 5: MCNP model of the beagle head phantom (plan view), numbers are cell labels  
Figure 1. 10: MCNP model of the beagle head phantom (coronal view), numbers are cell labels (Watkins 
1992) 
The calculations generated the various dose rates over a mesh that is superimposed on the 
target volume. A simplified shape of a dog head was used as computer model for dog 
irradiations (Fig. 1.10). The results from these calculations are presented as depth dose 
distributions along the central axis of the model (cell 54, Fig. 1.10, Fig. 1.11). The scheme 
used was with a single portal. In the calculations the incident gamma field was assumed to 
be uniform at 1 Gy h-1 over the whole target volume. MCNP calculated gamma-ray dose 
rate induced in tissue amounted to about one Gy h-1. Although these calculations have been 
performed in a dog phantom with the old beam configuration, 10 instead of 2 degrees of 
divergence, SSD: 0 versus 30 cm and an angulated PDD they are in reasonable agreement 
with the measured gamma-ray dose rates in 15*15*15 cm3 water phantom at the thermal 
fluence maximum reported in section 1.3.4.2. At 2.25 cm depth, thermal neutron fluence 
rate amounted to 6.7 108 nth cm-2 s-1. The results from MCNP/TREAT calculations were 
usually displayed as tables of the different dose components at specified positions or line 
graphs, as shown in table 1.2 and figure 1.11. The MCNP beagle head model has been used 
50  Chapter 1 
for the planning of the different irradiation experiments as well as for calculation of the 
actual dose for each individual dog. The dose rates at a specified depth in tissue and dose 
distributions obtained have subsequently been used as basis for the translation of BNCT 
into X-ray equivalent dose using the respective biological weighting factors (chapter 5 
 7). Throughout this thesis, the term physical dose will be used for absorbed dose and the 
term equivalent dose for X-ray equivalent dose, i. e. the dose that produces the same effect 
in tissue as the X-ray dose referred to. 
 
Table 1. 2: Beam characteristics calculated by MCNP for cell 54 in the beagle head model at a homogeneous 
10B concentration of 50 µg g-1. 
Depth 
[cm] 
10B 
(50 µg g-1) 
[Gy/h] 
N(n,p) 
[Gy/h] 
Fast n 
[Gy/h] 
Gamma
[Gy/h]
inc. 
Gamma
[Gy/h] 
total 
gamma
[Gy/h]
Other 
[Gy/h]
Total 
[Gy/h] 
nth 
[cm-2 h-1] 
0.25 
0.75 
1.25 
1.75 
2.25 
2.75 
3.25 
3.75 
4.5 
5.5 
6.5 
7.5 
8.5 
9.5 
3.26 
5.96 
7.76 
8.66 
8.82 
8.92 
8.46 
8.08 
7.06 
5.33 
3.80 
2.57 
1.36 
0.59 
0.11 
0.20 
0.27 
0.30 
0.30 
0.31 
0.29 
0.28 
0.24 
0.18 
0.13 
0.09 
0.05 
0.02 
1.21 
1.03 
0.85 
0.71 
0.62 
0.52 
0.36 
0.29 
0.20 
0.11 
0.08 
0.05 
0.04 
0.03 
0.52 
0.73 
0.90 
1.13 
1.12 
1.01 
1.11 
1.12 
1.12 
0.93 
0.82 
0.60 
0.42 
0.32 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.52 
1.73 
1.90 
2.13 
2.12 
2.01 
2.11 
2.12 
2.12 
1.93 
1.82 
1.60 
1.42 
1.32 
0.06 
0.11 
0.15 
0.17 
0.18 
0.18 
0.17 
0.16 
0.13 
0.10 
0.08 
0.06 
0.03 
0.01 
6.16 
9.03 
10.93 
11.97 
12.04 
11.94 
11.39 
10.93 
9.75 
7.65 
5.91 
4.37 
2.90 
1.97 
8.989E+11
1.625E+12
2.141E+12
3.398E+12
2.429E+12
2.408E+12
2.301E+12
2.170E+12
1.891E+12
1.445E+12
1.018E+12
6.739E+11
3.629E+11
1.593E+11
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Figure 1. 11: MCNP calculated depth dose distribution along the central axis (cell 54) in tissue at a 
homogeneous 10B concentration of 50 µg g-1 
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Binary systems for the treatment of cancer potentially are among the most attractive 
of the new therapeutic modalities that are currently under investigation. Several 
laboratories in Europe, the USA, Asia and Australia are working intensively on a type of 
radiotherapy, called neutron capture therapy (NCT). Boron neutron capture therapy 
(BNCT) is the binary system that has been the subject of this preclinical study on long term 
normal tissue damage in brain. It combines external and internal radiotherapy, theoretically 
allowing the selective delivery of high linear energy transfer (LET) radiation to tumors 
while at the same time sparing surrounding normal tissue. 
Currently, nuclear reactors are the primary source of neutrons for BNCT. The radiation 
produced from the nuclear fission reaction within the reactor core is a mixture of gamma-
rays, fast or high energy neutrons, and lower energy epithermal and thermal neutrons. The 
poor penetration properties of thermal neutrons have led to the development of specially 
filtered beams with a large epithermal neutron component. Epithermal neutron beams have 
a greater depth of penetration and should therefore be clinically more effective than 
thermal neutrons in destroying more deep seated tumors. They allow treatment of tumors at 
depth without resorting to intraoperative techniques of radiotherapy. However, because of 
the past failure of BNCT, which was mainly due to a poor non selective compound, the re-
initiation of clinical trials of BNCT is to be done with great care. Two aspects need to be 
considered especially. These aspects concern the safety and the efficacy of BNCT. The 
effectiveness of a treatment modality (therapeutic gain) mirrors the difference between the 
observed benefit (i.e. tumor control) and risk (i.e. damage to normal tissue). The 
conceptual efficacy of BNCT on tumor tissue has been shown in numerous studies (for 
example: Clendenon et al. 1989, Coderre and Rubin 1994). True efficacy studies of the 
BNCT modality on glioblastoma or other human malignancies require human clinical 
trials. However, such an approach must be dictated by the over-riding aspect of inflicting 
minimal harm to healthy tissue. Therefore, a dose escalation study can proceed only very 
carefully, and in small increments. It must allow enough time for possible late tissue 
damage to develop before the dose can be increased. For glioblastoma with its short 
median survival time, the response of healthy brain to the treatment might therefore not be 
seen, especially with the lower doses.  
The use of epithermal neutron beams for treatment of deep-seated tumors presents a very 
heterogeneous radiation field. Technically unavoidable radiation doses are delivered by the 
Scope of the present study  65 
 
beam itself. Others, like the neutron capture reactions in hydrogen and nitrogen, induced 
within the target volume are unavoidable, but indirectly related to the boron capture dose. 
The efficacy of BNCT depends greatly on the amount of additional dose that a given beam 
can deliver to a boron-enriched volume by the boron neutron capture reaction. From the 
physical and biological aspect of BNCT it must be concluded that safety and efficacy of a 
given treatment modality for BNCT can only be determined experimentally. The 
contaminants in an epithermal beam have very different LET and different biological 
effectiveness. The relative contribution of the various radiation components changes with 
depth in tissue. The biological effect associated with the physical dose delivered to healthy 
tissue from the neutron capture reaction of a boronated substance is dependent on the 
microdistribution of the compound in that tissue.  
Healthy tissue tolerance studies have been initiated in animals to investigate late effects in 
normal brain tissue to BNCT. While induced tumors in rodents are often used to study 
tumor response, the total body dose accompanying BNCT, severely limits their use for 
normal tissue tolerance studies with epithermal neutron beams. The size of a dogs head 
enables the complex dosimetric variables to be approximately matched to that found in 
human radiation therapy. The use of large animals, primarily dogs, to study the effects of 
BNCT permits the estimation of late normal tissue tolerance in the tissues exposed at an 
acceptable total body dose. The dog brain has been used as a model for radiation effects in 
the human central nervous system (CNS). With conventional photon irradiation the 
induced changes as a function of dose, time, volume and other factors closely resemble the 
changes that occur in human patients (Fike and Gobbel 1991). 
The aim of this investigation was to estimate the tolerance of normal brain to BNCT as a 
prerequisite for glioma patient treatment. Late effects to boron neutron capture irradiation 
were studied in canine healthy brain tissue. Animals were irradiated at the epithermal 
neutron beam (HB11) of the High Flux Reactor (HFR) in Petten, The Netherlands. The 
dose-response relationship for different radiation doses and boron concentrations were 
investigated after systemic application of borocaptate sodium (BSH) as the neutron capture 
agent. Materials and methods as well as the observed effects are described in chapter 3. 
Dose-fractionation effects within this mixed radiation field were studied in a limited 
number of animals (chapter 4).  
66  Chapter 2 
The presence of various dose components with different radiation transport characteristics 
poses a unique problem to the dosimetry and treatment planning of BNCT. Numerous 
researchers are investigating the large and complex field of translation of physical doses 
into biologically equivalent doses. Treatment planning for clinical trials with BNCT is 
complicated by the fact that the radiation field generated by the activating external neutron 
beam is composed of several different types of radiation, i.e. fast neutrons, recoil protons 
from elastic collisions with hydrogen, protons from nitrogen capture, and the products of 
the NCT interaction. Furthermore, the relative contribution of each type of radiation varies 
with depth in tissue. Because each type of radiation has its own relative biological 
effectiveness (RBE), and the RBE of the fast neutron component will not be constant as the 
neutron spectrum changes with depth, the problem of predicting the severity of the 
biological effect in depth becomes very complex. No overall RBE factor can be assigned to 
this kind of treatment. The major problem of this study was that only overall-effects could 
be detected. Based on the assumption that radiation effects of every single radiation quality 
involved behave additively, three different dose description models have been worked out.  
Due to the fact that experimental data were lacking for the healthy tolerance study at the 
HFR using BSH, the initial dose planning involved deduction of essential parameters from 
a similar study being carried out in the US. The RBE and a so-called compound factor 
values for BSH in brain tissue had to be deduced from skin effects in four dogs irradiated 
at the Brookhaven Medical Research Reactor (BMRR). Chapter 5 deals with the results of 
this analysis, giving a dose response relationship based on derived factors. The second 
approach (chapter 6) based on the data of the present study, involves mathematical 
modeling with the RBE and compound factor value as two independent variables. This 
model results in a range of values for the proton RBE and compound factor of BSH after 
systemic application of BSH. The third approach to describe dose effects to tissue after 
boron neutron capture irradiation is the combined analysis of two independent studies on 
dogs, which is presented in chapter 7. By evaluating the effects in dogs irradiated with the 
BMRR epithermal neutron beam only, a combined RBE for protons was derived and a 
compound factor for BSH could be extracted. Finally the results of this thesis are discussed 
in a wider context in chapter 8 along with their implications for the treatment of brain 
tumor patients with BNCT using an epithermal neutron beam. 
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3.1 INTRODUCTION 
The conventional treatment of cancer is comprised of three modalities: surgery, 
radiotherapy and chemotherapy or a combination of these. Radiotherapy is very effective 
for a number of tumors. However, several tumors are resistant to conventional 
radiotherapy. Several laboratories in Europe, the USA, Asia and Australia are currently 
working on a radiotherapy, called boron neutron capture therapy (BNCT). With this 
bimodal treatment modality, each component induces only minor effects in healthy cells 
when exposed to it separately. The first component is a stable isotope of boron (10B) that if 
the right carrier molecule is used can be concentrated in tumor cells. The second 
component is low energy (thermal) neutrons. BNCT is based on a nuclear reaction between 
these components. When a nucleus of 10B captures a thermal neutron, it becomes unstable 
and instantly decays, yielding a lithium nucleus (7Li) and an α-particle. These particles, 
which carry 2.79 MeV of energy, have a short range in tissue, in the order of about one cell 
diameter and cause dense ionization events. These events can break chemical bonds 
thereby destroying essential molecules, which again can lead to cell death or inhibition of 
cell proliferation. 
In the course of the joint project of the European Union towards realization of a clinical 
facility for treating patients with BNCT, an epithermal neutron beam has been developed at 
the High Flux Reactor (HFR) in Petten. This facility has been designed for use in treating 
more deep-seated brain tumors such as glioblastomas and astrocytomas through the intact 
skin (and skull). The goal of healthy tissue tolerance studies prior to clinical trials is the 
estimation of tolerance of the normal tissue, such as brain, skin and bone marrow to 
BNCT. As at the time, no data for brain damage after epithermal beam only irradiation 
were available, data of the ongoing US BNCT study in combination with literature were 
used to establish dose groups for the Petten facility (see Chapter 5). In this preclinical 
study, normal beagle dogs were used, infused with borocaptate sodium (BSH) and 
irradiated at the epithermal neutron beam (HB11) of the HFR in Petten. Biological 
endpoints of this study were detectable brain lesions on contrast enhanced magnetic 
resonance imaging (MR) and neurologic symptoms due to white matter necrosis. 
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3.2 MATERIALS AND METHODS 
3.2.1 Animals 
All experiments have been performed on normal female beagle dogs supplied by 
Harlan CPB, The Netherlands. The animals had been dewormed (Panacur®, Hoechst) and 
vaccinated against parvovirosis, rabies, distemper, hepatitis contagiosa and parainfluenza 
(Nobivac®, Intervet). There were no clinical signs of sickness in any of the dogs and the 
age of the dogs at the start of the experiment varied between two to six years (most of the 
animals were irradiated at the age of two to three years). They were housed in groups in the 
animal facility (Gemeenschappelijk Dieren Instituut, GDIA) of the Academisch Medisch 
Centrum Amsterdam and fed separately once per day with a commercially available pellet 
feed (Hope Farms D.B.). Water supply was ad libitum. The dogs were under daily 
observation. Specific extensive examinations on the animals were performed prior to 
irradiation, at about four weeks, two months, four months, six months and one year 
post-irradiation and whenever clinically indicated. These examinations included complete 
physical and neurologic examination with blood cell counts, serum chemistry analyses, 
magnetic resonance imaging (MR) and whenever lesions were found in MR, protein 
analysis of cerebro-spinal fluid (CSF). 
Tattooed numbers, on the left ear of each individual dog, were used for identification of 
particular animals. Dogs were randomly allocated to the different dose groups. Whenever 
the animals had to be transported (irradiation facility in Petten, MR scans in Utrecht) they 
were not fed for at least 12 hours, weighted and put in cages usually used for transporting 
animals by plane (Sky Kennel®). These cages were carried to a mini-transporter and 
shipped. The study has been elaborated in close contact with Dutch institutional animal 
care and use committees, such as the local ethical committee for use of animals in research 
and the ministerial veterinarian inspection. 
3.2.2 Boron compound  
10B-enriched (95.6 %) borocaptate sodium (BSH), supplied by Centronics, served 
as the boron carrier. The compound had been checked for mercury contamination (< 10 
µg g-1). BSH solution was freshly prepared on the day of irradiation. The extremely 
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hydrophilic white salt was delivered in sealed vials à 1g. The content of one vial was 
quantitatively washed out with 2 ml saline and subsequently filter sterilized. An amount of 
this stock solution, equivalent to 25 or 50 mg 10B kg-1 bodyweight, was dissolved in 11 ml 
0.9 % NaCl solution kg-1 bodyweight, checked for the actual 10B content by prompt 
gamma-ray analysis (PGRA) and infused prior to irradiation via a peripheral vein using an 
infusion pump over a time period of 60 minutes. 
At the start of the study no information was available on pharmacokinetics of BSH in 
beagle dogs. Therefore a pilot study was performed on four dogs. Two dogs received an 
one hour infusion with 25 mg 10B kg-1 bodyweight (dog no. 517 and 790) and two 50 mg 
10B per kg bodyweight (dog no. 480 and 491). All four dogs were sedated for infusion 
(ketamine, xylacine). Blood samples were taken with increasing time intervals up to 45 
hours post infusion and subsequently analyzed for boron with both PGRA and inductively 
coupled plasma - atomic emission spectroscopy (ICP-AES).  
3.2.3 Boron analysis 
At the HB 7 of the High Flux Reactor near the irradiation facility of HB 11 a 
prompt gamma-ray analysis (PGRA) system had been installed. This location, together 
with the relatively fast acquisition time of PGRA and the simple sample preparation, made 
an almost on-line measurement of the blood 10B content possible before and during 
irradiation. For a measuring time of 5 minutes and a sample volume of 1 ml, the accuracy 
in 10B concentration amounts to 1 µg g-1 (1 SD) in the range of 1 to 100 µg g-1, which is the 
interval of experimental (and clinical) interest. PGRA is a method for measuring the 10B 
content of a sample based on the BNCT nuclear reaction: 10B + n ⇒ 7Li + 4He + γ, and 
therefore allows a direct measurement of the 10B isotope concentration. When a sample, 
containing a homogeneously distributed amount of 10B, is irradiated with thermal neutrons, 
a measurement of the emitted 478 keV gamma-rays, e.g. by means of a Ge detector, yields 
the 10B content (Raaijmakers et al. 1995). 
PGRA is not sensitive enough for small samples of tissue. In this project inductively 
coupled plasma-atomic emission spectroscopy (ICP-AES), as another boron analysis 
technique has been used to first cross calibrate with PGRA and secondly to enable a more 
exact measurement of the boron content in a sample. ICP-AES is a destructive method, 
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which requires complete digestion of a sample. Biological samples were digested for 15 
minutes in a pressure controlled microwave (CEM MDS-81D) operating at maximal 630 
watts. An acid mixture composed of 90 % nitric acid (HNO3 65 % suprapur, Merck 
Chemical), 5 % perchloride acid (HClO4, 68 % suprapur, Merck Chemical), 5 % 
hydrofluoric acid (HF 38 %, Merck Chemical) was used. Before digestion 0.5 ml of a 40 
mg kg-1 cobalt solution in 0.1 M HNO3 was added to the samples as recovery standard. 
After digestion the acid volume was four times diluted with de-mineralized and de-ionized 
water, and 0.5 ml of a 40 mg kg-1 yttrium solution in 0.1 M HNO3 was added as an internal 
standard for the ICP-AES spectrometer. A Jobin-Yvon JY plus ICP-AES (Instrument S.A. 
Longjumeau Cedex, France) was used for all measurements. This method has an 
uncertainty of 0.05 µg g-1 (1 SD) for a sample volume of 30 mg. 
Since the knowledge of the 10B concentration is of vital importance for BNCT, the 10B 
content of the blood has been monitored almost on line by PGRA. Blood samples were 
taken at frequent time intervals (about every 20 minutes) from the vena jugularis and 
immediately analyzed for 5 minutes. Sampling frequency was increased the closer the 
blood 10B content was to the prescribed level. Samples in the reactor hall were taken from 
a peripheral vein in order to not affect the positioning of the head. One sample was taken 
right before the beam shutters were opened and the last sample just after the end of 
irradiation. To be able to follow the decrease of the boron concentration in the blood as 
close as possible, irradiation was interrupted half way for taking an additional sample. 
The average 10B concentration in blood during irradiation and the elimination half-life in 
each individual dog have been determined by fitting the data (about 12 data points per dog) 
to a one compartment (single exponential decay) as well as a two compartment (bi-
exponential decay) pharmacokinetic model. The data points were weighted by their inverse 
value in order to reduce the influence of data points obtained at small time intervals. 
The10B concentration during irradiation has been obtained from the integral of the fitted 
curve over the irradiation time. Mean blood 10B content was also calculated by using the 
formula: ((A-B)/2+(B-C)/2+B+C)/2, where A is the 10B concentration right before opening 
of the beam shutters, B the value obtained from the blood sample collected half way, and C 
the blood 10B concentration at the end of irradiation. 
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3.2.4 Irradiation  
Prior to irradiation a dose of 1 mg kg-1 bodyweight dexamethasone (Dexaline®) was 
injected intravenously to avoid acute brain edema. During irradiation dogs were kept under 
general anesthesia and monitored using an electro-cardiograph (ECG). Each animal was 
pre-positioned outside the irradiation area on a specially designed table using a positioning 
device, which represented the center and the outer rims/margins of the original beam  
(Fig. 3.1). The circular beam opening was centered over both hemispheres of the dog's 
brain. Laying on the left side, its head was aligned to the beam, supported by foamrubber 
wedges and fixed with tapes to avoid any movement. In front of the actual beam, 
positioning was checked using a laser set up (Fig. 3.2). 
Figure 3. 1: Photo of a dog at the pre-positioning 
device showing a gray foam rubber wedge, the tape 
for fixation of the monitor set with the center of the 
head marked and the circular outline of the beam.  
Figure 3. 2: Photo of laser set up in irradiation position for 
accurate positioning. 
 
As soon as the blood B10 concentration approached the prescribed level, beam shutters 
were opened and irradiation was started. Irradiation time was kept constant within each 
dose group and varied between 76 and 132 minutes (Table 3.1). To take an additional 
blood sample for boron analysis and check the dog's condition, irradiation was interrupted 
half way for approximately five minutes. 
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Neutron beam irradiations were performed at two different mean blood 10B concentrations: 
25 and 50 µg g-1. A group of three dogs received the epithermal neutron irradiation alone. 
At each boron level up to five dose groups were investigated, where the groups are defined 
by peak physical dose (Table 3.1). Every irradiation with respect to time, reactor power, 
on-line measurements, dog number, 10B concentration, etc. was recorded and written in the 
log-book of the irradiation facility and on data sheets for the dog's file. 
3.2.5 Neutron monitoring 
The standard neutron measurement is that of a stack of resonance and threshold 
foils, which was positioned at the beam center immediately on exit from the final aperture. 
The foils are responsive to the thermal, low epithermal and fast neutron energies. 
For actual neutron dose measurements at different points for individual dogs manganese-
nickel, copper and gold-aluminum foils were used in two different sets. The sequence of 
foils in set A, which was positioned on the top of the dog's head (center of the beam), was 
from the reactor side AuAl (1%Au; 99%Al), Cu and MnNi (88%Mn;12%Ni). Set B just 
contained a gold-aluminum foil and was used as monitor in all other positions. Reaction 
rates have been measured for the reactions: 197Au(n,γ)198Au, 63Cu(n,γ)64Cu, and 
55Mn(n,γ)56Mn. The main resonance energies for the three reactions are at 4.9 eV, 337 keV 
and 580 keV, respectively. Ratios of foil activation were evaluated as these give some idea 
of the consistency of the spectrum of the beam. The Mn foil activation is essentially due to 
thermal neutron absorption, the Au activation is epithermal and the Cu activation 
intermediate between thermal and epithermal. Note that in this case referring to Au as an 
epithermal absorber has to be qualified since virtually all of the activation derives from 
absorption of neutrons of energies below 10 eV. Traditionally in BNCT the epithermal 
range is from 0.414 eV to 10 keV, so the Au foil really only gives information on the very 
lowest energy part of the epithermal region. 
The foil sets were encapsulated in rice paper and placed between two pieces of yellow 
electrical tape (Scotch®). The sets were attached to the dogs with tape at the following 
positions: 1. top/center of the head (center of the midline indicated by the crista sagittalis 
ext. and the fossa frontalis between the protuberantia occipitalis ext. and a line drawn 
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Table 3. 1: Individual doses and in vivo detectable brain reactions. 
 projected dose group    MCNP brain reaction 
blood 10B 
conc.  
[µg g-1] 
peak 
phys. dose 
[Gy] 
irrad. 
time 
[min] 
dog 
no. 
Actual/mean 
blood 10B 
conc. [µg g-1]  
calculated peak 
physical dose* 
[Gy] 
MR 
contr. 
enhanc. 
lesion 
lethal 
white 
matter 
necrosis
50 15 76 638 
661 
667 
765 
42.9 
39.7     45.7 
48.8   (± 5.4) 
51.4 
13.7 
13.0      14.3 
15.0    (± 1.2) 
15.6 
0 
0 
0 
0 
0 
0 
0 
0 
 17 86 491 
494 
517 
614 
845 
53.3 
58.8     54.3 
44.8   (± 5.4) 
58.3 
56.2 
18.1 
19.5      18.3 
15.9    (± 1.5) 
19.4 
18.8 
+ 
+ 
+ 
+ 
+ 
0 
0 
0 
0 
0 
 19 96 516 
627 
778 
790 
803 
47.0 
52.0     49.7 
47.6   (± 5.1) 
45.0 
50.7 
18.4 
19.8      18.8 
18.6    (± 0.8) 
17.8 
19.5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
0 
 21 106 504 
518 
573 
763 
976 
62.3 
50.2      49.6 
50.4    (± 8.7) 
46.9 
38.0 
25.1 
21.3      21.1 
21.4    (± 2.7) 
20.3 
17.5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
25 9.5 76 659 
660 
764 
817 
26.4 
25.0      25.3 
25.6    (± 0.9) 
24.3 
10.0 
9.7         9.8 
9.8      (± 0.2) 
9.5 
0 
0 
0 
0 
0 
0 
0 
0 
 12 96 561 
665 
813 
832 
29.4 
26.2      25.8 
24.1    (± 2.7) 
23.3 
13.4 
12.6      12.5 
12.0    (± 0.7) 
11.8 
0 
0 
0 
0 
0 
0 
0 
0 
 13.5 108 180 
480 
637 
644 
773 
25.4 
24.1     24.5 
23.1   (± 1.0) 
25.5 
24.2 
13.9 
13.5      13.6 
13.2    (± 0.3) 
13.9 
13.5 
0 
+ 
+ 
+ 
0 
0 
0 
0 
0 
0 
 15 120 467 
626 
812 
820 
20.6 
27.9      25.1 
26.5    (± 3.2) 
25.3 
13.8 
16.2      15.3 
15.8    (± 1.1) 
15.4 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 16.5 132 1059
1283
0118
29.1 
29.3      27.8 
25.3    (± 2.2) 
18.4 
18.5      17.9 
16.9    (± 0.9) 
+ 
+ 
+ 
+ 
+ 
+ 
0 6.2 116 535 
643 
760 
0 
0 
0 
6.4 
6.4 
6.4 
0 
0 
0 
0 
0 
0 
* obtained by Monte Carlo calculation (MCNP), assuming a uniform distribution of 10B (see Chapter 1) 
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through both eyeballs), 2. right supraobital region, 3. intraoral part of the tubus, 4. rear of 
the skull (just caudal of the protuberantia occipitalis externa), and 5. thyroid gland. 
The reaction rates have been corrected for decay during the interruption of irradiation. No 
corrections have been made for fluctuations of the reactor power during irradiation. 
Nevertheless, the deviation of the reactor power from 45 MW was less than 1 percent 
during the experiments. The consistency of the measurement can be demonstrated by 
comparison of the spectrum indices measured for the foil set at the top of the head. 
Especially the variation in the index Mn/Cu gives an indication of the reproducibility of the 
measurements.  
3.2.6 Gamma-ray monitoring 
The incident photon component has been measured using thermoluminescent 
dosimeters (TLD) placed at the same position as the foil sets. For monitoring the gamma-
ray dose to the dogs three TLDs were used per position. They were enclosed in small 
transparent plastic bags and stuck with tape at various positions on the dog: 1. top/center of 
the head, 2. intraoral part of the tubus, 3. thyroid gland, 4. regio interscapularis, and 5. 
abdomen at the last but one mamma complex, right teat. The TLD crystals consisted of 
LiF, enriched in 7Li (type 700 from Harshaw, 0.007% 6Li) in order to reduce the response 
to thermal neutrons. 
3.2.7 Beam monitoring  
During irradiation five beam monitors were read out for 30 seconds over 1 minute 
intervals. The main monitor, giving an indication of the intermediate (epithermal) neutron 
fluence rate, was a Cd covered 235U fission counter positioned in the large collimator 
behind the main beam shutter tangential to the conical collimator. In front of the collimator 
two Geiger-Müller (GM) counters were positioned above (top) and below (bottom) the 
collimator opening. The fast neutron fluence rate (neutron energies above 1 MeV) could be 
monitored with a 237Np fission counter placed into a parallel hole at the top of the large 
collimator. Beside these four monitors a thermal neutron detector, made of a np-silicon α 
semi-conductor detector with a lithium disk manufactured by the Czech Technical 
University, was positioned in the beam port in the last polybor plate. 
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3.2.8 Monte carlo calculations 
An MCNP model of a dog head (Fig. 1.10) was contrived to evaluate the expected 
doses imparted by irradiation. Various dose components occurring with BNCT were 
estimated on the basis of these computer model calculations. The model included a 
representation of the beam geometry including the beam shutter assembly, part of the 
irradiation room and the polymethylmethacrylate (PMMA) dog phantom itself. The model 
was extended to include the activation foil pack at the center of the beam and thereby 
calculate the foil activations directly. The foil pack was represented explicitly in the 
MCNP model with realistic geometrical dimensions and material compositions. In this 
MCNP model the HB11 beam is represented as a neutron source with a fixed intensity, a 
neutron energy spectrum and a simple angular spread. 
3.2.9 Anesthesia  
Animals were kept under general anesthesia for irradiation and magnetic resonance 
imaging (MR) to avoid stress reactions and any movements on the part of the dogs. The 
animals did not receive food for at least 12 hours before induction. Induction of anesthesia 
was done by the intra venous (i.v.) injection of about 0.8 ml kg-1 bodyweight of Methadone 
(methadon HCL 10 mg ml-1 by AUV Cuijk Holland) in combination with circa 0.3 ml kg-1 
bodyweight Acepromacine (Vetranquil® by Albrecht). The amount of anesthetics was 
adapted to the susceptibility of each individual dog to the drugs. Inhalation anesthesia with 
1 - 2 % Isoflurane (Forene®) in an oxygen and nitrous oxide mixture (1:2) was used for 
maintenance. Ventilation was controlled by a respirator. A CO2- Monitor (Carpnograph) 
was used for control of anesthesia with the MR scans, and with the irradiations an 
electrocardiograph (ECG) was available. Animals were connected to an intravenous 
infusion with 0.9 % NaCl solution during the MR scanning procedure. Each anesthesia was 
recorded in detail on a protocol form. 
3.2.10 Recording skin reaction  
Animals were observed daily by professional animal caretakers and checked 
regularly for skin reactions. Findings were recorded in writing, sketching and photographs. 
The items recorded were: color of the skin, pigmentation, onset of epilation, degree of 
epilation, size of the area involved, onset of hair regrowth, color of re-grown hair, degree 
of hair regrowth, presence of scales, exudation, and/or ulceration. 
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Table 3. 2: Numerical grading system for radiation induced skin reaction and X-ray refercence dose 
acute skin reaction  X-ray reference dose (Park et al 1974) 
0           no observable changes 
1           erythema 
2           dry desquamation 
3           moist desquamation 
4           ulcers / skin loss 
  
6.1   Gy 
12.2 Gy 
18.3 Gy 
> 24.4 Gy 
chronic radiodermatitis (stable after 120 days)   
0           no observable changes 
1           graying of hair but good hair growth 
2           graying of hair but thinning hair growth
3           epilation and atrophy 
4           recurrence of chronic ulcers 
  
6.1   Gy 
12.2 Gy 
18.3 Gy 
> 24.4 Gy 
A numerical grading system for skin reactions (Table 3.2) was developed based on a 
scoring system described by Park et al. (1974) for Beagles to be able to judge skin damage 
qualitatively. The skin scoring system was used to judge on the degree of skin involvement 
in the radiation reaction. Since there was no strict dose-effect relation and no serious 
reaction in the sense of a dose limiting factor, the system was used just as course control 
protocol for skin reaction. 
3.2.11 Blood parameters  
Blood samples were taken at least two times before irradiation and frequently 
within the four weeks following irradiation. Since cell counts then were normally back to 
pretreatment levels sampling was continued with much larger intervals. To get an 
indication of the whole body dose or the dose to bone marrow, blood samples of about  
1 ml were taken from the vena jugularis, filled in heparinized vials and prepared for cell 
counting.   
For white blood cell counts (WBCC) blood was mixed in a leucocyte-pipette with Türk's 
solution and shaken. The mixture was filled in a hemocytometer and after sedimentation 
the white blood cells were counted by hand using a microscope. Determination of 
differentials was done in smears stained according to Pappenheim. For the red blood cell 
count (RBCC) blood was mixed in a erythrocyte-pipette with Hayem's solution and 
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shaken. The mixture was filled in a hemocytometer (Neubauer) and erythrocytes were 
counted by hand using a microscope. 
The packed cell volume (PCV) gives the percentage of red blood cell mass in the whole 
blood. It depends on one hand on the volume of erythrocytes and on the other hand on the 
plasma volume. The blood was drawn in a heparinized PCV-capillary, sealed in with 
special cement and spun for 6 minutes in a micro-hematocrit centrifuge. Readout was in 
percentage by the aid of a Hawksley micro-hematocrit reader. 
For analysis of hemoglobin (Hb), 5 µl blood were diluted in 1000 µl reaction solution 
(2.2 mmol l-1 phosphate buffer, 0.6 mmol l-1 potassiumhexacyanoferrat (III), 1 mmol l-1 
potassium-cyanide, 1.5 mmol l-1 NaCl, 0.05 % detergent). The resulting Hb-cyanide was 
measured versus a control by a photometer (CompurR M 2000 S/CS). Different indices 
were calculated i.e. mean corpuscular hemoglobin concentration (MCHC=Hbx100/Htc), 
mean corpuscular hemoglobin (MCH=Hbx10/number of erythrocytes) and mean 
corpuscular volume (MCV=Htcx10/number of erythrocytes). 
For analysis of blood chemistry (mainly liver enzyme screening), about 4 ml of blood were 
taken and spun for 10 minutes with 3000 rpm (1400 - 1500 G). Serum was carefully taken 
of, filled in 2 ml Eppendorf vials and stored in a freezer. Samples were analyzed in batches 
photometrically for alanine amino transferase (ALAT), alkalic phosphatase (AP), aspartate 
amino transferase (ASAT), creatinine, gamma glutamyl transferase (γ-GT), protein (total) 
and urea. Since these parameters were not effected in the dogs by the experimental 
procedure analysis was terminated. 
3.2.12 Recording brain response 
CSF (cerebro spinal fluid) samples were taken along with the main checks while 
the dogs were still under general anesthesia from the MR scanning. The neck of the dog 
was bent so that the foramen atlanto-occipitale was easily accessible. Hair was shaved and 
skin disinfected with alcohol. Special disposable CSF needles (22 G 1½ // 0.7 x 40 Yale 
spinal needle, Becton-Dickinson) were used for puncture and inserted pointing to the top of 
the dog's heart. The mandrain was pulled out and about 25 CSF drops collected in glass 
tubes. Samples were frozen and analyzed in batches for higher reproducibility. Protein 
content was determined photometrically following the Biuret method (1000 µl liquor and 
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100 µl Biuret concentrate). Later, CSF samples were only taken if indicated by changes 
seen in the MR scans. 
MR. Magnetic resonance imaging was used as a non-invasive method to record brain 
response. Scans went along with the main checks before irradiation as control and within 
the first two weeks, 2 months, 4 months, 6 months and one year post irradiation. Since the 
first MR scans directly after irradiation had been negative even in the high dose range 
dogs, the first post-irradiation MR procedure was subsequently skipped in order to reduce 
stress on the animals. Additional checks and MR scans were performed whenever clinical 
signs of neurologic damage occurred. 
Dogs were transported from Amsterdam to Utrecht, prepared (shaved, vein catheter, 
infusion line with saline, induction of anesthesia) in the preparation room at site and 
positioned under general anesthesia in dorsal recumbence in a halve pipe. The head was 
aligned in a specially designed Teflon cradle for symmetry. The whole preparation and 
scanning procedure took about one hour per animal. 
MR scans were obtained using the system of the "National in vivo NMR facility" at the 
Bijvoet Center for Biomolecular Research in Utrecht, The Netherlands. The basis of the 
system was a SISCO 200 MHz (4.7 Tesla) NMR spectrometer equipped with a horizontal 
cryomagnet (Oxford Instruments) with a clear bore up to a maximum of 40 cm. The 
machine had an active shielded gradient of 18 mT m-1 and is tailored for in vivo MR 
imaging and spectroscopy experiments with different nuclei. For evaluation and processing 
of data a computer network was available based on four SUN graphical workstations with 
3 GB disc storage and an extensive software library. The system was linked to the NMR 
spectrometer. 
Images of the dogs' heads based on hydrogen proton spectroscopy were obtained. A 
sagittal median slice was used as localizer to be able to delineate the image slices desired 
for each pulse sequence series. Axial images were obtained using a spin-echo sequence in 
a multi-slice technique with a slice thickness of 5 mm and no gap (slice selection pulse: 
SINC 5 ms, slice selection gradient: 4.5 mT m-1). Magnetic resonance imaging was 
performed pre and post administration of the paramagnetic contrast medium gadolinium-
DTPA-dimeglumine (Magnevist®, Schering AG, Berlin, Germany). Predominantly T2 
weighted images were acquired with an echo-time (TE) of 60 ms and a repetition-time 
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(TR) of 1000 ms. For T1 weighted images a TE of 30 ms and TR of 800 ms were used. 
The T1 weighted images were repeated 2 minutes after intravenous administration of 0.1 
mmol kg-1 bodyweight Gd-DTPA (0.2 ml Magnevist®/kg) via the infusion line. Data 
obtained were stored on exabite tape and images photographed for evaluation. 
Clinical recording. During daily observation changes in behavior, liking for water and 
feed, urination, defecation and changes in the ability to move properly were checked. All 
animals underwent regular physical and neurologic examinations. Physical examination 
was mainly performed to exclude other reasons for neurological symptoms than radiation 
and to record the radiation induced damage of other tissues than CNS. These checks 
included the control of major organ systems and their function like the respiratory tract, the 
cardiac and vascular system, skin, intestines and abdominal organs as far as possible, eyes 
and ears and peripheral lymphatic nodes. Observations were recorded in writing. 
Neurological examinations included testing of reflexes, proprioception and coordination. 
Eyesight and ability to hear were controlled as well as sensitivity and abnormal bearing or 
posture. Observations were recorded on neurologic examination forms. 
Pathology. At the end of the observation period of 1 - 2 years or when severe neurological 
symptoms had occurred, the animals were injected intra muscular with 1 ml of ketamine 
(Nematek®) in combination with 1 ml xylacine (Rompun®) for sedation. Subsequently, 
they were killed by an intravenously injected overdose of barbiturates (Euthesate®). The 
head was detached at the atlanto occipitale joint. The scalp was reflected and sampled. The 
scull was opened by three saw cuts and carefully removed following removal and sampling 
of the musculi temoporales. Brain nerves and pituitary stem were severed. The entire brain 
was removed avoiding any compression and the surface judged as a whole for 
configuration, symmetry, color etc. The complete organ was stored in 10 % formaldehyde 
for a few days. Gross section was done following a standard protocol except for the pelvis, 
which was usually not opened. Tissue samples were taken and fixated in 10 % 
formaldehyde. Findings were recorded in writing and photographs or sketching whenever 
indicated. 
Histology. Histological slides of tissues were prepared by standard techniques and stained 
with Hematoxilin-Eosin. The brain was cut in about 0.5 cm thick transversal slices and 
allowed to fixate for another few days in 10 % formaldehyde before they underwent 48 hrs 
of dehydration and embedding in paraffin. Slices of 8 µm thickness were mounted on 
slides and stained with Hematoxilin-Eosin and Nissl. Slides were microscopically 
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evaluated and findings recorded in written and location as well as the dimensions of 
damage was indicated on sketches. 
3.2.13 Data processing 
Each individual dog was classified as MR positive or negative and having 
developed white matter necrosis or not. The mean physical dose per group was plotted 
against the fraction of responders per group. Points were fitted with a sigmoidal response 
function (Origin 4.1). 
3.3 RESULTS 
3.3.1 General observations 
The irradiation and post-treatment MR procedures were generally well tolerated by 
all animals. The dogs endured the course of the one hour infusion without having to be 
sedated or moving too much. All individuals were irradiated at approximately the desired 
mean blood 10B concentration. Irradiation times were kept constant within the respective 
dose groups. MCNP calculated peak physical doses are given in Table 3.1. Although there 
were considerable long times of irradiation no anesthesia related problems were observed. 
3.3.2 Boron  
During infusion of BSH some dogs, which received 50 mg 10B kg-1 bodyweight, 
showed a slight indisposition which in one case led to vomiting. Heartbeat was generally 
very hard and strong, but frequency was not obviously altered.  
Cross calibrations between PGRA and ICP-AES have been performed on a regular basis, 
using samples of boric acid and BSH diluted in water. Good agreement has been obtained 
in cross-calibrations using blood samples of a beagle dog in the healthy tissue tolerance 
study. The average PGRA to ICP-AES ratio was 0.99 ± 0.02 (1 SD), using an 10B 
enrichment factor of 95.8 % for the respective batch. No systematic differences were 
detected. Good agreement has been obtained also in the other cross-calibrations. 
Four dogs were used in a pilot pharmacokinetic study and underwent later the standard 
treatment procedure with BHS infusion and irradiation. No differences in the 10B 
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elimination from blood were observed within one animal after different doses of BSH. 
Sedation with the infusion for the pharmacokinetic study or anesthesia with the irradiation 
did not influence the pattern (Fig. 3.3). 
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Figure 3. 3: Pharmacokinetics of 10B in blood of dog 490 after application of 50 µg g-1 (irradiation) and 
25 µg g-1 (pharmacokinetic study) 10B in the form of an 1 hour BSH infusion. Samples were analyzed by 
PGRA 
The deviation of mean blood boron values during irradiation calculated by a formula or the 
fitting procedure was in each case smaller than the accuracy of 1 µg g-1 (1 SD) of the 
PGRA. For most dogs, the bi-exponential decay model resulted in a better fit than the 
single exponential model, due to a more rapid decrease within the first hour. When, 
however, the data points obtained in the first hour were excluded, no significant difference 
was found in the elimination half-life nor in the mean blood boron concentration during 
irradiation, obtained from the fitted curves. The uncertainty in this value, determined from 
the standard error of the fit, amounted to about 0.3 µg g-1 (1 SD). A mean blood 10B 
concentration during irradiation of 25.8 ± 2.2 µg g-1 (1 SD, n=18) and 49.3 ± 5.3 µg g-1 (1 
SD, n=17) has been obtained for the 25 µg g-1 and 50 µg g-1 group, respectively. The 
individual mean blood 10B values are listed in Table 3.1. The mean elimination constant 
has been obtained by averaging the individual elimination constants, determined using the 
one compartment model with exclusion of the data points obtained in the first hour. The 
elimination constants for the two boron groups were not significantly different. The 
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resulting mean elimination half-life was 320 ± 20 minutes (1 standard error of the mean,  
n = 35). No evidence was found in this study for a disruption in the 10B elimination after 
induction of anesthesia. 
3.3.3 Neutron activation foils  
The foils located at all positions other than the beam center were of little use for 
confirming irradiation parameters that are consistent for all dogs. This was due simply to 
the variation in size of the dogs and hence, the foil alignment in the incident beam, was 
different for each irradiation. However, the foil sets at the top-of-the-head position were 
accurately located and were in the same position (center) in the beam for all irradiations. 
Consequently evaluation concentrates on the analysis of those activations from the three-
foil pack in the center-beam position. The other foil sets could possibly be used in future to 
confirm the actual fluences at various organs where they were sited. The reaction rates of 
the foil triplets of the "top of the head" position are saturated values derived from the 
measured raw data by standard methods (ECN report FYS/RASA-89/05, March 1989). 
Manganese means 88 % manganese and 12 % nickel, the copper foil was pure, and the 
gold foil contained 1 % gold in aluminum. The data were not corrected for self-shielding 
effects. The overall statistical errors were 6%, 5% and 3% for the Mn, Cu and Au foils, 
respectively taking all of the foils as sample size. All data fell between ± 2 (approx.) 
standard errors of the mean value. Compared to the values of the other foils sets the 
reaction rates with dog 504 were considerably lower. There were small increases in the Mn 
and Cu activations with time but this trend was not observed for the Au foil. Furthermore, 
the correlation coefficients have been evaluated for the foil activations, Cu/Mn and Au/Mn 
ratios with time. In general the correlation coefficients were close to zero indicating no 
time dependence of the results. The exceptions were for the Mn and Cu foils which 
appeared to increase slightly with time although the dependence was not strong. There was 
some indication that both ratios, the Au/Mn in particular, decreased with time. That is, the 
spectrum became more thermal although this was no significant time dependence. In 
summary, there was no evidence from the measured activation data of any significant 
change in the neutron beam over the period of the healthy tissue tolerance studies. Data 
suggested a slight softening of the neutron spectrum as the study progressed. It had been 
suggested that the foil activation is a function of the mass of the dogs. It was confirmed 
from the evaluation of the correlation coefficient of dog weights with time that there was 
no tendency for the weights to increase during the period of the healthy tissue tolerance 
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study. There were reasons to expect that the foil activations did depend to some extend on 
the size of the dog head since this will influence the backscatter of neutrons to the foils. 
However the experimental data presented here suggests that this effect is insignificant. 
3.3.4 Gamma-ray measurements 
In general TLD data showed no obvious abnormalities. The TLD measurements 
were not corrected for thermal neutron sensitivity. This is however a significant effect. The 
data showed a similar behavior to that of the activation foils, with the TLDs on the center 
beam position providing reasonably consistent values whilst the results from the other 
positions showed large variations. Although Raaijmakers et al. (1996) have determined 
correction factors for the thermal sensitivity of the used TLD, the TLDs were only used as 
check on the consistency of the beam. However, the center beam TLD measurements were 
in good agreement with the MCNP calculated gamma-ray dose component listed in table 
1.3. 
3.3.5 Skin reaction 
Physical skin doses (at 0.25 cm depth in tissue) as calculated by MCNP ranged 
from 5.7 Gy to 10.6 Gy and from 7 Gy to 12.3 Gy for the 25 µg g-1 and the 50 µg g-1 blood 
10B groups, respectively. The zero boron group received a physical dose to skin of 5.6 Gy. 
Erythema, as acute reaction to radiation, was difficult to diagnose because of the dense 
coat and the partially pigmented skin of the dogs. Dark pigment spots occurred in dogs of 
all irradiation groups around the same time as epilation. They tended to fade with time. 
Epilation started at about three weeks post-irradiation with a variation of 19 to 37 days. No 
significant dose dependence could be observed for the time of onset although there is a 
clear tendency to a shorter latency period with increasing dose. Individual times and means 
per group for onset of epilation are given for the 50 µg g-1 boron groups in table 3.3. Over 
all skin changes were within the tolerable margins indicating that skin is not a limiting 
factor for BNCT with the Petten epithermal neutron beam.  
The most severe effect that occurred was minor cases of dry desquamation with almost 
complete epilation (Fig. 3.4) of the irradiated skin field in some dogs. The degree of 
epilation was slightly higher with the higher dose groups, which was also reflected in the 
lower density of the re-growing hair within these groups. Note that hair regrowth is most 
prominent at the outer margins of the bald area (white rim phenomenon).  
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Table 3. 3: Duration of irradiation, physical skin dose as calculated by MCNP Monte Carlo, and time of 
onset of epilation in the 50 µg g-1 10B groups. 
 
*obtained by Monte Carlo calculation using the MCNP program, assuming a uniform distribution of 10B  
 
After three months hair regrowth was almost complete with all dogs, but hair was 
depigmented (white) (Fig. 3.5).  Only limited spreading of the beam could be detected in 
the skin. 
3.3.6 Blood changes 
No significant changes could be observed in the red blood cell counts, the 
hemoglobin content or the packed cell volume (PCV) after boron neutron capture 
irradiation. Leukocyte counts peaked at day one post irradiation and were back to pre-
irradiation values within two days. Around day 20 there was a transient decrease in 
leukocytes. Normal values were observed again two weeks later. No significant differences 
could be detected between different irradiation dose groups. The maximum depression in 
the lymphocyte concentration occurred within the first two days after irradiation, when it 
dropped in some dogs to 25 % of the average initial value. Values came back to pre-
irrad. time 
[min] 
physical skin dose 
(at 0.25 cm depth)* 
[Gy] 
onset of epilation 
[elapsed days] 
onset of epilation 
mean (±SD) 
 
76 
7.2 
7.0 
7.7 
7.9 
36 
37 
37 
36 
 
37 (± 1) 
 
86 
9.1 
9.7 
8.3 
9.6 
9.4 
27 
27 
25 
25 
49 
 
31(± 10) 
 
 
96 
9.5 
10.1 
9.6 
9.3 
9.9 
25 
31 
37 
42 
31 
 
33 (± 6) 
 
 
106 
12.3 
10.9 
10.9 
10.5 
9.5 
19 
21 
20 
26 
22 
 
 
22 (± 3) 
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irradiation levels within one week. Only moderate changes could be observed in the 
number of platelets. 
Figure 3. 4: Photo of the most severe skin reaction 
observed one month post irradiation: almost complete 
epilation within the irradiated area. This animal (dog 
0118) was irradiated for 132 min at a mean blood 10B 
level of 25.3 µg g-1. 
Figure 3. 5: Photo of the most severe skin reaction 
observed seven months post irradiation: less dense re-
grown depigmented hair after almost complete 
epilation. (dog 0118, irrad. 132 min at 25.3 µg g-1 10B) 
 
 
A nadir in the thrombocyte count was seen around day 20. Final regeneration started at the 
end of the third week post-irradiation and reached normal values at day 30. There were no 
signs of bleeding or hemorrhage at the time of maximum platelet depression. Time related 
pattern of blood cell changes as well as quantitative differences seemed to be independent 
of applied doses. 
 
3.3.7 Brain response 
CSF. The total protein content of CSF was not significantly different from pre-
irradiation levels (25 ± 3 mg dl-1) for the entire observation period. CSF protein levels were 
not significantly increased even in animals with severe brain damage detectable by MR 
scans and blood brain barrier impairment (contrast enhancement) (Fig. 3.6). Only in one 
dog increased CSF pressure was seen at the time when clinical symptoms occurred (dog 
no. 573).  
MR and clinical symptoms. Fifteen dogs did not develop clinical symptoms and had 
normal MR scans with no pathologic findings. MR scans were performed at fixed time 
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points. First changes, visible on the MR, occurred at the 5 - 6.5 months post-irradiation 
scans in twenty-two dogs (Table Annex A). 
 
days
50 10 15 20-500 -600 
20
30
0
 
Figure 3. 6: Total protein content of cerebrospinal fluid sampled before and after irradiation. 
 
In three dogs changes were seen eight to nine months post irradiation and another two dogs 
were first positive one year post irradiation. These five dogs and eight dogs with earlier 
occurrence of brain damage visible on MR stayed clinically normal for the time of 
observation. The only changes found in these dogs were areas of the white matter with 
increased signal intensity in the MR scans on mainly the T2- and the contrast-enhanced 
predominately T1-weighted images. Usually the T2 effect would decrease with time 
whereas the contrast enhancing lesions still were seen in the one year follow-up scans. In 
two dogs (no. 637 and 773) these changes were transient. Lesions were most prominent in 
the white matter dorsal and lateral of the ventricles. Thirteen dogs developed fatal radiation 
necrosis of the brain with acceptable skin damage (Table Annex A). These animals showed 
behavioral changes, followed by slight ataxia, reduced sensitivity and disorientation and 
progressed within 24-48 h to inability to walk which then led to euthanization of the dogs 
involved. Usually application of corticosteroids (dog no. 516, 504, 518, 812, and 820) 
would slow down this process without any therapeutical effect. One dog (dog no. 467) was 
found dead bitten by the others in the kennel. Because of the histologically observed 
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extensive white matter necrosis this animal was scored to have reached the endpoint of 
lethal necrosis (Table Annex A). 
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Figure 3. 7: scatter plot of irradiation time versus mean blood boron concentration in relation to observed 
effects.  
 
The three dogs irradiated with the epithermal beam alone did not show any in vivo 
detectable brain damage. Of the twenty dogs irradiated at a mean blood 10B level of about 
25 µg g-1, ten dogs stayed negative as far as detectable by MR techniques. Brain damage 
could be detected by MR in ten dogs. Three of these dogs stayed clinically normal and 
seven developed fatal white matter necrosis leading to death (Table 3.1, Fig. 3.7). The dose 
that resulted in MR changes and lethal white matter necrosis in 50 % of the irradiated 
animals (ED50) was found to be 13.6 and 15.2 Gy peak physical dose, respectively.  
The group of dogs irradiated with a blood B10 concentration of around 50 µg g-1 had four 
animals without any in vivo detectable brain damage.  Fifteen were positive on MR scans, 
eight without clinical symptoms and seven, which were killed due to fatal white matter 
necrosis. The ED50 values found for this group of animals was 16.8 Gy peak physical dose 
for MR detectable changes and 18.8 Gy peak physical dose for clinical symptoms caused 
by white matter necrosis (Fig. 3.8). (The errors resulting from the fitting procedure are 
several orders of magnitude smaller than the ED50 values and therefore not indicated.) 
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Figure 3. 8: Brain response to BNCT irradiation in dogs for the 25 µg g-1 and 50 µg g-1 mean blood 10B 
groups. Triangles are MR detectable brain changes (∆) and (lethal) brain necrosis (▲) for the 25 µg g-1 
group. The circles stand for dogs of the 50 µg g-1 group: open circles (O) are MR detectable brain damage, 
and solid circles (!) are (lethal) white matter necrosis. Error bars indicate spread in physical dose per dose 
group. Points were fitted with a sigmoidal response function (upper and lower limits constrained to 1 and 0, 
respectively). 
 
Histopathology. On gross examination of the brains findings varied from no apparent 
changes, slight swelling with focal areas of opacity of the white matter tracts to opacity, 
discoloration, and focal hemorrhage of a significant proportion of the white matter. 
Animals not showing changes on MR scans were histopathologically found to be normal or 
have just very limited diffuse demyelination of primarily the dorsal white matter horns 
accompanied with some chronic vascular changes (teleangiectasia) and minor glial reaction 
of mainly the corpus callosum. Histologic examination of MR positive dogs revealed in 
lesions consistent with higher degrees of demyelination and white matter necrosis in areas 
found to be abnormal in the MR scan. In dogs found to be clinically normal but MR 
positive, necrotic areas were very small or more aged. The older necroses were 
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histopathologically accompanied by scar tissue and/or partial reorganization. All animals, 
which reached the endpoint of lethal necrosis, were positive in MR scans. The histological 
evaluation of these animals revealed in large areas of necrosis without any signs of 
reorganization. These findings often concurred with fresh hemorrhages mainly in the outer 
dorsal regions of the white matter or in close neighborhood of necrotic tissue. Vessels not 
involved in necrosis were considerably changed: a thickening of the vessel walls 
(proliferation or swelling of endothelial cells) up to actual occlusion of the lumen was 
found. Diffuse raise in glial cells was noted as well as focal accumulations of small round 
cells (probably infiltrated white blood cells) around the vasculature. There were increased 
intercellular spaces consistent with massive edema in some animals. Histopathology 
revealed more areas of grossly detectable abnormalities than were anticipated on the basis 
of MR scans obtained the day before euthanasia (Table Annex A).  
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Figure 3. 9: Scatter plot of demyelination versus dose after single dose epithermal neutron irradiation with or 
without BSH (n=42). Score for the degree of demyelination was: 0 for no demyelination, 1 for mild 
demyelination, 2 for distinct demyelination, and 3 for massive demyelination. 
The vascular changes observed in dogs killed after one year or more of observation were in 
general more moderate. The most frequent findings were teleangiectasia together with 
various degrees of demyelination. Glial reaction was usually minimal and areas of necrosis 
frequently showed reorganization (living cells invading) and/or calcification. Pigment 
deposition was found as small granules or larger patches of brown and/or golden color. 
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Sporadically, fresh single cell necroses of neurons were found. The degree of 
demyelination was found to be dose depend (Fig. 3.9). At BNCT doses applied in this 
study gray matter appeared practically unaffected. The plexuus choroidei were frequently 
found to be edematous. 
3.4 DISCUSSION 
Irradiation and post-treatment procedures were generally well tolerated by the 
animals. The slight indisposition of some dogs during infusion of 50 mg 10B kg-1 
bodyweight might have been due to pharmacologic effects of one or more decomposition 
products of BSH with concentrations being high enough to cause the symptoms observed 
in a few individuals during the study. It has been reported by Gavin et al. (1994) that 
vomiting during infusion was noticed in most animals infused with 50 mg boron kg-1 
bodyweight of BSH. Doses of 100 mg boron kg-1 bodyweight, in form of a BSH infusion, 
caused sudden death in some dogs. Histopathology revealed in no detectable abnormalities 
in these animals. The authors suggested a direct cardiovascular toxicity because of the 
rapidity of death and cardiac failure prior to any respiratory problem or other 
abnormalities. In a follow-up study, instrumented dogs were administered BSH doses of up 
to 555 mg 10B kg-1 without fatal cardiotoxicity although some cardiac effects (i.e. systemic 
and pulmonary vascular resistance, decrease in cardiac output) were observed (Moore et al. 
1994). The toxicity differences noted for the dogs administered BSH implies that some 
other characteristic of or contaminant in the BSH lots used may have been responsible for 
the fatalities. Locksley and Farr (1955) reported adverse effects like facial flush, nausea, 
vomiting, defecation and micturition after the systemic application of borax in patients. 
The authors accounted these to the toxicological picture of boron. The median dose was 
25 mg of boron per kg. An European study on pharmacokinetics and biodistribution of 
BSH in tumor patients was initiated in the late eighties. Boron concentrations up to 50 mg 
10B kg-1 weight were applied as an intravenous infusion. No major side effects were 
encountered even at the highest BSH dose. Highly concentrated solutions sometimes 
caused irritation at the injection site. Two patients suffered from nausea and chest pain 
during infusion. These symptoms were not accompanied by any change in vital functions 
and disappeared spontaneously after temporary interruption of infusion or slowing down of 
the infusion rate (Stragliotto et al. 1993). No measurable acute side effect of BSH was 
found after single doses of 30 mg boron per kg body weight or two doses of 15 mg kg-1 
with an interval of 48 hours. Patients did not complain of any disorders like nausea or 
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vomiting (Haritz et al. 1993). In the Austrian part of the study ten glioma patients were 
infused with 75 mg BSH kg-1 bodyweight corresponding to 43 mg 10B kg-1 bodyweight 
(Haselsberger et al. 1994). Boron concentrations in tissue were determined by ICP-AES 24 
hours after BSH infusion. Boron uptake in tumor was sufficiently selective compared to 
concentrations in normal and endematous brain. Mean concentration ratio of tumor to 
blood was slightly above unity. The only side effect was an inconsistent facial flush during 
infusion, which ceased rapidly after BSH application. There were no subjective complaints 
and no allergic reactions. Bauer and his coworkers (1996) have analyzed the volatile head 
space over BSH and found compounds that may contribute to the apparently variable 
toxicity associated with BSH. Many of these compounds could produce symptoms similar 
to those noted in patients administered high doses of BSH. The various contaminants found 
may come from any number of sources including degradation of the BSH or reaction 
intermediates, actual reaction intermediates or byproducts, impurities in the starting 
materials, and/or impurities in the solvents. The nature of impurities appears to be quite 
variable and future work will need to focus on optimizing the production of a reliable and 
clean BSH. Goodman et al. (2000) reported a biodistribution and pharmacokinetic study of 
BSH in brain tumor patients. They infused doses up to 88.2 mg BSH per kilogram body 
weight in a one-hour infusion and did not observe any adverse side effects due to the BSH 
infusion. The BSH was supplied by Centronic, Ltd. (Croydon, UK). 
Blood boron concentration can be readily determined following intravenous infusion of 
BSH. Both methods used in this study, the almost online facility of prompt gamma-ray 
analysis and ICP-AES method are in good agreement. The average PGRA to ICP-AES 
ratio was very close to 1 using a 10B enrichment factor. Kraft et al. (1992) have performed 
a large study involving the pharmacokinetics of BSH in normal dogs and dogs with 
spontaneous brain tumors. The clearance of BSH could be described by a two compartment 
model during the first 10 hours post administration. Boron concentrations in normal tissue 
can be accurately predicted from blood boron measurements. The boron concentration in 
the skin of the head was slightly lower than the blood boron concentration (Gavin et al., 
1993), which is consistent with tissue uptake studies in humans where boron 
concentrations in skin were found to be as high as those in blood (Goodman et al., 2000). 
Pharmacokinetics of BSH were also studied in normal Beagle dogs and showed 
elimination constants that are in agreement with values reported for Labradors (Kraft et al., 
1992).  
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The pharmacokinetic study performed at the very beginning of the present study resulted in 
consistent values, which fitted well in the data obtained from the pharmacokinetics after 
infusion of BSH for irradiation. Nevertheless, since mean blood boron levels during 
irradiation are of utmost importance the individual starting point for irradiation was 
assessed on the bases of blood pharmacokinetic curves estimated from on-line PGRA 
readings of the blood samples taken.  
In the present study a biphasic kinetic of the boron excretion from blood was observed. 
The elimination constants for the two boron concentration groups were not significantly 
different. A mean elimination half-life of 320 ± 20 minutes was calculated. Haritz et al. 
(1994) found also a biphasic kinetic in human glioma patients infused with BSH. The 
authors calculated a first half-life of 10 hours and a second half-life of about 25 hours, but 
with large variations from patient to patient. One day post infusion the boron 
concentrations were already down to a few µg g-1. In contrast to the Lausanne group 
(Stragliotto et al. 1992), no early half-life within one hour after cessation of the BSH 
infusion was found. The marked difference in elimination half-life can be accounted to the 
considerably faster metabolism of dogs. However, it is difficult to compare the values for 
the elimination half-life for BSH in normal dogs and human patients due to species 
differences and the fact that the human volunteers in the reported studies underwent 
surgery and additional treatment for their disease. 
Erythema as acute reaction of skin to radiation was an inconsistent finding and could not 
be scored effectively because of the dense coat and the partially pigmented skin of the 
dogs. No obvious dose dependence was found to time of onset of epilation. However, it 
should be taken into consideration that epilation occurs as a slowly developing process 
rather than abrupt event. Therefore, the extent of epilation was estimated by the time of 
occurrence and the completeness of loss of hair. The degree of epilation was slightly 
greater with the high dose groups, which was also reflected in the lower density of the re-
growing hair within these groups. The principal measure was whether or not a moist 
desquamation occurred. A moist reaction is defined as the loss of sufficient epidermis to 
permit loss of serum and crust formation, abrasion, ulceration or necrosis. All skin changes 
in this study were within tolerable margins, no moist reaction was observed even with the 
high doses. The most severe effect that occurred was minor cases of dry desquamation 
along with almost complete epilation. Therefore, skin damage is not regarded as a limiting 
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factor for BNCT at doses applied in this study. The Petten HB11 epithermal beam is highly 
collimated and most of the skin reaction was observed within the 8 cm irradiation field. 
There was a rim of about 1 cm where changes were milder. The edge was rather sharply 
defined. The remainder of the head and skin appeared unaffected (Philipp et al. 1993). 
Physical skin doses applied in this study ranged from 5.6 Gy to 12.3 Gy. Skin reaction was 
restricted to some dry desquamation with complete hair loss within the margins of the 
incident irradiation field and after 120 days the incomplete regrowth of depigmented hair. 
Park et al. (1974) observed these reactions after 12.2 Gy of X-rays (Table 3.2). 
Skin tolerance to BNCT after systemic application of BSH was also investigated in dogs 
using the epithermal neutron beam of the Brookhaven National Laboratory reactor 
(BMRR) (Gavin et al. 1994, Gavin et al. 1993). Reactions varied from mild epilation and 
hair color change to dermal necrosis. The higher range of doses used revealed, in some 
animals, a biphasic skin reaction. The initial epithelial reaction peaked at three weeks post 
irradiation. In the highest dose groups this reaction consisted of total epilation, 
depigmentation, and moist desquamation. These areas healed and became re-epithelialized 
over the next several weeks. At three months post irradiation dermal necrosis ensued. The 
nature of the epithermal beam prevented surgical resection of the necrotic tissue and even 
prevented successful grafting techniques containing their own vascular supply. The BMRR 
epithermal beam is isotropic and the margins of the irradiation field become indistinct after 
scattering in the tissue. While the moist desquamation in the early phase and the dermal 
necrosis in the later phase occur within the incident beam irradiation field, significant 
irradiation spreads from the incident beam and histologic damage to the dermis was 
detected throughout the dorsal region of the head. This loss of sharp beam edges was 
readily seen in hair color changes. It should be emphasized that dermal necrosis should not 
be a problem when patients are irradiated with blood boron concentrations of between 25 
and 100 µg g-1. At those concentrations brain necrosis occurred at a dose significantly 
below that required for dermal necrosis. The dermal necrosis observed was too severe to 
maintain animals long enough to ensure changes would occur within the CNS. 
Rogers (1991) compared canine and human skin and stated that dog skin has more terminal 
hairs per unit area than human skin, but lacks sweat glands and ducts. The follicular 
adnexae of dog skin have a greater number of sebaceous glands and larger pilar erector 
muscles than human skin. Both the pilar and epidermal components of dog skin have a 
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higher rate of turnover than does human skin. The cutaneous vasculature of both man and 
dog have a superficial and deep system, however, the vasoreactivity of human skin is 
greater. Humans can shunt blood to and away from skin more readily than dogs. Thus, the 
erythema response of acute radiodermatitis in humans has the potential to be greater than 
in dogs. Due to the relative lack of flomus cells to regulate blood flow, one would expect 
the risk of acute skin necrosis to be greater in dogs. These findings suggest that dog skin 
can be expected to be more sensitive to the toxic effects of BNCT than human skin. 
Pig skin is regarded as an excellent model for human dermal radiation reaction. The 
irradiation geometry, the anatomy with a subcutaneous fat layer, the histology and known 
response to irradiation, all approach that found in humans. Studies using thermal and 
fission neutron beams and BNCT following BSH administration have been performed in 
pig skin by Archambeau and coworkers (Archambeau et al. 1971). The authors did not find 
a dose dependence for the onset of epilation or moist reaction. Yet, there was a dose 
dependent involvement of skin with moist reaction for all kinds of irradiation. Difficulties 
in obtaining a relative biological effectiveness (RBE) for the boron capture reaction were 
reported and accounted to mainly the uncertainty in the distribution of the boron. However, 
the dose at which 50 % of the irradiation fields were unhealed following the 10B(n, α)7Li 
reaction was lower than the dose obtained following irradiation with X-rays. The 
evolution, time course, and dose dependence of the reaction measured were not the same 
for boron neutron capture irradiation and X-rays. The moist reaction following boron 
neutron capture irradiation occurred after 15 days as compared to 18 or 20 days after X-
irradiation on shoulder and ham, respectively. Maximal healing was for boron neutron 
capture irradiated skin at day 45, and 36 (shoulder) or 38 (ham) days after X-irradiation. 
The ED50 at which 50 % of the fields were not healed within 49 days was found to be 
11.0 ±1.12 Gy for the 10B(n, α)7Li reaction, and 22.73 ±1.03 Gy or 22.78 ±1.41 Gy for X-
irradiation on shoulder and ham, respectively (Archambeau 1989). The concentration of 
boron in the blood from large vessels exceeded the concentration in the skin. If the 
concentration of boron in the capillaries was the same as in the large vessels, the dose to 
the capillaries would have been higher than to the epidermis. If this occurred, the effect of 
capillary damage on cell kinetics of epidermis has to be considered.  
Time related pattern of blood cell changes as well as quantitative differences seem to be 
independent of the doses applied. The whole body dose and dose to bone marrow is well 
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tolerated by all animals. The initial increase in white blood cell counts and at the same time 
reduction of lymphocytes is accounted to the application of dexamethasone prior to 
irradiation. This was done following the requirements of the ethical committee in order to 
prevent radiation induced edema of the brain. The changes in the circulating white blood 
cells could be due to the blood-pool irradiation that would occur during the lengthy 
irradiation. However, a depression of platelets would indicate significant total body bone 
marrow irradiation. Platelet counts between 50.000 and 100.000 mm-3 have been observed 
around day 20 post irradiation. All changes in the blood count monitored have been 
responsible for no significant clinical problems, and have returned to normal values within 
40 days post irradiation. Gavin et al. have noted similar changes in the complete blood 
counts with their healthy tissue tolerance studies in dogs after BNCT (Gavin et al. 1993). 
Liver enzymes were monitored as well. There was no effect of BSH application or boron 
neutron irradiation on these parameters. 
Magnetic resonance imaging is an excellent method for revealing radiation induced 
changes in brain tissue after boron neutron capture irradiation. Edema of the brain is 
visualized in T2 weighted images by a higher signal intensity due to free water in these 
areas. An increase in tissue water content causes an increase in mobile proton density and 
prolongation of T1 and T2 relaxation times. These changes result in decreased signal in T1 
weighted images and increased signal intensities in T2 weighted and proton density 
images. Hemorrhage and necrosis are detectable in T1 weighted images as areas of high 
signal intensity after administration of Gd-DTPA (m.w.=545.6 dalton) which is leaking 
into brain tissue where the blood-brain barrier is disrupted. Fike and Gobbel reported a 
small focus of low density (necrosis) surrounded by a well-defined ring of contrast 
enhancement as typical finding in canine brain after interstitial 125I irradiation. Edema was 
observed around the focal lesion, which appeared to be permeable to Gd-DTPA. This was 
shown by enhancement of the lesion relative to the untreated hemisphere (Fike and Gobbel 
1991). Although some of the lesions found in this study presented as such circumscribed 
foci, most disorders observed were more diffuse and in most cases more or less 
homogeneous in enhancement. Contrast enhancing lesions were exclusively found within 
the white matter. Fike and Gobbel (1991) considered this apparent selectivity of damage to 
the white matter in large animals and humans to be one of the characteristics that define the 
clinical, radiological, and pathologic changes associated with delayed radiation injury. No 
changes were detectable in MR scans obtained shortly (within days) after irradiation, 
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indicating that no acute damage is done to the blood-brain barrier even with radiation doses 
being lethal at the long run. This is mostly accounted to the corticosteroids applied right 
before irradiation. When acute reactions occur in humans, they are distinguished by 
symptoms of increased intracranial pressure or an intensification of the neurologic 
symptoms or signs caused by the lesion being treated by conventional X-irradiation. The 
ethiology of the acute syndrome is purported to be radiation-induced edema. Computerized 
tomographic scans taken during the course of radiation therapy, however, have not shown 
a radiographically measurable increase in peritumoral edema (cited from Leibel et al. 
1991). It has been demonstrated that in general the dose-response curves for neurological 
damage are very steep and that severe late neurologic damage occurs in Beagles between 
five and six months after X-irradiation of brain tissue (Fike et al. 1984). A similar latent 
period for lethal white matter necrosis after BNCT was observed in this study.  For both 
MR detectable changes and lethal white matter necrosis extremely steep dose-response 
curves are observed. These curves are characterized by ED50 values of 13.6 and 15.2 Gy 
peak physical dose for MR detectable changes and lethal white matter necrosis, 
respectively, for dogs irradiated with a mean blood 10B level of about 25 µg g-1. ED50  
values were found to be 16.8 and 18.8 Gy peak physical dose for MR detectable changes 
and lethal white matter necrosis, respectively, for the group of dogs irradiated at higher 
mean blood boron levels. These differences in physical dose ED50 values for different 10B 
levels demonstrate the need of translation of physical doses into the biologically equivalent 
doses prior to any clinical trial in patients.  
Histologic evaluation of irradiated brain revealed in damage of different quality and extent: 
necrotic areas, demyelination, glial reaction, teleangiectasia, hemorrhages and edema. 
Large necrotic areas, always in combination with fresh hemorrhages, were found in 
animals killed because of their clinical symptoms. Van der Kogel described similar 
findings after X-irradiation of the rat spinal cord (Van der Kogel 1979). In his study, 
symptoms developed gradually. However, sometimes severe neurological side effects were 
seen within hours, and ascribed to the sudden onset of bleeding. In the present study 
contrast enhancement in MR scans was in all cases related to necrosis. Animals with a 
positive MR, but not showing clinical symptoms during the observation period tended to 
have more aged necroses (fibronoid connective tissue, droplets of pigment). This finding 
indicates that white matter necrosis must not be of clinical relevance in all cases. The 
degree of demyelination was found to be dose dependent with a wide spread of data points. 
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In the high dose range the degree of demyelination tended to be lower than one would 
expect. In this dose range the histopathologic finding of demyelination probably became 
superimposed/dominated by necrosis. Therefore, scores accounted to the degree of 
demyelination outside the main area of damage in these cases were somewhat lower. As 
mentioned above, fresh hemorrhages were strongly correlated with rapidly progressing 
clinical symptoms i.e. lethal necrosis. Somewhat older hemorrhages were found in only 
four clinically normal dogs. Two of them, being MR positive, had large areas of necrosis. 
In one dog, old hemorrhages were found along with a small necrotic lesion and transient 
MR changes. However, they also were found in one dog, which was negative in MR and 
had just some mild teleangiectasia. The pigments found in close neighborhood of altered 
vasculature is most probably of hemoglobinogenic origin. Hemoglobinogenic pigments are 
frequently found after bleedings in the form of hemosiderin and hematotoidin deposits. 
Hemosiderin is the iron containing decomposition product of hemoglobin. It usually shows 
as intracellular golden or yellow-brownish granules. With larger bleedings (often related 
with necrosis) hemoglobin can decompose in iron free hematotoidin, a crystalline or 
amorph brown sometimes yellowish deposit. It is mostly found extracellular as more or 
less homogeneous appearing droplets. Other findings like the extend of glial reaction could 
not be related to dose. The different pattern observed in glial reaction might account for 
two different pathophysiologic pathways. The more diffuse type could be attributed to a 
neuroglial (astrocytes) or mesoglial (Hortega-cells) proliferation, whereas the focal 
accumulation around the vasculature partially could also be explained by an enhanced 
extravasation of round (white blood) cells from the luminal side of the vessel involved. 
Teleangiectasia was generally very mild and often located dorsolateral of the corpus 
callosum and only observed in clinically normal animals, thus indicating a more chronic 
type of damage. Edema in brain tissue usually manifestates intracellularely. A special form 
of edema is seen in white matter as edema of the myelin. This shows with disruption of the 
blood-brain barrier a special affinity to aqueous components. The myelin edema can be 
reversible, but usually proceeds to degeneration (demyelination). With massive edema of 
brain tissue, fluid might emerge also into the intercellular space leading to dissociation of 
cells and fibers. 
Observed pathologic radiation effects are comparable with data of Yamaguchi (Yamaguchi 
et al. 1991). In their study 19 dogs were irradiated with a single X-ray dose of 15 Gy using 
a linear accelerator with an electron beam energy of 10 MeV. The dogs were killed at 3, 6, 
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9, 12, 15 or 30 months after irradiation and histologic examination of the brain was 
performed. No changes were observed 3 months after irradiation. At six months after 
irradiation, spongy degeneration accompanied by small cell infiltration was observed, 
especially in the frontal white matter. At 9 months, necrotic foci appeared and developed 
until 15 months after irradiation. Blood vessels around the necrotic area showed luminal 
narrowing with endothelial hyperplasia and proliferation. At 30 months, no fresh necrotic 
lesions were observed. The authors suggest vascular impairment as the driving force in 
pathogenesis of delayed radiation necrosis. This was confirmed by Hopewell and van der 
Kogel (1999) at least with respect to the glial cell theory. The capillary endothelial cell is 
regarded as a critical target of the CNS. In the case of BSH, which is in normal brain tissue 
restrained to the vascular space, this target is primarily irradiated with fission fragments 
from the luminal side. In addition the boron capture fission fragments originating in the 
vascular lumen will not reach the glial cell population to a significant degree.  
The dose of 15 Gy administered in this study is very close to the ED50 value of 14.9 Gy, 
reported Fike and his coworkers (Fike et al. 1984, 1988) for lethal brain necrosis in dogs 
following irradiation of one hemisphere with 4 MeV X-rays. In our study ED50 values for 
lethal white matter necrosis of 15.2 and 18.8 Gy peak physical dose were found for 
animals irradiated at the 25 µg 10B g-1 level and at the 50 µg 10B g-1 blood level, 
respectively. With 15 Gy at a mean blood 10B level of 50 µg g-1 not even MR changes were 
seen, whereas at the 25 µg g-1 level all animals reached the endpoint of lethal white matter 
necrosis (table 3.1).  There is an inverse relationship between the blood boron 
concentration and the peak physical dose required for an isoeffect indicating an significant 
dose sparing most probably to the capillary endothelium from boron fission fragments 
following neutron capture. The physical dose required to reach a biological isoeffect 
appears to increase directly as the proportion of boron capture dose increases (Fig. 3.8). 
Viewing the relative dose contributions, it is noticed that with a lower blood 10B 
concentration, the boron capture dose is lower with at the same time a relative increase in 
non-boron dose. For the 50 µg g-1 group the ratio is 75% boron capture dose to 25% 
non-boron dose (table 1.3) versus about 60% boron dose and 40% non boron dose for the 
25 µg g-1 10B group. Gavin et al. (1993) modeled the endothelial response to an uniform 
and a non-uniform 10B distribution within brain tissue. Following this microdosimetric 
model, approximately 83% of the physical boron capture dose with BSH do not contribute 
to the CNS endothelial nuclear dose. On the other hand, the relative contribution of high 
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LET radiation (nitrogen capture proton and fast neutrons) almost doubles, leading to the 
impression that BNCT was more efficient with lower boron concentrations. This has 
certain implications for BNCT: the uniform non-boron dose damages healthy tissue to the 
same extent as the tumor unless the nitrogen content in both tissues is not the same and 
both tissues react differently to gamma-ray irradiation. The boron dose also effects the 
healthy tissue but to a much lower extent: with BSH roughly 5 of 6 fission events do not 
contribute to the central nervous system endothelial dose (Gavin et al. 1993). In tumor 
tissue there is no vascular sparing because BSH is thought to extravasate through the 
impaired blood brain barrier. Therefore, the boron dose is expected to be much more 
effective than in normal brain. Gavin et al. (1993) calculated a two to three times higher 
biological effectiveness of the boron dose in tumor as compared to normal brain tissue. 
The increase of boron concentrations in tumor (and blood) has a large effect on the 
equivalent tumor dose compared to the equivalent brain endothelial vascular dose. This 
means that the therapeutic gain with BNCT using BSH as boron carrier will be more 
pronounced the higher the boron concentration is. 
The three dogs irradiated with the epithermal beam alone did not show any radiation 
induced effect in brain tissue or had just very little focal demyelination and some chronic 
vascular changes (teleangiectasia) (Annex A). It is concluded that a brain irradiation at the 
HB11 of almost two hours (116 min.) is not exceeding tolerance. With a mean blood boron 
concentration of about 25 mg 10B kg-1 bodyweight the epithermal neutron irradiation time 
is reduced to less than 75 minutes for causing the same effect. With 50 mg 10B kg-1 
bodyweight an irradiation time of about 76 minutes caused a comparable effect in normal 
brain tissue in this study. However, these minimal effects are difficult to quantify and 
therefore not very useful in comparing dose dependencies. The irradiation time 
(epithermal neutron beam dose) needed to reach the ED50 of MR contrast enhancement 
with 25 or 50 mg 10B kg-1 bodyweight is between 108 - 120 and 76 - 86 minutes, 
respectively. For the ED50 of lethal necrosis, irradiation times of about 120 and slightly 
above 96 minutes are needed at the 25 and 50 mg 10B kg-1 bodyweight level, respectively. 
Unfortunately, the present experimental setup did not allow a dose escalation study with 
the epithermal neutron beam in the absence of boron. 
Dosimetry is one of the major difficulties with BNCT. Already measuring the physical 
properties of the incident beam creates problems where the detection of epithermal 
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neutrons probably is one of the biggest. The for these experiments important epithermal 
region from 1 keV to about 0.5 MeV is relatively untouched by the stack of resonance and 
threshold foils used for neutron monitoring with the dog irradiations. This is recognized as 
a major deficiency and is being remedied by the development of a technique, which uses 
resonance foils within moderating medium. However, the existing foil set has the 
advantage of being capable of detecting any gross change in the beam parameters. With the 
foil activation measurements all data fell between ± 2 (approx.) standard errors of the mean 
value indicating a consistent set of values (data not shown).  
Another problem complex related to dosimetry with BNCT is the characteristics of 
incident radiation. The beam used in this study is not monoenergetic but consists of a wide 
range of different kinds of radiation. It is not known how different radiation qualities 
contribute to total dose in a mixed field. MCNP calculations were used to model the 
spectrum of the beam and could be verified where possible by measurements. Assumptions 
were made concerning input (neutron fluences, incident gamma-ray and boron distribution 
within the brain) and the dose resulting from a mixed irradiation field (additively).  
In this study, late effects in canine brain to boron neutron capture irradiation were 
investigated. The dose response relationship was investigated for different radiation doses 
and boron concentrations after systemic application of BSH as neutron capture agent and 
subsequent irradiation with an epithermal neutron beam. The major problem of this study 
was that only overall effects could be detected. Based on the assumption that radiation 
effects of every single radiation quality involved behave additively, physical dose response 
curves could be established and ED50 values for the different endpoints were extracted. The 
difference in ED50 values for this kind of irradiation in the presence of different boron 
concentrations in tissue demonstrates the need of a sophisticated model for dose 
description with the mixed radiation field. 
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4.1 INTRODUCTION 
The clinical experience with boron neutron capture therapy (BNCT) has mostly 
been with single dose treatments. This was primarily because of the necessity to irradiate 
intraoperatively with scalp reflection, which was practiced to avoid excess damage to 
superficial normal tissues from the low energy (thermal) neutrons. Better depth doses and 
lower superficial tissue doses are obtained by the application of epithermal neutron beams. 
Epithermal neutron beams allow irradiation without surgery and thus fractionated 
irradiation schemes, the division of the total radiation dose into smaller increments over a 
period of time. For most radiation oncologists the use of four treatment fractions holds 
some attraction for safety reasons. The clinical benefit of fractionated photon radiation has 
been established for higher dose rates, and dose fractionation schemes are commonly used 
in conventional radiotherapy. Several investigators have suggested that fractionated BNCT 
would be highly preferable to single dose treatment. The primary reasons include repair of 
the low dose rate, low linear energy transfer (LET) irradiation to normal tissue and better 
distribution of the boron carrier within the tumor following repeated administrations. 
Nuclear reactor derived neutron beams are imperfect with a spectrum of neutrons of 
different energies and usually a considerable gamma-ray contamination, i. e. BMRR: 1.74 
Gy MW-1h-1 (Joel et al. 1992) and HFR Petten about 1 Gy h1(see chapter 1). There is 
about 1 additional Gy h-1 of induced gamma radiation in matter at the HB11 in Petten. For 
the HFR beam the gamma-ray component amounts to 67% of total physical dose at 0 
boron, to 27% at a 10B level of 25 µg g-1, and to 17% in the presence of 50 µg g-1 10B. The 
gamma-ray component represents a radiation of relatively low LET. It will be necessary to 
consider means of reducing its toxicity to normal tissue. With fractionation, repair of low-
LET damage would provide a safety margin for normal tissue. However, the dose rate for 
the gamma-ray component with the available epithermal neutron beams is low. This would 
already allow repair during irradiation and may change the biologically effectiveness of the 
gamma-ray component (application of a dose rate factor of about 0.6 (Fu 1991)). Thus, the 
benefit of fractionation may be lost. However, there might be interactions of the low- and 
high-LET components at the cellular level (Mc Nally 1988). This could possibly lead to 
the inability to repair low-LET low-dose rate gamma radiation damage in cells during 
irradiation.  
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The recoil protons induced by high energy neutrons have a high LET. Therefore, almost no 
benefit from fractionation is expected (van der Kogel 1979). The same is valid for the high 
LET products resulting from the 10B(n, α)7Li reaction. In addition, lower energy neutrons 
in the thermal neutron range produce significant surface tissue damage (Archambeau et al. 
1971) without contributing to the 10B(n, α)7Li tumor dose in depth. With fractionation 
there is the possibility to increase the sparing of superficial normal tissue by choosing 
different irradiation fields. 
Many sources of appropriate energy neutrons are being explored for their use in BNCT 
with several different outputs and dose rates and different filters. It is probable that each 
center will have unique problems before the safety of clinical therapy can be established, 
for none of the beams used is entirely perfect for BNCT. The ideal neutron beam would 
contain no considerable gamma-ray contamination, would have a high epithermal neutron 
flux and low high energy neutron flux, with the only significant radiation being that of the 
10B(n, α)7Li reaction occurring within tumor cells. However, even in this situation, if there 
is a large tumor cell kill in a short period of time, there may be acute complications as 
observed with the tumor lysis syndrome. Although this occurs less commonly with solid 
tumors and its toxicity usually is systemic, the released metabolites after single fraction 
BNCT may produce acute local toxicity even in the absence of radiation toxicity to normal 
tissue.  
The boron distribution itself is not ideal. Since BNCT is a bimodal treatment, the 
distribution of the boron compound within the tumor plays a major role. Tumor hypoxia 
and hypoperfusion are dynamic phenomena. Therefore a compound applied several times 
(prior to each fraction) might reach areas in a tumor previously hypoperfused, and thus 
increase tumor control. Haritz et al. (1993) reported a better boron uptake in tumor after 
multiple application of BSH. 
The inevitable conclusion from this is that some degree of fractionation is desirable even 
with BNCT. However, nothing is known about fractionation effects in a mixed radiation 
field as it occurs with BNCT and there is another aspect, which is of importance for 
fractionated BNCT using borocaptate sodium (BSH) as boron carrier, namely the integrity 
of the blood-brain barrier. BSH is not taken up by the normal brain tissue and virtually all 
boron measured within the normal brain can be accounted for by the blood volume of the 
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tissue (Kraft et al. 1992). BSH does not cross the normal blood brain barrier and its 
hydrophilic nature would suggest that the boron would be confined to the vascular lumen. 
Thus, the vasculature was regarded as the dose limiting tissue with fractionation of BNCT 
using the compound BSH. If disruption of the blood-brain barrier occurred during the 
fractionation scheme, BSH would be able to penetrate into normal tissue and eventually 
spoil the advantageous sparing of the healthy tissue by this bimodal treatment modality. 
Dose distribution in normal tissue would be considerably different since the high LET 
radiation resulting from the boron capture reaction is no longer restricted to the vascular 
system but could cause direct damage in normal brain tissue. 
The effects of dose fractionation with this mixed radiation field were studied in a limited 
number of animals in the framework of the healthy tissue tolerance studies performed at 
the Petten epithermal neutron beam after application of BSH. This study has been 
performed to spot changes in normal tissue tolerance after an irradiation scheme of four 
fractions separated by one day. This fractionation scheme for preclinical trials was among 
other reasons chosen since it was suggested in a BNCT treatment protocol proposal for 
glioma patients (Fankhauser et al. 1993). More fractions seemed not to be advisable 
because of the mainly high LET character of radiation occurring with BNCT. The 
possibility of even increased damage as compared to single dose experiments because of 
the possible disrupture of the blood brain barrier (BBB) was investigated. 
4.2 MATERIALS AND METHODS 
Ten female Beagle dogs aged between two and two and a half years at the 
beginning of the experiment were randomly assigned to two groups of five animals each. 
The dogs were under daily observation. Extensive physical and neurologic examinations 
took place prior to and at defined time points (1, 2, 4, 6, 9, and 12 months) after irradiation, 
including blood cell counts, serum chemistry, cerebro spinal fluid (CSF) analysis, and 
magnetic resonance (MR) imaging of the dogs head. MR images were obtained prior to 
and after application of appropriate contrast enhancement (0.2 ml Magnevist® kg-1 
bodyweight) using 5 mm contiguous slices. 
Prior to irradiation animals were infused over one hour with 95.5 % 10B-enriched BSH 
(supplied by Centronics, LTD.) at a dose of 25 mg 10B kg-1 bodyweight in 
11 ml kg-1 bodyweight 0.9 % saline. For the group of five dogs, which received the dose in 
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four fractions, infusion was repeated ahead of each irradiation session. Neutron beam 
irradiations were performed as soon as the mean blood boron concentration reached the 
projected level. The boron content of the blood was analyzed by a prompt gamma-ray 
spectroscopy facility at site. Prior to irradiation a dose of 1 mg dexamethasone per 
kg bodyweight was injected intravenously and the animals were kept under general 
anesthesia during irradiation. They were positioned on the irradiation table and activation 
foils and thermo-luminescent dosimeters (TLDs) were attached at various positions. All 
dogs were irradiated at the epithermal beam (HB11) of the High Flux Reactor (HFR) of the 
European Community at Petten, The Netherlands (Moss 1990).  
 
Table 4. 1: Actual mean blood 10B concentrations, irradiation times and doses 
projected dose group    MCNP MCNP 
mean 
blood 10B 
conc. 
[µg/g] 
peak phys. 
Dose 
[Gy] 
irrad. 
time 
[min] 
dog no. Actual / mean 
blood 10B 
conc. 
[µg/g] 
calculated peak 
physical dose 
(1.75 cm depth) 
[Gy] 
calculated 
physical skin dose
(0.25 cm depth) 
[Gy] 
25 13.5 108 180 
480 
637 
644 
773 
25.4 
24.1   24.5(± 1.0) 
23.1      
25.5 
24.2 
13.9 
13.5     13.6(± 0.3) 
13.2       
13.9 
13.5 
8.2 
8.1 
7.9 
8.2 
8.1 
25 
(4 fract.) 
13.5 4 x 27 194 
 
 
 
641 
 
 
 
647 
 
 
 
746 
 
 
 
804 
27.6 
25.4 
25.9 
27.6 
25.9 
22.1   25.2(± 1.5) 
24.5      
27.4 
23.9 
25.1 
26 
26.4 
25.8 
23.6 
23.9 
25.9 
25.5 
23.7 
23.4 
23.8 
3.6 
3.5 
3.5 
3.6 
3.5 
3.2       13.8(± 0.3) 
3.4       
3.6 
3.4 
3.4 
3.5 
3.5 
3.2 
3.1 
3.2 
3.2 
3.2 
3.1 
3.1 
3.1 
2.1 
2.1 
2.1 
2.1 
2.1 
2.0 
2.0 
2.1 
2.0 
2.0 
2.1 
2.1 
2.1 
2.0 
2.0 
2.1 
2.1 
2.0 
2.0 
2.0 
The gamma-ray contamination of the incident beam amounts to 1 Gy h-1. The circular 
beam opening was 8 cm in diameter and centered over both hemispheres of the dogs brain 
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for all irradiations (see figure 3.1). The dose aimed at was 13.5 Gy peak physical dose at 
the 25 µg g-1 mean blood 10B level. Irradiation time was 4 x 27 minutes for the fractionated 
irradiation schedule with each fraction separated by one day. The five dogs of the single 
dose experiment were irradiated for 108 min. Actual mean blood 10B concentrations, 
irradiation times and doses are listed in table 4.1.  
4.3 RESULTS 
Irradiation and follow-up procedures including post-treatment MR and CFS 
procedures were generally well tolerated by all animals. No acute reaction to the irradiation 
or BSH infusion could be observed. Single boron infusion as well as four times 25 mg 
10B kg-1 bodyweight were well tolerated. There was no change in blood pharmacokinetics 
of the boron compound with multiple application (Fig. 4.1). After twenty-four hours most 
of the boron was excreted and the blood 10B concentration was down to a few µg g-1. No 
acute breakdown of the blood-brain barrier could be detected by MR after single dose or 
fractionated irradiation. The protein content of CSF stayed at pre-irradiation levels.  
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Figure 4. 1: Pharmacokinetics of 10B in blood after repeated intravenous application of 25 mg 10B kg-! body 
weight in the form of BSH solution. Infusion interval was twenty-four hours (dog 804). 
All ten dogs lost the hair on top of the head in the area of incident radiation. After three 
months hair regrowth was complete but hair was depigmented. The extent of hair loss and 
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depigmentation was slightly less with the five dogs that received the dose in four fractions. 
The calculated physical dose to the skin (at 0.25 cm depth) was 8.2 (± 0.1) Gy for the 
fractionated irradiations and 8.1 (± 0.1) Gy for the single dose group (Table 4.1). 
No significant differences were found in the blood parameters of the two irradiation 
groups. One dog of the fractionated group (no. 641) was suffering from a cervical 
enchondrosis intervertebralis. The treatment of this problem caused a significant increase 
in the white blood cell counts between day eight and twenty four, which was mainly due to 
an increase in the platelet concentration. In both groups the white blood cell counts were 
high the day after irradiation and amounted to about 1.5-2 times the pre-irradiation values. 
Thereafter blood cell counts were back to normal levels. No irradiation related changes 
were observed in serum chemistry. 
The physical dose peaked at 1. 75 cm depth and amounted to 13.8 (± 0.3) and 13.6 (± 0.3) 
Gy for the fractionated irradiations and the single dose group, respectively (Table 4.1). 
Brain damage detectable by contrast enhanced MR occurred in three dogs of the single 
dose group. In one of these dogs the diffusely contrast enhancing region was not visible 
anymore three months after the initial observation. The fractionated group had no 
responders. All dogs appeared clinically normal over the entire observation period (Annex 
B). 
Postmortal histological examination revealed lesions consistent with white matter necrosis 
and demyelination to different extent in four out of five single dose dogs. In only one of 
the single dose dogs acute vascular changes like edema of the plexus choroideus, and 
hyalinization and thickening of vessel walls could be observed. Vascular changes were of a 
more chronic nature in the four other dogs of this group: old hemorrhages with deposition 
of brown pigment and teleangiectasia. There was no evidence of necrosis in the dogs 
having received fractionated irradiation. Here was some demyelination and vascular 
changes like hemorrhages, vessel wall thickening or teleangiectasia the most prominent 
findings. All lesions were restricted to the white matter dorsal of the ventricles. 
4.4 DISCUSSION 
With conventional radiotherapy, the therapeutic ratio of fractionation is based on 
the assumption that the repair capacity of the tumor is somewhat compromised. The 
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healthy tissue sparing is achieved by taking advantage of mechanisms like repair, cell cycle 
progression effects and repopulation. There also is the possibility to increase the sparing of 
the superficial healthy tissue with fractionation by choosing different irradiation fields. The 
effects of repair and reoxygenation observed after fractionation are expected to be 
negligible with BNCT where mainly high LET radiation and only low dose rates of low 
LET radiation are involved. However, there are some points to consider, like the tumor 
lysis syndrome, the boron compound distribution, and the up to date unavoidable gamma-
ray contamination of epithermal neutron beams. All these factors will result in a higher 
toxicity to normal tissue than would be ideal. With proper boron compounds targeting the 
tumor, normal tissue could be spared to a larger extent using fractionation even with 
BNCT. 
Healthy tissue tolerance studies were carried out in dogs as a prerequisite for clinical trials 
on glioma patients. Irradiations were performed at the epithermal port of the High Flux 
Reactor in Petten, The Netherlands. Tolerance of BNCT was investigated using BSH as 
boron carrier (see chapter 3). Within the framework of these healthy tissue tolerance 
studies five Beagle dogs have been irradiated at the 25 µg g-1 boron level to a peak 
physical dose of 13.5 Gy in four fractions spaced 24 hours. BSH infusion was repeated 
prior to each irradiation session. The results were compared to a cohort of five animals (see 
Chapter 3) that had a single dose irradiation to the same peak physical dose following BSH 
infusion.  
Single boron infusion as well as four times 25 mg 10B kg-1 body weight at a twenty-four 
hours interval were well tolerated. Mean blood boron concentration during irradiation for 
the single dose group was 24.5 (± 1.0 SD) µg g-1 10B. For the fractionated dogs a mean 
blood boron concentration of 25.2 (± 1.5 SD) µg g-1 10B was calculated (Table 4.1). No 
change in pharmacokinetics of 10B in blood could be observed after multiple application of 
BSH (Fig. 4.1). Haritz and his coworkers (Haritz et al. 1994) reported similar findings in 
glioma patients. These authors found no differences in boron pharmacokinetics after two 
infusions of 15.3 mg boron kg-1 bodyweight separated by forty-eight hours. Blood boron 
concentrations were down to a few µg g-1 the day after the infusion as observed in our 
canine studies. Best tumor to blood ratios for glioma bearing individuals are reported 
around 24 hours post application of BSH. Fankhauser and co-investigators (Fankhauser et 
al. 1992) found an improvement of the tumor to blood ratio over the first 18 hours and 
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possibly later in glioma patients. Maximum tumor concentrations were measured 2-3 hours 
after infusion. With regards to the initial distribution volume, it is probable that the 
compound distributes only in the plasma and interstitial spaces during the first 24 hours. 
Stragliotto and his team (Stragliotto et al. 1993) described a clearance of boron from the 
high grade gliomas leading to a decrease of the concentration by a factor of two in 24 
hours. During the same interval, the blood boron decreased by a factor three or more. This 
difference gave rise to a tumor to blood ratio that was below one at three hours and 
increased to 1.5 or 2 at 24 hours. Haritz (Haritz et al. 1994) also found a biphasic kinetic in 
human glioma patients infused with BSH. The authors calculated a first half-life of 
10 hours and a second half-life of about 25 hours with large variations from patient to 
patient. One-day post infusion, the boron concentrations were already down to a few 
µg g-1. In contrast to the Lausanne group (Stragliotto et al. 1992), no early half-life within 
one hour after cessation of the BSH infusion was observed. Half-lives of about 320 
minutes found in this study are about half those reported in human glioma patients. This is 
most probably due to the relatively high metabolism of dogs as compared to humans. 
However, in tumor patients one could take advantage of the above described relative 
retention of boron in the tumor and at the same time increase the absolute tumor boron 
concentration by multiple application of BSH. Nevertheless, repeated BSH administration 
may lead to progressive accumulation of boron in the edematous peritumoral brain due to 
bulk flow and diffusion, with consecutively decreased tolerance. This question has not yet 
been fully investigated. However, the Bremen pharmacokinetic study of BSH in glioma 
patients revealed in no significant boron uptake in healthy brain tissue adjacent to the 
tumor bed up to 72 hours post infusion (Haritz et al. 1994).  
No acute breakdown of the blood-brain barrier was observed after BNC irradiation, not by 
the means of MR techniques nor was the protein content of CSF elevated as one could 
expect with a loss of integrity of the blood-brain barrier. Its integrity with fractionated 
BNCT has been of major concern since boron in the form of BSH does note penetrate the 
blood-brain barrier and is therefore restricted to the vascular system within normal brain. A 
negative influence of radiation fractions on the blood-brain barrier (i.e. disrupture) would 
result in a different biodistribution of BSH during consecutive administrations. Boron 
could leak into normal brain and therefore significantly increase the dose to healthy tissue. 
For the case of normal brain tissue with an intact blood brain barrier, Gavin and coworkers 
(Gavin et al. 1993) postulated on the bases of a microdosimetric computer model a 
118  Chapter 4 
significant dose sparing. They calculated dose in normal brain tissue to BNCT for different 
boron distribution modi. With the use of BSH as boron compound a significant vascular 
sparing occurred. The non uniform compound distribution of BSH within brain tissue and 
vasculature resulted in a microscopic physical dose to the endothelial nucleus that is only a 
fraction of the macroscopic physical dose. This model indicated that roughly 5 out of 6 
boron fission events do not contribute to the BSH related central nervous system 
endothelial nuclear dose.  
MCNP calculated peak physical doses at 1.75 cm depth were 13.8 (± 0.3) Gy and 13.6 
(± 0.3) Gy for the fractionated irradiations and the single dose group, respectively. This 
dose is fairly close to the ED50 of 13.6 peak physical Gy found for MR contrast enhancing 
lesions at a mean blood boron level of 25 µg g-1 (see chapter 3). In the single dose group 
there were three animals with contrast enhancing lesions visible in the MR scans, where in 
one of these this finding consisted of a diffusely contrast enhancing spot, which was not 
seen anymore three months later. The five dogs, which received approximately the same 
dose in four fractions, had no responders with respect to MR detectable lesions. Histology 
revealed in four out of five single dose dogs with white matter necrosis. There was no 
evidence of necrosis in the fractionated animals. Here some demyelination and vascular 
changes were the most prominent findings. Also skin reactions within the irradiation field 
were somewhat milder with fractionated irradiation as compared to the single dose dogs 
although for practical reasons no use was made of the possibility of a multi-field irradiation 
technique. Though the groups were rather small (five animals per group), the fractionation 
study performed at the HFR suggests that fractionation was beneficial in that fewer 
changes were observed in the fractionated dogs versus approximately the same dose in a 
single fraction. A sparing effect of fractionation could be observed in both skin and brain 
tissue. However, observed dose response curves are steep. Based on the dose-response 
curves reported in chapter 3, the increase in dose after fractionation to obtain the same 
response as after single fraction irradiation should be in the order of about 1 Gy or even 
more. Since only five dogs per group were investigated, the degree of sparing of normal 
tissue with fractionation cannot be ascertained. But it should be stressed that fractionation 
was not deleterious as others have proposed. 
Within the framework of the Brookhaven normal tissue dose response studies to BNCT in 
dogs with BSH as boron carrier, some animals were given the dose in two or four daily 
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fractions (Gavin et al. 1997). Split dose studies at the epithermal port of the Brookhaven 
Medical Research Reactor (BMRR) were done with the total dose (14.5 Gy equivalent or 
15.75 Gy equivalent) divided into two equal fractions and administered 24 hours apart. 
Effects were studied in eight dogs after infusion of 25 mg 10B kg-1 bodyweight. Additional 
twelve dogs received four equal fractions of BNCT with doses ranging from 13.4 to 18 Gy 
equivalent. The fractions were separated by 24 hours, and boron was administered at 
25 mg 10B kg-1 bodyweight as an intravenous infusion prior to irradiation. Gavin and his 
coworkers reported no gain from this fractionated irradiation scheme as compared to single 
dose irradiations. The split dose studies performed indicated no demonstrable normal tissue 
sparing. With the blood boron concentrations used (25 µg g-1), the low LET contribution to 
total physical dose at peak was approximately 50 %. According to Gavin and his 
coworkers (Gavin et al. 1997) such large low LET fractions would normally imply 
approximately 3 Gy sparing when the total dose is splitted into equal fractions. The dogs 
that received two or four fractions at a blood boron concentration of 25 µg -1 were 
compared to animals that received a single fraction at blood boron levels of 50 µg -1. Total 
dose was adjusted for expected fractionation effects. The increase in relative amount of 
high LET radiation in the single dose study versus the relatively higher contribution of low 
LET radiation to total dose at low boron concentration should allow more repair with 
fractionated irradiation. Sparing of normal tissue by fractionation could not be observed by 
the investigators. This implicates that reasons for fractionation with BNCT should not 
focus on increased sparing of normal tissue from low LET radiation repair but on improved 
compound distribution within a tumor. The normal tissue sparing achievable by the 
selection of different radiation fields with fractionated BNCT might hold some additional 
attraction for this kind of treatment.  
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5.1 INTRODUCTION 
At the time the healthy tissue radiation response study at the High Flux Reactor in 
Petten, The Netherlands, was planned only very limited radiobiological data were available 
on epithermal neutron irradiation and late brain effects. Specially no data were available to 
estimate the RBE of the fast neutron component for brain damage after epithermal neutron 
irradiation. At that time, there was an ongoing study on canine brain tolerance to BNCT 
performed by American scientists using borocaptate sodium (BSH) as the boron carrier and 
the epithermal neutron beam of the Brookhaven National Laboratory Research Reactor. 
Data of the US BNCT study in combination with literature values were used to estimate 
irradiation times and radiation effects to brain and overlaying tissue with the Petten 
epithermal neutron beam. This chapter describes the determination of the relative 
biological effectiveness (RBE) of the fast neutron beam component for skin, based in 
animals of the healthy tissue tolerance study at the BMRR epithermal neutron beam which 
received epithermal neutron beam irradiation in the absence of boron.  
 
Table 5. 1: dose groups for the Petten healthy tissue tolerance studies. Boron concentrations are projected 
and physical doses calculated by the means of Monte Carlo MCNP simulation 
 
dose group
mean
blood 10B
conc.
[µg/g]
peak phys.
dose [Gy]
irrad.
time
[min]
number
of dogs
50 15 76 4
17 86 5
19 96 5
21 106 5
25 9.5 76 4
12 96 4
13.5 108 5
15 120 4
16.5 132 3
0 6.2 116 3
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Since late skin reactions are also mediated by vascular damage, the fast neutron RBE for 
late skin damage was used as the best estimate for the response of the brain to the fast 
neutron component. These data served as input for the calculation of the effectiveness of 
the boron neutron capture reaction in our own data set. The complexity of the boron 
reaction involving microdosimetry and geometric factors has necessitated the term 
compound factor (or compound biological effectiveness factor) instead of RBE to describe 
the relative dose contribution of the 10B(n,α)7Li reaction. A compound factor, i.e. geometry 
x RBE, for the 10B(n,α)7Li reaction was derived for dogs irradiated at the BMRR and the 
HFR epithermal neutron beam in the presence of boron. Calculated equivalent doses and 
dose effect curves are shown.  
5.2 MATERIAL AND METHODS 
A total of fifteen dogs had been irradiated at the epithermal neutron beam of the 
BMRR by Gavin and coworkers with doses ranging from 11 Gy to 16.5 Gy. A detailed 
description of dosage groups as well as observed radiation effects has been reported 
elsewhere (Gavin et al. 1992). In the Petten healthy tissue tolerance study neutron beam 
irradiation was performed at two different mean blood 10B concentrations (Table 5.1). All 
dogs had repeated physical and neurological examinations, complete blood counts, and 
brain imaging via computed tomography (CT) and/or magnetic resonance imaging (MR). 
Brain imaging was performed prior to and following the administration of appropriate 
contrast agents. During imaging and irradiation procedures animals were anaesthetized. 
For protocol details see chapter 3 and Gavin et al. 1992. Physical and dosimetric 
characteristics of both beams and field sizes have been reported elsewhere (chapter 3, Nigg 
et al. 1991, Watkins et al. 1993) as well as radiation dose component calculations (Gupta et 
al. 1994, Nigg et al. 1991 and 1994, Belli et al. 1989). Observations in relation to doses 
applied were compared to historical values reported in literature for photon irradiation. The 
RBE for the fast neutron beam component was derived using the beam only irradiated dogs 
of the US tolerance study. Observed skin effects were compared to literature reports and 
applied doses have been related to the respective X-ray doses reported by Park et al. 1974. 
The fast neutron RBE was calculated by subtracting the physical doses multiplied by their 
respective dose modifying factors from the respective X-ray dose and deviding it by the 
physical dose due to the fast neutron beam component. RBE or dose rate factors used in 
the calculations were equal to 1.0, 2.7 and 1.0 for all gamma sources, the 14N(n,p)14C 
reaction (Archambeau 1989) and other capture reactions, respectively (table 5.2).  
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Table 5. 2: calculation of fast neutron RBE based on radiation effects in skin of BMRR epithermal neutron 
beam only irradiated dogs. 
response
type
biological
endpoint
ref. X-ray
dose [Gy]1
radiation
component
phys.
dose [Gy]
equiv. Dose
(RBE*Gy)3
fast neutron
RBE
early
skin
moist
desquamation
(11.0 Gy dogs)
18.3 other
2
N(n,p)
gamma
fast n
0.52
1.35
4.49
3.18
0.52
3.65
4.49 3.0
reactions moist
desquamation
+ ulceration
(13.7 Gy dogs)
24.4 other
2
N(n,p)
gamma
fast n
0.65
1.69
5.61
3.97
0.65
4.55
5.61 3.4
late skin
≤ 50% skin
necrosis
(16.5 Gy dogs)
36.6
other2
N(n,p)
gamma
fast n
0.78
2.03
6.76
4.78
0.78
5.48
6.76
4.9
reactions
> 50% skin
necrosis
>36.6 other
2
N(n,p)
gamma
fast n
0.78
2.03
6.76
4.78
0.78
5.48
6.76
>4.9
1Park et al., 1974
2other: dose coming from neutron capture reactions by other elements in tissue, primarily Na and Cl
3RBE other: 1.0; RBE N(n,p): 2.7; DRF gamma: 1.0
4RBEfast neutrons= ref. X-ray dose[(equiv. dose gamma)+(equiv. dose N(n,p))+(equiv. dose other)]
physical dose fast neutron  
Compound factors were calculated for dog brain irradiated with the HFR epithermal 
neutron beam (table 5.4), using the fast neutron RBE derived from the American tolerance 
study (table 5.2). Observed biological effects were related to dose in tissue and dose effect 
curves established (figure 5.1). 
5.3 RESULTS 
5.3.1 BMRR irradiated animals 
Observed skin changes were biphasic with the early epidermal changes most 
prominent at three to four weeks post irradiation. With a 11 Gy peak physical dose, 
non-boron dogs showed dry desquamation with small patchy areas of moist desquamation 
and epithelial ulceration. These dogs did not develop any detectable brain lesions within 
one year post irradiation. Epidermal neutron-induced changes, scored as moist 
desquamation with ulceration in greater than 50 % of the incident radiation field, were 
observed in the non-boron dogs that received a peak physical dose of 16.5 Gy. The late 
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skin reaction of dermal necrosis occurred in the 16.5 Gy non-boron dogs. These animals 
had to be euthanized before brain damage could develop. 
5.3.2 Fast neutron RBE (BMRR) 
The fast neutron RBE for early and late skin reactions were derived from the 
epithermal neutron beam only irradiated (non-boron) dogs using published data on skin 
tolerance in dogs to 200 kVp X-rays (Park et al. 1974). Separate RBE values of 3.0-3.4 and 
≥4.9 were calculated for early and late skin effects, respectively (table 5.2). 
No brain damage has been detected with the 11 or 13.7 Gy non-boron dogs. The 16.5 Gy 
non-boron dogs had to be euthanized due to severe dermal necrosis. However, both, skin 
and brain tolerance to radiation in general is thought to be determined by the tolerance or 
renewal capacity of the vascular endothelial system (Barendsen 1991). Therefore, the RBE 
for the fast neutron component in brain was assumed to be similar to that calculated for 
skin. 
5.3.3 HFR irradiated animals 
Irradiation and post-treatment MR procedures were generally well tolerated by all 
animals of the Petten tolerance study. All dogs were irradiated at approximately the desired 
mean blood 10B concentration. Irradiation times were kept constant within the respective 
dose groups. 
Epilation started at about three weeks postirradiation varying from 19 to 37 days. No 
significant dose dependence could be observed for the time of onset (Philipp et al. 1993). 
The degree of epilation was slightly higher with the high dose groups, which was also 
reflected in the lower density of the regrowing hair within these groups. Over all skin 
changes were within the tolerable margins. The most severe effect that occurred was minor 
cases of dry desquamation with almost complete epilation of the irradiated skin field in 
some dogs. After three months hair regrowth was almost complete with all dogs, but hair 
was depigmented (white). 
The first neurologic changes visible on MR scans of the brain were seen at 5 - 6 months 
post-irradiation in twenty-four dogs. Eleven of these dogs were clinically normal. The only 
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observable changes were persistent areas of increased signal intensity on the T1, the T2 
and the contrast-enhanced T1 weighted MR images. Lesions were most prominent in the 
white matter dorsal and lateral of the ventricles. Thirteen dogs developed fatal radiation 
necrosis of the brain with acceptable skin damage. Clinically, these animals showed 
behavioral changes, slight ataxia, reduced sensitivity and disorientation, and progressed 
within 24-48 h to inability to walk. This led to euthanization of the dogs involved. 
The three dogs irradiated with the epithermal beam alone did not show any in vivo 
detectable brain damage. For the nineteen dogs irradiated at a mean blood 10B level of 
25 µg g-1 the dose that would produce effects in 50% of the animals (ED50) for MR 
changes and lethal white matter necrosis were 13.6 and 15.2 Gy peak physical dose, 
respectively. The ED50 values at the 50 µg g-1 mean blood 10B level were found to be 16.8 
Gy peak physical dose for MR detectable changes and 18.8 Gy peak physical dose for 
clinical symptoms caused by white matter necrosis (table 5.3 and fig. 3.8). 
 
5.3.4 Compound factors and equivalent doses (HFR) 
Table 5. 4:  Estimation of BSH compound factors derived for MR detectable brain damage and white matter 
necrosis for HFR irradiated dogs. Other dose modification factors used for the calculation were: 1.0  for 
gamma radiation and others, 2.7 for the N(n,p) reaction, and 4.9 as RBE for the fast neutron component. 
Compound factors were calculated for each individual dog and subsequently averaged. 
endpoint 
 (ref. dose)3 
mean blood 
10B conc. 
dose group 
irrad. time 
non-boron 
equiv. dose1 
[Gy] 
phys. dose2 
from B(n,α) 
reaction [Gy] 
compound 
factor4 
BSH 
CT/MR 
contr. 
enhancement  
(12.8 Gy) 
25 µg g-1 
50 µg g-1 
108 min. 
   76 min. 
   86 min. 
11.87 
   8.36 
   9.23 
 7.79 
10.97 
12.41 
 0.12 
< 0.41 
> 0.26 
lethal white  
matter necrosis 
(14.9 Gy) 
50 µg g-1 
25 µg g-1 
  96 min. 
108 min. 
120 min. 
10.56 
11.87 
13.18 
13.89 
  7.79 
  8.66 
  0.31 
< 0.39 
> 0.2 
1 dose modification factors used: gamma and others: 1.0, N(n,p) reaction: 2.7,  fast neutrons: 4.9 
2 as calculated by Monte Carlo MCNP 
3 Fike et al. 1988 
4 compound factorB(n,α)= (ref. X-ray dose - equiv. non-boron dose) / phys. dose B(n,α) 
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Table 5. 3: individual doses and brain reactions as detectable by means of MR and clinical examination for 
the HFR irradiated dogs. 
irrad. 
time 
[min] 
mean blood 
10B conc. 
[µg g-1] 
MCNP calculated 
peak physical dose 
[Gy] 
equivalent dose
to brain tissue1a) 
[equiv. Gy] 
MR 
contrast 
enhance-
ment 
Equivalent dose 
to brain tissue1b) 
[equiv. Gy] 
lethal 
white matter 
necrosis 
76 42.9 
39.7 
48.8 
51.4 
13.7 
13.0 
15.0 
15.6 
11.5 
11.2 
11.9 
12.1 
0 
0 
0 
0 
11.3 
11.1 
11.7 
11.8 
0 
0 
0 
0 
86 53.3 
58.8 
44.8 
58.3 
56.2 
18.1 
19.5 
15.9 
19.4 
18.8 
13.8 
14.3 
13.1 
14.2 
14.1 
+ 
+ 
+ 
+ 
+ 
13.6 
14.0 
12.9 
13.9 
13.8 
0 
0 
0 
0 
0 
96 47 
52 
47.6 
45 
50.7 
18.4 
19.8 
18.6 
17.8 
19.5 
14.8 
15.3 
14.9 
14.7 
15.2 
+ 
+ 
+ 
+ 
+ 
14.6 
15.0 
14.6 
14.4 
14.9 
+ 
+ 
0 
0 
0 
106 62.3 
50.2 
50.4 
46.9 
38 
25.1 
21.3 
21.4 
20.3 
17.5 
17.9 
16.7 
16.7 
16.4 
15.5 
+ 
+ 
+ 
+ 
+ 
17.6 
16.4 
16.4 
16.1 
15.3 
+ 
+ 
+ 
+ 
+ 
76 26.4 
25 
25.6 
24.3 
10.0 
9.7 
9.8 
9.5 
9.0 
9.0 
9.0 
9.0 
0 
0 
0 
0 
10.0 
9.9 
10.0 
9.9 
0 
0 
0 
0 
96 29.4 
26.2 
24.1 
23.3 
13.4 
12.6 
12.0 
11.8 
11.5 
11.4 
11.3 
11.3 
0 
0 
0 
0 
12.9 
12.7 
12.9 
12.4 
0 
0 
0 
0 
108 25.4 
24.1 
23.1 
25.5 
24.2 
13.9 
13.5 
13.2 
13.9 
13.5 
12.8 
12.8 
12.7 
12.8 
12.8 
+ 
+ 
0 
+ 
0 
14.2 
14.0 
14.0 
14.2 
14.1 
0 
0 
0 
0 
0 
120 27.9 
26.5 
25.3 
16.2 
15.8 
15.4 
14.3 
14.3 
14.2 
+ 
+ 
+ 
16.0 
15.8 
15.7 
+ 
+ 
+ 
132 29.1 
29.3 
25.3 
18.4 
18.5 
16.9 
15.8 
15.8 
15.7 
+ 
+ 
+ 
17.7 
17.7 
17.3 
+ 
+ 
+ 
116 0 
0 
0 
6.4 
6.4 
6.4 
12.7 
12.7 
12.7 
0 
0 
0 
 0 
0 
0 
1 calculated at 1.75 cm depth; dose modifying factors used for the calculation: 1.0 for all gamma sources, an 
RBE of 4.9 for the fast neutron component, 2.7 for the N(n,p) reaction, and for the boron capture reaction a) 
the respective compound factor for MR contrast enhancement and b) for lethal white matter necrosis as 
endpoint (values see text). 
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BSH compound factors (CF) were calculated for two different endpoints: lethal 
white matter necrosis or contrast enhancing brain lesions on MR. For the calculations it 
was assumed that the ED50 for CT changes was identical to the ED50 for MR detectable 
brain lesions. A fast neutron RBE of 4.9, derived from evaluation of late skin effects in the 
BMRR non-boron dogs (see table 5.2), was used as the CNS fast neutron RBE for the 
calculation of CF. Three dogs of the group irradiated for 108 minutes at 25 µg g-1 10B were 
MR positive, two were negative (table 5.3). These animals were regarded to have received 
a dose equivalent to the 12.8 Gy X-ray reference dose. Two out of five animals showed the 
CNS necrosis endpoint within the group of dogs irradiated for 96 minutes at the 50 µg g-1 
10B level. They were regarded to have received a dose equivalent to the ED50 of 14.9 Gy. 
The dose equivalent to the ED50 for the MR endpoint for dogs irradiated at a 25 µg g-1 10B 
level should be in-between the doses of the groups irradiated for 108 and 120 minutes. 
Likewise for 50 µg g-1 of 10B the dogs irradiated for 76 and 86 minutes were used to bound 
the range for the CF value. Compound factors of 0.12 and 0.2 - 0.39 were derived for CNS 
white matter necrosis and MR detectable brain damage, respectively, for the 25 µg g-1 10B 
level, and of 0.26 - 0.41 and 0.31 for the 50 µg g-1 10B level (table 5.4). For equivalent dose 
calculation, the physical dose of each radiation component was multiplied with its 
respective factor. As CF for the 10B(n,α)7Li reaction, the factors calculated in table 5.4 
were taken. For the dogs where only a range of values for CF could be determined, the 
respective median was used: 0.33 for MR contrast enhancement in combination with 
50 µg g-1 mean blood boron concentration, and 0.29 for the endpoint of lethal white matter 
necrosis in animals irradiated with a 25 µg g-1 mean blood boron level. Total equivalent 
dose is then described as the sum of these doses, calculated at about 1 cm within the brain 
(i.e. at 1.75 cm depth in tissue), the location where most of the damage occurred. Physical 
doses and equivalent doses for both endpoints are listed in table 5.3 along with the brain 
reactions as detectable by means of MR and clinical examination. Equivalent dose 
response curves were generated and plotted in figure 5.1. An ED50 of 12.8 Gy equivalent 
for the MR contrast enhancing lesions resulted from the fitted data for the 25 µg g-1 10B and 
the 50 µg g-1 10B group. The ED50 values for lethal white matter necrosis were 14.8 with 
the 25 µg g-1 10B dogs and 14.7 Gy equivalent for animals irradiated at 50 µg g-1 10B. 
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Figure 5. 1: dog brain response to BNCT irradiation at the Petten HB11 epithermal neutron beam. 
Equivalent doses were calculated using an RBE for the fast neutron component of 4.9, the respective BSH 
compound factor (see text) for lethal white matter necrosis and MR contrast enhancing lesions, an RBE for 
the N(n,p) reaction of 2.7, and for all gamma radiation and others a factor of 1.0. Open markers (O ∆) are 
contrast enhancing brain lesions in MR scans. The solid markers (! #) stand for clinical symptoms due to 
white matter necrosis. Circles represent the 50 µg g-1 and triangles the 25 µg g-1 group, respectively. Mean 
doses per group with 1 standard deviation as error are plotted. Points were fitted with a sigmoidal response 
function. 
 
5.4 DISCUSSION 
5.4.1 Fast neutron RBE in skin 
Comparison of the observed skin reactions with those observed for X-rays were 
difficult and have their limitations. The reactions seen in the present study occurred in 
either none or all of the dogs per group. Park had small numbers of animals and did not 
find dermal necrosis in 100 % of any of his dose groups (Park et al. 1974). Based on these 
quantitative differences for the compared biological endpoints, they would imply that in 
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general the calculated RBE for the fast neutron component in the epithermal neutron beam 
might be an underestimate. It could be argued that all of the proton reactions including the 
hydrogen recoil proton have similar RBEs. However, the literature reveals marked 
differences in RBE values with relatively minor changes in proton energy (Belli et al. 
1989). Therefore, the calculated RBE was limited to the fast neutron induced hydrogen 
recoil proton, and a literature value was used for the protons induced by nitrogen capture. 
The difference in the apparent RBE with late skin reactions compared to the early skin 
response is in agreement with observations in human patients. Human skin was irradiated 
with X-rays and fast neutrons, both to equivalent early responses. Two years later, the fast 
neutron treated area showed a much more severe late response than the area treated with 
X-rays. This demonstrated that the neutron RBE is greater for late than for early 
responding tissues (Hall 1988) probably due to different cell populations involved in the 
damage pattern. The skin is accounted to the rapid self-renewing systems. The 
parenchymal cells are more sensitive than the cells of the connective tissue and 
vasculature. Consequently, parenchymal cells are affected by moderate doses of radiation. 
At doses high enough to damage the connective tissue and blood vessels, the parenchyma 
cells may be able to repopulate in the short term but may suffer delayed secondary damage 
from progressive breakdown of connective tissue and an impairment of circulation (Hall 
1988). Acute radiation damage to the skin is primarily a consequence of changes in the 
epidermis. Recovery of the epidermis occurs as a result of the proliferation and migration 
of viable cells. Late radiation damage in skin is primarily a function of radiation effects on 
the vasculature (Hopewell 1990).  
Hornsey plotted data of Hopewell (Hopewell 1990) for late dermal necrosis in pig skin 
against RBE values for fast neutrons in spinal cord (Hornsey 1991). The RBE for late 
dermal necrosis fell about the curve for the RBE for spinal cord injury. Thus, it is thought 
that the fast neutron RBE obtained for late dermal necrosis in the present study may be 
applied also for lethal white matter necrosis of the brain. Hornsey also reported studies 
where the RBE for tumor growth in an irradiated tumor bed was measured for low energy 
fast neutrons. The reduction in growth of the tumor implanted after irradiation of the tumor 
bed is believed to be a result of a reduced capillary growth that fails to support the growing 
tumor. The similarity of RBE data for this tumor bed effect and spinal cord is consistent 
with the hypothesis that both effects are the result of damage to the same target cell 
(Hornsey 1991).  
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5.4.2 BSH compound factor in dog skin 
The skin contained boron levels similar to that observed in the blood and this would 
necessitate a large extravascular component for the skin boron values. A Monte Carlo 
computer model of capillaries was developed and used to simulate the physical and 
equivalent dose to endothelial cell nuclei in skin or brain as a function of boron level and 
distribution pattern of the compound (Gavin et al. 1994). Known macroscopic and inferred 
microscopic information from the canine studies was used in the model to predict the effect 
of epithermal beam irradiation and the B(n,α)Li reaction on the endothelium. The charged 
particle transport methods employed have been described elsewhere (Wheeler 1994). The 
computer modeling resulted in a compound factor of almost two for the endpoint of canine 
skin necrosis after the application of BSH. Late damage to the skin has been attributed 
primarily to radiation effects on the vasculature. Dermal necrosis occurs as a consequence 
to vascular insufficiency (Hopewell 1990). A BSH compound factor for late radiation 
effects (dermal necrosis) in canine skin of 0.48 resulted from the BMRR healthy tissue 
tolerance studies (data not shown). The discrepancy between the biologic and the computer 
modeled compound factors for BSH in skin hints at a non-uniform distribution of boron in 
relation to dermal vessels. The microdistribution has a major effect on the dose distribution 
of boron capture fission fragments. Microscopic quantification of boron in the skin is 
required before this discrepancy can fully be explained. 
None of the HFR irradiated animals reached the endpoint of dermal necrosis. Therefore, no 
compound factor could be calculated. However, equivalent doses to the skin were 
calculated using the dose weighting factors derived from the BMRR irradiated animals.  
This revealed in values well below the ones needed for reaching the endpoint of dermal 
necrosis, which is in agreement with the clinical observation. 
5.4.3 Fast neutron RBE in brain 
Attempts to date to obtain brain tolerance values for the epithermal neutron beam 
alone with acceptable skin reactions have failed, and this has necessitated the use of the 
same vascular endothelial RBE for the fast neutron dose component in skin and brain. The 
peak equivalent dose of the 11 Gy non-boron dogs exceeded the reported tolerance for the 
brain (Fike et al. 1988). However, a large fraction of the equivalent dose was due to fast 
neutrons and their effect diminished rapidly with increasing depth. Therefore, it is believed 
that with the BMRR non-boron dogs only the surface of the brain was irradiated to the 
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peak dose and that the majority of the brain was exposed to tolerable equivalent doses. 
Severe atrophy of the irradiated temporal muscle was observed in these dogs at twelve 
months post irradiation. This finding may indicate an increased contribution of the fast 
neutron component to the human brain since the brain lies much closer to the surface than 
in the Labrador dog used with the BMRR irradiation.  
5.4.4 BSH compound factor in brain 
Observed radiation effects after BNC irradiation with BSH in normal brain are 
thought to be driven mainly by the destruction of the blood brain barrier. The irradiation of 
dogs in the absence of boron revealed information concerning the relative biological 
effects of the fast neutron component. Once this estimate was obtained, the results of the 
tolerance studies in dogs following an intravenous infusion of BSH could be better 
understood. That value allowed the boron capture physical dose to be converted to an 
equivalent dose to yield the desired equivalent dose for a biologic isoeffect. The total 
physical dose required to reach a biological isoeffect appears to increase directly as the 
proportion of boron capture dose increases, indicating a compound factor being smaller 
than 1. This effect together with the knowledge of the macrodistribution, let to estimates on 
the influence of the microdistribution of the BSH compound. The use of BSH as boron 
carrier basically excludes boron from the normal brain parenchyma. Small amounts 
measured in normal brain could largely be accounted for by remaining blood volume of the 
analyzed tissue (Kraft et al. 1992). The hydrophylic character of BSH and the restrictive 
nature of the blood brain barrier implies an exclusion of this compound from the cytoplasm 
of endothelial cells. This geometry would result in a large dose sparing effect mainly due 
to a lack of charged particle equilibrium in smaller diameter vessels and up and down 
stream energy depositions not contributing to the endothelial nuclear dose. RBE values 
used in the computer modeling (Gavin et al. 1994) of dose to the endothelial nuclei were 
2.7, 2.3, and 4.5 for the nitrogen capture reaction (Archambeau 1989), 10B(n,α)7Li 
(Archambeau 1989) and the fast neutron beam component, respectively. Using the BMRR 
epithermal beam parameters, the brain capillary model with a 10B distribution similar to 
BSH of 25 µg g-1 in the lumen and 1 µg g-1 in the endothelial cell cytoplasm and 
surrounding parenchyma resulted in a capillary endothelial nuclear physical dose of 
9.62 Gy with a peak physical dose of 20 Gy. The calculated equivalent dose to the 
endothelial nuclei was 17.14 equiv. Gy. The percentages of boron capture total physical 
dose to the capillary endothelial nucleus from interregional transport of 10B capture 
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fragments were 22 % from the lumen, 2.2 % from the parenchyma, and 2.1 from the 
endothelial cytoplasm. The fraction of the total boron dose that struck the endothelial 
nucleus multiplied by the RBE of 2.3 resulted in a compound factor for brain endothelium 
of 0.4 with BSH (Gavin et al. 1994). This value is remarkably close to that calculated from 
the dog head irradiation studies. The compound factor is the product of RBE and 
microscopic physical dose divided by the macroscopic equilibrium physical dose. A 
compound factor of 0.4 would indicate that approximately 83 % of the peak physical boron 
capture dose (roughly five out of six capture events) do not contribute to the endothelial 
nuclear dose. 
For all scenarios investigated a CF of 0.31 is justifiable, except for the 25 µg g-1 10B group 
and the endpoint of contrast enhancement in MR scans. The tendency of CF values being 
slightly higher in the 50 µg g-1 10B groups could be explained by an altered 
microdistribution of the compound. With a higher blood concentration it might seem 
likely, that relatively more BSH was taken up by the endothelial cells causing more 
effectively damage to the respective cell nuclei. Such would be reflected in a higher CF 
value. However, Morris et al. (1996) have shown that the compound factor does not 
change significantly with variable doses of borocaptate sodium in rat spinal cord treated 
with BNCT indicating that the microdistribution of boron does not change considerably. 
On the other hand, the estimation of CF at higher boron concentrations is less depending 
on beam dose estimation. Thus, the CF value obtained for the 50 µg g-1 10B concentration 
is probably more accurate. 
 It is not understood why the compound factor should be different for MR contrast 
enhancing lesions and the endpoint of white matter necrosis since both manifestations of 
radiation injury are thought to be vascular driven and should therefore have a very similar 
CF with BSH. A lower CF value for the MR contrast enhancement suggests that the 
10B(n,α)7Li reaction is less harming with respect to this endpoint than to the endpoint of 
lethal white matter necrosis. This seems biologically at least doubtful. All animals having 
lethal white matter necrosis showed extensive changes in MR scans. On the other hand, 
there were animals displaying only MR detectable changes without any clinical signs of 
brain damage. The point might be the use of a fast neutron RBE assessed for late skin 
reaction. Hornsey reported the RBE for late dermal necrosis falling about the values for 
late spinal cord injury (Hornsey 1991). Nevertheless, if the endpoint of MR detectable 
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lesions in brain should have a different, in this case lower RBE, CF values would greaten. 
They would be increased for both boron levels used in this study, but to a lesser extend 
with 50 mg g-1 10B than with the 25 mg g-1 10B group since the relative contribution to dose 
resulting from the fast neutron component is significantly lower.  
The fast neutron contamination of the available epithermal neutron beams and the incident 
and induced gamma components indicate a need for high boron concentrations in tumor 
tissue to effectively use the boron capture reactions for targeted radiotherapy. The fast 
neutron and gamma dose result from non-targeted radiation and contribute significantly to 
normal tissue dose. The fast neutron dose could make the superficial tissues the bottle neck 
of BNCT at low blood boron concentrations. 
5.4.5 Equivalent Doses 
Equivalent dose response curves were generated and plotted in figure 5.1. An ED50 
value of 12.8 equivalent Gy was obtained for the MR contrast enhancing lesions from the 
fitted data for the 25 µg g-1 10B and the 50 µg g-1 10B group. The dose that produced lethal 
white matter necrosis in 50% of the animals was 14.8 Gy equivalent with the 25 µg g-1 10B 
and 14.7 Gy equivalent for animals irradiated with 50 µg g-1 10B in blood, respectively. 
Theoretically, equivalent dose response plots should reasonably match the ones for the 
reference X-radiation data, i.e. the ED50 values should be 12.8 for MR contrast enhancing 
lesions and 14.9 for lethal white matter changes. This is the case in this analysis. 
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ABSTRACT 
In order to make clinical trials of boron neutron capture therapy safe for the patient, 
it is necessary to know the Relative Biological Effectiveness (RBE) of the radiation 
components and the compound factor of the boron carrier to be used. Here a method is 
derived to determine the RBE of recoil protons and the compound factor of compounds 
from in vivo experiments with varying concentrations of boron. The method uses a 
simultaneous fit of both these parameters to all experimental data. This method is applied 
to the studies of healthy tissue tolerance in dogs at the High Flux Reactor in Petten, The 
Netherlands. The RBE for the recoil protons generated by the neutrons present in the 
epithermal neutron beam (together with the RBE of the protons from the 14N(n,p)14C 
reaction) for induction of severe neurological symptoms was found to be 3.93 ± 0.43, and 
2.33 ± 0.14 for induction of changes detectable by magnetic resonance imaging,. The 
compound factor for Na2B12H11SH in brain tissue, using severe neurological symptoms as 
endpoint, was determined to be 0.37 ± 0.06 (95% confidence limits 0.24-0.50). For 
changes detectable by magnetic resonance imaging, the value was found to be 0.65 ± 0.04 
(0.58-0.73).  
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6.1 INTRODUCTION 
As in all radiotherapy modalities, the aim of BNCT is to deposit a tumoricidal 
radiation dose in the tissue to be eliminated, while at the same time sparing the healthy 
tissue. In contrast to conventional radiotherapy, in BNCT this is not achieved by physical 
targeting of the beam, but rather by physiological targeting of the tumor with boron-
containing compounds. 
The Relative Biological Effectiveness of the protons resulting from the 10B(n,α)7Li 
reaction is of great importance in determining whether a sufficient dose differential can be 
achieved between tumor and healthy tissue. The RBE of these protons has been determined 
in cell culture (Davis et al. 1970, Gabel et al. 1984, Ichihashi et al. 1989) and in tissue 
(Coderre et al. 1993, Morris et al. 1996). The RBE measured in tumor cell culture is not 
necessarily applicable to the in vivo situation (Coderre et al. 1993), as the target cell 
type(s), which is important in vivo for the response of tumor tissue, might not be limited to 
tumor cells, but could e.g. also include the vascular system. In healthy tissue showing a 
typical late response, the cells, which determine tissue breakdown long after the 
irradiation, cannot always be identified readily. For BNCT, this problem is augmented by 
the fact that the particles emitted have very short ranges and therefore do not produce a 
uniform dose on the cellular level. The situation has been modeled by Kitao (Kitao 1975), 
Kobayashi and Kanda (Kobayashi and Kanda 1982) and Gabel (Gabel et al. 1987). 
When predicting the radiobiological effect of a given concentration of boron-10 in tissue, 
the location of boron in relation to the critical target and the possible heterogeneity of the 
boron distribution in different types of cells in the tissue must be taken into account. 
Gahbauer (Gahbauer et al. 1992) have therefore defined a compound factor (CF) that 
describes the radiobiological effectiveness, for a given end point, of the particles emitted in 
the 10B(n,α)7Li reaction using a specified boron compound. The CF takes into account the 
geometrical distribution of the particles generated, in relation to the appropriate target 
cells. CF can be used in the same way as RBE; however, it is dependent on the compound 
used. For BPA, the CF for early skin reaction in the hamster has been determined to be 2.4, 
assuming an RBE of the protons from the 14N(n,p)14C reaction of 2.9 (Hiratsuka et al. 
1991).  
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In BNCT, there are further dose components in addition to the 10B(n,α)7Li reaction, all of 
which contribute to the total dose deposited in tissue. These components are partly 
contaminations in the neutron beams used, and partly unavoidable neutron capture 
reactions in the target tissues. The former ones consist of γ-rays and fast neutrons, and the 
latter are mostly neutron capture reactions in hydrogen [1H(n,γ)2H] and nitrogen 
[14N(n,p)14C]. The RBE for recoil protons from fast neutrons has been assigned values 
between 1.6 (Clement et al. 1990) and 6 (Dorn et al. 1992). (In the context of this paper, 
the neutrons present in epithermal neutron beams are called fast neutrons, despite the fact 
that their mean energy is only around 10 keV.) For the protons from the 14N(n,p)14C 
reaction, experimental evidence from cells in culture suggests an RBE of around 2, with a 
rather large uncertainty (Gabel et al. 1984). For the skin of hamsters, the RBE of the 
protons from the 14N(n,p)14C reaction has been determined to be 2.9 (Hiratsuka et al. 
1991). 
In this paper, the CF of the 10B(n,α)7Li reaction for BSH in brain as target tissue and the 
combined RBE of the recoil protons from fast neutrons of the neutron beam and from the 
14N(n,p)14C reaction are derived. To this end, a method is devised which allows the 
simultaneous determination, through non-linear fitting procedures, of the CF and RBE for 
the mixed field irradiations of BNCT to experimental data for individual animals, with 
different concentrations of boron in blood.  
BSH is presently under investigation in Europe for clinical trials of glioma at the High 
Flux Reactor (HFR) in Petten, The Netherlands (Gabel et al. 1992). Boron concentrations 
in blood exceeding 25 µg g-1 are obtained, with concentration ratios between tumor 
average and blood of between 1-2 (Haritz et al. 1994). Uptake in healthy brain is very low. 
The radiobiological significance of the particular boron concentration and its 
microdistribution must be known, as well as the radiobiological contribution from the fast 
neutrons, before clinical trials can be initiated with confidence. 
6.2 METHODS AND MATERIALS 
6.2.1 The Healthy Tissue Tolerance Study 
BSH was intended for the treatment of malignant glioma with epithermal neutrons 
at the High Flux Reactor (HFR) Petten (Gabel et al. 1992). To this end, a study has been 
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set up to determine CF for BSH in healthy brain tissue in dogs (Siefert et al. 1992). This 
study follows the initial study of Gavin et al.(1992) at the Brookhaven Medical Research 
Reactor (BMRR). The results are now available, and allow the determination of CF and 
RBE of the dose components. 
In the present study, beagle dogs were exposed to the HB11 epithermal neutron beam of 
the HFR Petten, collimated to a diameter of 8 cm, and centered on the top of the head. For 
details see chapter 3. Table 6.1 lists the data for the dogs in the study. Dogs not progressing 
to neurological symptoms were sacrificed after one year or more.  
6.2.2 Dose Rates and Dose Point 
 
Figure 6. 1: MR image (T1-weighted, with Gd-DTPA contrast) of a Beagle dog brain. The section is in the 
center of the beam (diameter 8 cm), which is centered on the skull. The beam is indicated by the white bar. 
 
Table 6.2 lists the calculated dose rates for the different dose components at 
different depths. The data are adapted from Watkins (1992), with adjustment of the 
nitrogen dose rate to a nitrogen composition of the white matter of 2.187% (Moran et al. 
1992). The maximum of the thermal neutron fluence occurs at the listed depth of around 
2.25 cm. White matter occurs at a depth of around 1.5 cm, as shown in Figure 6.1. The 
point in the center of the beam and 1.5 cm into tissue is taken as the dose point. Figure 6.2 
shows the dose-volume histograms for the Beagle brain, with boron concentrations of 25 
and 50 µg g-1 and the RBE and CF values derived in this paper. 
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Table 6. 1: List of all dogs analyzed in this paper. "MR" refers to changes visible in magnetic resonance 
imaging, "N" to neurological symptoms, "-" to no observable changes during at least one year of observation. 
Total dose refers to the sum of all physical doses (physical) at 1.5 cm depth, or equivalent doses, which 
were calculated as sums of all components using the RBE and CF values for the respective endpoint in this 
study, and are given under the headings RBE (neuro) and RBE (MR), respectively. The grouping of the 
animals according to dose, for construction of Figure 6.5 is indicated by the numbers under "group N" for 
neurological symptoms and "group M" for MR-visible changes. 
irradiation 
time 
 
boron 
concentration
symptoms time to 
neurological 
symptoms 
Total dose 
(Gy or Gy equivalent) 
group 
N 
group
M 
(h) (µg g-1)  (months) Physical RBE 
(neuro) 
RBE 
(MR) 
  
1.93 0 -  5.9 12.2 8.8 3 1 
1.93 0 -  5.9 12.2 8.8 3 1 
1.93 0 -  5.9 12.2 8.8 3 1 
1.27 24.3 -  8.7 9.9 9.0 1 1 
1.27 25.0 -  8.8 9.9 9.1 1 2 
1.27 25.6 -  9.0 9.9 9.2 1 2 
1.27 26.4 -  9.1 10.0 9.3 1 2 
1.6 23.3 -  10.7 12.3 11.2 3 3 
1.6 24.1 -  10.9 12.4 11.3 3 3 
1.6 26.2 -  11.4 12.6 11.7 4 3 
1.6 29.4 -  12.2 12.9 12.2 4 4 
1.8 23.1 -  12.0 13.8 12.5 5 4 
1.8 24.1 MR  12.3 13.9 12.7 5 5 
1.8 24.2 -  12.3 14.0 12.7 5 5 
1.8 25.4 MR  12.7 14.1 13.0 6 5 
1.8 25.5 MR  12.7 14.1 13.0 6 5 
2 25.3 N 7 14.0 15.6 14.4 7 6 
2 26.5 N 7 14.4 15.8 14.6 7 7 
2 27.9 N 6 14.8 15.9 14.9 7 7 
2.2 25.3 N 9 15.4 17.2 15.8 8 8 
2.2 29.1 N 6 16.7 17.7 16.7 8 9 
2.2 29.3 N 7 16.8 17.7 16.7 8 9 
1.27 39.7 -  11.8 11.0 11.0 1 3 
1.27 42.9 -  12.4 11.2 11.4 2 3 
1.27 48.8 -  13.6 11.7 12.2 2 4 
1.27 51.4 -  14.1 11.9 12.6 2 5 
1.43 44.8 MR  14.4 12.8 13.2 4 6 
1.43 53.3 MR  16.3 13.5 14.4 5 6 
1.43 56.2 MR  17.0 13.7 14.9 5 7 
1.43 58.3 MR  17.4 13.9 15.2 5 8 
1.43 58.8 MR  17.5 14.0 15.2 5 8 
1.6 45.0 MR  16.2 14.3 14.8 6 7 
1.6 47.0 N 7 16.7 14.5 15.1 6 8 
1.6 47.6 MR  16.8 14.6 15.2 6 8 
1.6 50.7 MR  17.6 14.9 15.7 6 8 
1.6 52.0 N 10 17.9 15.0 15.9 6 8 
1.76 38.0 N 6 15.9 15.1 15.0 7 7 
1.76 46.9 N 7 18.3 16.0 16.6 7 9 
1.76 50.2 N 6 19.2 16.3 17.2 8 9 
1.76 50.4 N 5 19.3 16.3 17.2 8 9 
1.76 62.3 N 6 22.6 17.5 19.4 8 9 
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Table 6. 2: Dose components for the HB 11 epithermal neutron beam in skin and at depth. The dose rates 
were obtained from Watkins (Watkins 1992) with modification of the nitrogen dose rate to reflect an average 
nitrogen composition of 2.187 %. Data for 1.5 cm were derived by linear interpolation. The values pertain to 
the dog irradiations and give the dose rates in a perspex beagle head phantom exposed to a circular beam 
delimited to 8 cm diameter. The depth of 2.25 cm corresponds to the thermal neutron flux maximum, values 
are included for comparison. 
 
Depth (cm) 0.25 1.25 1.5 1.75 2.25 
Dose component dose rate / Gy h-1 
Fast neutrons 1.29 0.91 0.82 0.73 0.54 
14N(n,p)14C 0.13 0.29 0.32 0.34 0.36 
Gamma-rays 
(total) 
1.55 1.85 1.90 1.93 2.07 
1 µg g-1 10B 0.063 0.145 0.157 0.169 0.176 
percent dose of thermal maximum
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Figure 6. 2: Dose-volume histogram of the brain of Beagle dogs, exposed to the HB11 beam collimated to 8 
cm diameter. Doses for the indicated RBE and CF values and two boron concentrations are shown. The point 
of 100% dose is the voxel of 1x1x1 cm3 in which the thermal neutron maximum occurs. Therefore, voxels 
exist which show a higher dose. 
148  Chapter 6 
6.2.3 Analysis of Data 
The analysis of data was carried out with the assumption that the different doses 
occurring in the target tissue can be treated additively, and that their RBE values are not 
influenced by the presence of the additional dose from boron. The endpoints considered are 
the incidence of neurological symptoms or MR-visible changes. From such data the doses 
associated with a 50% incidence of each effect is calculated using common fitting 
procedures. 
In the absence of boron, the beam itself and the neutron capture reactions in hydrogen and 
nitrogen will in them selves deliver a dose to tissue. The tolerance dose Dref for a given 
endpoint will then be given by 
[1] D D RBE D RBEref gamma gamma proton proton= ⋅ + ⋅  
Here, Dgamma refers to the sum of the physical doses delivered by the beam directly and 
through neutron capture reactions in hydrogen and nitrogen, to the sum of the incident 
gamma-ray dose and the gamma-ray dose from neutron capture reactions in hydrogen, and 
Dproton to the sum of the doses delivered through recoil protons by the incident neutrons 
and the protons from neutron capture reactions in nitrogen. RBEx is the appropriate RBE 
for the particular quality of radiation and the chosen endpoint. 
In the presence of boron, in addition to the doses delivered by the beam and the neutron 
capture reactions in hydrogen and nitrogen, the neutron capture reaction in boron must be 
considered. Therefore, the dose Dref will consist of: 
[2] D D RBE D RBE D CF cref gamma gamma proton proton boron= ⋅ + ⋅ + ⋅ ⋅  
The dose delivered, Dboron, pertains to a unit boron concentration of 1 µg g-1 when the 
boron concentration c is measured in units of µg g-1. The appropriate factor for converting 
the physical dose to biological dose is the Compound Factor CF. 
The reference dose Dref is reached at an irradiation time tc, given by equation [3] 
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[3] D t D RBE D RBE D CF cref c gamma gamma proton proton boron= ⋅ ⋅ + ⋅ + ⋅ ⋅( & & & )  
The irradiation time tc required to reach the reference dose Dref is then consequently given 
by 
[4] t
D
D RBE D RBE D CF cc
ref
gamma gamma proton proton boron
=
⋅ + ⋅ + ⋅ ⋅& & &
 
The irradiation time required to reach the tolerance dose Dref  in the absence of boron is a 
constant t0: 
[5] t0 =
⋅ + ⋅
D
&D RBE &D RBE
ref
gamma gamma proton proton
 
In order to fit equation [4] to the experimental observations, a dose-response curve of 
probabilistic or logistic form is required. Here, a general logistic equation [6] for a general 
equation y=d·x+b was used: 
[6] p
y
d x b
a=
+
⋅ +
⎡
⎣⎢
⎤
⎦⎥
1
1
 
which with a denominator of 2 results in a 50% probability of response. When equation [6] 
is applied to equation [4], taking into account that both c and t are independent variables, 
equation [7] results: 
 [7] p
t
D
D RBE D RBE c D CF
ref
gamma gamma proton proton boron
a=
+ ⋅ ⋅ + ⋅ + ⋅ ⋅
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
1
1 ( & & & )
 
When substituting the value for t0 in equation [7], equation [8] results, which contains only 
t and c as independent variables, and only CF as parameter to be fitted. 
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[8] p
t
t
t
D
c D CF
ref
boron
a=
+ + ⋅ ⋅ ⋅
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
1
1
0
( & )
 
In equations [6], [7], and [8], p is the probability of response, and a is a measure of the 
steepness of the dose-response function. The parameters obtained pertain to a 50% 
incidence of the endpoint considered. At this rate of incidence, the denominator of the 
logistic functions is 2, and t is equal to tc. 
The reference dose for X-rays was taken as 14.9 Gy with neurological symptoms as 
endpoint, as reported by Fike et al. (1988) for hemispheric brain irradiation. No data are 
available in the literature for single doses required to induce MR-visible changes in dog 
brain. Fike et al. (1988) has observed focal CT-visible changes with an X-ray dose of 12.8 
Gy. This value is taken here as reference dose for MR-visible changes, assuming that focal 
CT changes, which are seen in brain tumor patients after radiotherapy, will be induced by 
the same dose as MR-visible changes, which are also widely observed.  
It should be pointed out that dose rates and dose-volume histograms are different in the 
experiments described here and in the X-ray experiments. For the RBE and CF values 
determined in this paper, and for two different boron concentrations, the dose-volume 
histograms for the brain tissue are found in Figure 6.2.  
6.2.4 Statistical Analysis of Data 
All parameters (CF, the RBE of recoil protons RBEproton, and a) were determined 
through fitting procedures, using equation [7]. 
Individual animals showing response for a given endpoint were assigned a value for p of 1; 
if they did not show the response under consideration, a value for p of 0. Animals 
developing neurological symptoms were also scored as responders for MR-visible changes, 
although sometimes their physiological state did not allow images to be obtained. 
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Fitting was carried out using the nonlinear multi-variant curve fitting procedure of the 
software package Sigmaplot (Jandel Scientific). The parameters were derived from 
simultaneous fitting.  
6.3 RESULTS 
In this paper, it is assumed that 14.9 Gy of X-irradiation are needed to produce 
neurological symptoms, and 12.8 Gy for MR-visible changes. Fike et al. (1988) observed 
neurological symptoms with 14.9 Gy X-ray irradiation, and CT-visible changes with 12.8 
Gy. No data are available in the literature for the dose required to induce MR-visible 
changes. It should be kept in mind, however, that dose rates and volumes irradiated are not 
identical for the X-ray data set on one hand and the BNCT data set on the other hand. A 
change in the X-ray dose required to reach the same endpoint under different conditions 
would change both RBE and CF.  
6.3.1 RBE for Recoil Protons from Fast Neutrons and the 14n(N,P)14c Reaction 
The RBE values for recoil protons for the two endpoints are found in Table 6.3.  
Table 6. 3: RBE and CF values for 1.5 cm depth and the different endpoints. Values are given ± SD. a is the 
steepness parameter of the logistic equation [7]. 
endpoints  
neurological symptoms MR-visible changes 
CF 0.37 ± 0.06 0.65 ± 0.04 
RBE of recoil protons 3.93 ± 0.43 2.33 ± 0.14 
a -55 ± 21 -72 ± 27 
 
For an RBE of the gamma radiation of 1.0, a value of 3.9 ± 0.4 (95% confidence interval 
3.1-4.8) for neurological symptoms as endpoint (at 1.5 cm depth) is found. This differs 
from the value for MR-visible changes, which is determined to 2.3 ± 0.1 (2.1-2.6), and thus 
is significantly smaller (p<0.05) than the value obtained for neurological symptoms as 
endpoint. 
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If a dose rate factor (DRF) of the gamma radiation of 0.8 is assumed (which could be 
debated as the dose rate in the present experiment is lower than that in the reference 
experiment), the corresponding RBE values for the recoil protons are increased in 
proportion to the relative dose rates. In the fitting procedure, values of 4.3 ± 0.4 and 
2.7 ± 0.1 result for neurological symptoms and MR-visible changes, respectively. 
6.3.2 Compound Factor for BSH 
Table 6.3 lists also the values for CF for the different endpoints measured. The 
values obtained are considerably below unity. For MR-visible changes, a value of 
0.65 ± 0.04 (95% confidence interval 0.58-0.73) is obtained. For neurological symptoms, 
the value of 0.37 ± 0.06 (0.25-0.50) is even lower. The difference between them is 
statistically significant (p<0.05). 
The values for CF depend solely on the assumptions that within the boron concentration 
interval studied, doses behave additively, and that the target tissue remains at a constant 
depth, with a negligible volume effect caused by the presence of different concentrations of 
boron. Over an even larger boron concentration interval, Morris et al. (1996) found that 
boron doses and other dose components could be treated additively. 
There is no dependency of the value of CF on the RBE of the gamma radiation. The values 
derived from the fitting procedure with an RBE for the gamma radiation of 0.8 do not 
differ from those derived with RBEgamma=1. This result is expected from inspection of the 
equations [7] and [8]. In the absence of boron, a change in RBEgamma must lead to a 
compensating change in RBEproton, as the time t0 required to reach Dref  in the absence of 
boron is a constant, whose value is independent of the dose mixture. 
From theoretical considerations, the values for CF can change by up to a factor of 10, 
depending on the geometrical arrangement of boron in relation to the critical target 
(Kobayashi and Kanda 1975, Gabel et al. 1987). Experimentally, it is observed that BSH is 
excluded from the healthy brain; therefore all boron capture reactions which influence the 
endothelial cells originate in the lumen of the blood vessels. Glia cells are therefore not 
exposed to the boron capture radiation products. The observed low value of CF for BSH is 
consistent with the exclusive localization of boron in the lumen of blood vessels. 
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6.3.3 Dose-Response Curves 
The knowledge of the parameters for the logistic equation [7] can be used to 
construct dose-response surfaces for the two independent variables, irradiation time t and 
boron concentration c. Such curves are found in Figures 6.3 and 6.4 for MR-visible 
changes and neurological symptoms as endpoint. As expected (Fike et al. 1988), these 
curves show a steep dose response. 
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Figure 6. 3: Fit of equation [7] to the experimental results, with MR-visible changes as endpoint. Symbols: 
observations. The surface corresponds to equation [7], with values of a = -72, RBE for recoil protons of 2.33, 
and CF for BSH of 0.65. 
 
With the knowledge of the CF and RBE, the two independent variables t and c can be 
combined to yield a biologically weighted dose. With these doses available for all animals, 
two-dimensional dose-response curves can be constructed for the two endpoints 
considered. They are found in Fig. 6.5. For the construction of these curves animals were 
grouped according to the groups indicated in Table 6.1. For MR-visible changes, 9 groups 
were formed, for neurological symptoms, 8 groups. 
 
It should be noted that the curves of Figure 6.5 can be constructed only with knowledge 
about RBE and CF; these values cannot be extracted from the curves shown. For deriving 
RBE and CF, three-dimensional analysis must be carried out. 
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Figure 6. 4: Fit of equation [7] to the experimental results, with neurological symptoms as endpoint. 
Symbols: observations. The surface corresponds to equation [7], with values for a of 55, and for RBE for 
recoil protons of 3.93, and CF for BSH of 0.37. 
6.4 DISCUSSION 
In BNCT, the total dose delivered to tissue consists of gamma-rays, recoil protons, 
and the product of the 10B(n,α)7Li  reaction. For a given combination of beam size, target 
composition and irradiated volume, exposure time and boron concentration determine the 
total dose delivered. 
These two variables are treated as independent variables and are used here to analyze the 
response of tissue to the mixed radiation field of BNCT. Therefore, values for CF for a 
given boron compound and RBE values for the other high-LET components can be derived 
from all data available. It is not necessary to carry out an experiment in the absence of 
boron in order to derive a value for the RBE of the beam or its components. Such an 
experiment might prove impossible, if the tissue for which a response is monitored is 
positioned at depth, as the intervening tissue might receive a dose exceeding its tolerance. 
In order to prevent damage to skin and other overlaying tissue during irradiation, Gavin 
(personal communication) has, by means of surgery, removed a tissue flap during 
irradiation. 
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Figure 6. 5: Dose-response curve for neurological symptoms (circles, solid line) and MR-visible changes 
(triangles, dotted line). The doses are given in biologically weighted dose (i.e. sum of physical doses each 
multiplied by the respective RBE or CF). For calculation of the doses, values of 3.93 for RBE and 0.37 for 
CF were taken for neurological symptoms, and values of 2.33 for RBE and 0.65 for CF for MR-visible 
changes. The large bars refer to the dose where 50% of the indicated damage occurs. These values have been 
derived through a logistic fit of the data to the equation p ea dose Dref= + ⋅ −1 1/ ( )( ) . For neurological 
symptoms, Dref (given by bar) was obtained as 14.5±0.0 Gy equivalent, for MR-visible changes as 12.8±0.0 
Gy equivalent. Refer to Table 6.1 for grouping of the animals for the two sets of values. 
 
The method of analysis differs from those applied to similar problems by other authors 
(see, e.g., Hiratsuka et al. 1991, Morris et al. 1992 a). The method there uses dose-response 
curves as shown in Figure 6.5. The construction of these curves requires a constant boron 
concentration in blood. As can be seen in the inspection of Table 6.1, it proved difficult to 
achieve this. The group of dogs for which 25 µg g-1 boron was the target concentration had 
actual boron concentrations in blood between 23.1 and 29.3 µg g-1. For the group of dogs 
with a target boron concentration of 50 µg g-1, the variation was even larger, between 38.0 
and 62.3 µg g-1. Similarly, Morris et al. (Morris et al. 1996) observed variations of boron 
concentrations in rats that had a standard deviation of ±10%. 
The RBE for recoil protons in this analysis is considerably higher than the lower values of 
1.6 proposed by some researchers (Clement et al. 1990), but below the value of 6 proposed 
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by others (Dorn et al. 1992). The value of around 4 for the induction of neurological 
symptoms is slightly higher than the RBE of recoil protons from neutron therapy facilities 
(Hopewell et al. 1988) and the RBE for the 14N(n,p)14C reaction as determined by 
Hiratsuka (Hiratsuka et al. 1991). Experiments by Hall et al. (Hall et al. 1975), using 
neutrons of different energy to induce cell death, have shown that the RBE is a function of 
neutron energy, with a maximum RBE at around 1 MeV neutron energy. Such an effect 
could be a possible explanation for the difference in RBE. Another reason could be a 
misrepresentation of the neutron flux and spectrum in the calculations yielding the fast 
neutron dose rate, the uncertainty in kerma factor of the neutrons (ICRU29 was used 
(Watkins 1992)), or an erroneous assumption on either dose-volume effects or dose points. 
A possible influence of dose-volume effects or selection of the dose point could be 
clarified by experiments with beams of different angular distribution of neutrons, such as 
the beam at the Brookhaven Medical Research Reactor (Fairchild et al. 1990). 
The RBE for MR-visible changes is lower than that for induction of neurological 
symptoms, and more similar to the values found by Hopewell et al. (1988) and Hiratsuka et 
al. (1991) for early skin reactions. Its numeric value will be influenced greatly by the exact 
dose rate, on a microdosimetric level, of the 14N(n,p)14C reaction. The nitrogen content in 
blood is around 1% and thus lower than in white matter, where it is 2.2%. Hence, the 
endothelial cells will receive a smaller dose from the nitrogen capture reaction. This 
situation would require detailed modeling, in order to determine whether the RBE for 
recoil protons for the two endpoints are different or not, as the dose rates for recoil protons 
and the 14N(n,p)14C reaction were not separated in the present analysis. If two different cell 
types are involved in the phenomena observed, they might also have different 
radiosensitivity, either to high-LET radiation or to low-LET radiation, or to both, resulting 
in differential damage. It could also be that MR-visible changes is caused by cell damage 
at depths different from damage leading to neurological changes. 
Other explanations cannot be ruled out. Thus, transient changes in MR-visible changes 
might have not been recorded, if they occurred between imaging occasions. Not all MR-
visible changes must necessarily be attributed to radiation sequelae, as such changes are 
known to occur spontaneously. Also, the size of MR-visible lesions does not allow to 
predict the severity of neurological symptoms. Animals with spot lesions have been found 
to succumb to severe neurological symptoms. 
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The small values for CF of BSH for both endpoints indicate that the physical dose 
deposited by the boron reaction has a very low biological effectiveness. This effect has 
been called vascular sparing. This is caused by the fact that BSH appears to be virtually 
excluded from the healthy brain (Haritz et al. 1992, Kraft et al. 1992). The value obtained 
for MR-visible changes is in accordance with a boron distribution completely extracellular 
to the endothelial cells. For the induction of neurological symptoms, an even lower value 
for CF is found. They agree well with work by others. The response of the spinal cord in 
rats under BNCT conditions has recently been described (Morris et al. 1992 a). A value for 
CF for BSH, with paralysis as endpoint, of 0.46 ± 0.05 was reported. In view of the 
different endpoints, these values must be considered as being well in agreement with the 
present results. The relatively low CF values obtained for BSH and brain damage 
demonstrate that a variability in boron concentration has only a small impact on photon 
equivalent doses at these boron levels. 
The results could indicate that not all of the damage leading to neurological symptoms 
would stem from damage to the vasculature. In the literature, the question of glial atrophy 
dependent or independent of vascular degeneration has been discussed (Morris et al. 1992 
b, van der Kogel 1991). The experiments described here are the first ones in which the 
dose to the vascular endothelial cells could be varied independent of the dose to the glial 
cells. Further experiments with lower boron concentrations could lead to a better 
understanding of the role the vasculature plays in the induction, precipitation, or 
enhancement of neurological symptoms. Such experiments could also clarify whether the 
delivery of doses to other voxels in excess of those at the maximum of the thermal neutron 
fluence, which gains importance as the boron concentration in blood diminishes (see 
Figure 6.2) has a bearing on the differences of RBE between neurological symptoms and 
MR-visible changes. 
Compounds not excluded from the healthy brain will show much higher values of CF. This 
will probably pertain to BPA, whose brain concentration is very similar to the 
concentration in blood (Coderre 1992). For the rat spinal cord and paralysis as endpoint, 
Morris et al. (1992 a) derived a CF value of 1.33 ± 0.16. 
For clinical success of BNCT, it is important that the dose ratio between tumor and healthy 
tissue is the parameter to be maximized. CF data for healthy tissue are insufficient. They 
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must be accompanied by a pharmacokinetic study of the boron compound and its 
distribution in healthy and tumor tissue exposed to the beam. In addition, indications are 
required whether the compound intended for clinical trials distributes similarly or 
differently, on a subcellular level, in tumor and healthy tissue. The patterns of subcellular 
distribution of boron in these two tissue will influence greatly the dose ratio achievable. 
The values for RBE and CF derived here can be used to determine a safe biological 
starting dose for clinical trials of BNCT for brain tumors, and to adjust the irradiation time 
for varying boron concentrations in blood. 
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7.1 INTRODUCTION 
The dose that can be delivered to the tumor in conventional external beam radiation 
therapy of high grade gliomas is limited by the tolerance of adjacent normal brain (Packer 
et al. 1993). Traditionally, brain tissue was considered to be relatively radioresistant but it 
has become evident that irradiation schemes within the usual clinical range can cause 
functional changes, and even necrosis (Sheline, 1986). Late reactions, appearing several 
months or even years after radiotherapy, constitute the major hazard of brain irradiation. 
Boron neutron capture therapy (BNCT) theoretically allows the selective delivery of high 
linear energy transfer (LET) radiation to brain tumors while at the same time sparing 
surrounding normal brain tissue (for a review on BNCT see Barth et al. (1992 and 1994)). 
BNCT is a bimodal treatment based upon the nuclear reaction of low energy (thermal) 
neutrons with 10B, a naturally occurring, nontoxic, stable isotope. The 10B nucleus has a 
larger capture cross section for thermal neutrons than any other element present in normal 
tissue. Following neutron capture the 10B nucleus becomes unstable, and splits into two 
recoiling ionizing particles, an alpha-particle and a lithium ion [10B(n,α)7Li]. The short 
range of the particles (< 10 µm) implies that the macroscopic and microscopic distribution 
of 10B carrier will have a significant impact on biological effectiveness (Wuu et al. 1992). 
Innovations in the physics of neutron beam filtration have resulted in beams of higher 
energy (0.4 eV to 10 keV) epithermal neutrons (Fairchild et al. 1985). Epithermal neutrons 
are slowed down by collisions with hydrogen atoms in tissue to the thermal energy range 
(< 0.4 eV) at depth. These beams allow a greater penetration in tissue as compared to a 
thermal neutron beam. Epithermal neutron beams have been installed at the Brookhaven 
Medical Research Reactor (BMRR) (Fairchild et al.1990), the Massachusetts Institute of 
Technology Reactor (MITR) (Choi et al. 1990), the FiR in Finland (Kaita et al. 1997) and 
the High Flux Reactor (HFR) at Petten, The Netherlands (Moss, 1990). The use of 
epithermal neutron beams enables treatment of brain tumors with BNCT without surgical 
removal of the scalp and the skull, required for BNCT with thermal neutron beams. 
BNCT produces a complex mixed field of radiation in tissue, which consists of both low 
and high linear energy transfer (LET) radiation. The boron neutron capture 10B(n,α)7Li 
radiation dose is the major contributor to the total radiation dose in tissue when high boron 
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concentrations are present. The other important interactions which contribute to the dose 
during BNCT are hydrogen capture [1H(n,γ)2H], nitrogen capture [14N(n,p)14C], and recoil 
protons from the fast neutrons [1H(n,n')1H] (Gupta et al. 1994). The low-LET γ-radiation 
from the incident beam and the hydrogen capture in tissue, results in significant total body 
exposure. Thus, the use of small animals in normal tissue tolerance studies for late 
radiation effects is very limited (Gavin et al. 1992 and 1994). Moreover, the penetrating 
nature of epithermal neutron beams makes radiobiological studies in small animals such as 
rats and mice even more complicated. The dog brain has been used as a model system for 
radiation effects in the human central nervous system (CNS). Dogs irradiated with 
conventional photons show changes as a function of dose, time, volume and other factors 
closely resembling those occurring in human patients (Fike et al. 1991). In addition, dogs 
have been used as a large animal model for studies of the effect of BNCT on spontaneous 
brain tumors (Gavin et al. 1992 and 1989). 
Research programs investigating in the potential use of BNCT for brain tumors have been 
recently initiated in Europe and in the US. Several research teams are preparing for clinical 
trials with BNCT of glioblastoma using either the sulfhydryl borane Na2B12H11SH (BSH) 
or the amino acid analogue p-boronophenylalanine (BPA) as the boron carrier. Four groups 
have meanwhile proceeded to clinical trials using epithermal neutron beams (Petten, The 
Netherlands; Helsinki, Finland; Brookhaven (BNL) and Massachusetts (MIT), US). The 
preclinical studies presented here were carried out in dogs using beam only irradiations at 
the BMRR and animals administered BSH prior to irradiation at the HFR. The analysis 
presented in this chapter is intended as a further characterization of the combined 
biological effect of the various dose components in BNCT for normal brain tissue. 
7.2 MATERIALS AND METHODS 
Two healthy tissue tolerance studies of BNCT in dogs using an epithermal beam 
have been used for evaluation in this study: (a) Washington State University (WSU) in 
Pullman, WA, sponsored by the Idaho National Engineering Laboratory (INEL), and (b) 
the joint research project of the European Union (EU) at Petten, The Netherlands. The 
irradiations of the American study were done at the Brookhaven Medical Research Reactor 
(BMRR) (Fairchild et al. 1990) using retriever-type dogs and BSH as the boron carrier. 
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7.2.1 Beam only irradiation BMRR 
In the WSU protocol all animals were male, 1-3 years of age at the time of 
irradiation, and weighing approximately 35-45 kg. The protocols used and beam 
characteristics have been reported previously (Gavin et al. 1989, 1994). Irradiations were a 
single dose, dorsal portal, 5 x 10 cm incident field, centered over the right cerebrum and 
carried out at the epithermal port of the BMRR under general anesthesia1. Four dogs were 
irradiated with the isotropic epithermal beam alone after surgical reflection of the 
overlaying skin and muscle. This was done to irradiate specifically the healthy brain of 
dogs without the confounding influence of superficial tissue. Irradiation times, and 
physical doses at thermal neutron fluence peak are listed in Table 7.2. 
7.2.2 Brain tolerance study at the HFR Petten 
In the European (EU) project all experiments have been performed on normal 
female Beagle dogs weighing between 10 and 15 kg. The animals were infused over one 
hour with 95.6 % 10B-enriched BSH2 at a dose of 25 or 50 mg 10B kg-1 bodyweight in 11 
ml kg-1 bodyweight 0.9 % saline. Animals were kept under general anesthesia3 during 
irradiation. The HFR epithermal beam is highly collimated with an angular spread of less 
than 10 degrees. Further beam characteristics have been described earlier (Liu et al. 1994, 
and Moss 1990). The circular beam opening was 8 cm in diameter and centered over both 
hemispheres of the dog's brain. 38 dogs were irradiated at the HB11 beam line of the HFR 
in Petten after BSH infusion (Table 7.1). For further details see chapter 3. 
7.2.3 Biological endpoints 
Two in vivo endpoints were used: 1) contrast enhancing lesions in MR or CT scans 
of the brain, and 2) clinical symptoms, such as disorientation, loss of proprioception, 
ataxia, and therefore problems in coordination of movements, which could not be 
controlled even by corticosteroids. The latter endpoint was defined as "lethal necrosis" 
since animals showing these symptoms had to be euthanized and extensive areas of white 
matter necrosis were found at necropsy. 
                                                 
1 induction with thiamylalsodium, maintenance with isoflurane and oxygen 
2 supplied by Centronics, LTD. 
3 induction: acepromazine (0.3 ml kg-1 bw. Vetranquil®, Albrecht) in combination with 
methadon (0.8 ml kg-1 bw. methadon HCL, AUV Cuijk Holland) and maintenance with 
isoflurane (Forene®) in an oxygen and nitrous oxide mixture 
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7.2.4 Dose description 
 The total physical dose as referred to in this paper is the sum of physical doses, 
which result from incident gamma, gamma produced in tissue by hydrogen capture, 
nitrogen-capture protons, incident fast neutrons, and radiation from the fission fragments 
following boron capture. The formula for the physical doses at the thermal neutron fluence 
maximum (thermal neutron peak) was: Dose = (irradiation time)[(mean blood 10B 
concentration)(DB) + (DR)]. During the experiments the BMRR was operating at 3 MW 
power. The dose rate for the boron dose (DB) was 0.00571 Gy min-1 µg-1 g. The dose rate 
for the remaining non-boron dose (DR) was 0.0719 Gy min-1. For the irradiations at the 
HFR in Petten the dose rates are given for a reactor power of 45 MW, which was constant 
during all experiments. DB at thermal peak was 0.00294 Gy min-1 µg-1 g. DR was 0.0507 
Gy min-1. Depth dose profiles for the Petten beam are given in figure 7.1. 
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Figure 7. 1: Depth dose profiles calculated by the Monte Carlo computer code MCNP for the different 
BNCT dose components at the HFR epithermal neutron beam. Physical dose rates are given for 50 µg g-1 10B 
in tissue along the beam centerline for the beagle head model. Proton dose refers to the combined proton dose 
from nitrogen capture reactions and the fast neutron-hydrogen collisions. 
7.2.5 Dose deposition in tissue 
The total BNCT dose changes dramatically with depth in tissue. Technically the 
thermal neutron fluence reaches a maximum at a voxel rather than a plane or an area. Iso-
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dose contour plots were generated for the brain using MCNP computer codes for 
comparison of the different combinations of dog type and irradiation geometry. 
7.2.6 RBE of beam components 
In the absence of boron, the beam-only dose consists of fast neutrons generating 
recoil protons from collision with hydrogen, the protons produced by the capture of 
thermal neutrons by nitrogen (the 14N(n,p)14C reaction), and gamma-rays. For the purpose 
of this analysis, the biological effectiveness of protons produced by fast neutrons and the 
nitrogen capture reaction was said to be equal, and the resulting dose is referred to as the 
proton dose. The dose-rate factor for the gamma-ray component was assumed to be 1. Four 
labrador dogs underwent surgical reflection of the overlaying tissues prior to irradiation. 
These animals were irradiated with the BMRR beam only for estimation of the proton 
relative biological effectiveness (RBE) within this mixed radiation field (Table 7.1). Skin 
and muscle were removed in order to prevent interference of excessive skin damage due to 
the high doses of radiation needed to obtain brain effects as had been observed earlier by 
Gavin et al. (1994). The proton and gamma-ray dose components were treated as being 
additive and were compared with results obtained by Fike et al. (1991) in dogs after photon 
irradiation of the brain. 
With hemi-brain photon irradiation as performed by Fike and his coworkers, there is an 
almost homogeneous dose to the entire hemisphere as compared to BNCT irradiation. 
Dose distribution is completely different with BNCT. Therefore, we have selected the 
thermal neutron fluence peak at about 2 cm depth for dose calculation (figure 7.2). This 
was the observed predisposition area of radiation necrosis in the dogs, the white matter 
dorsal of the ventricles. The proton dose from fast neutrons and nitrogen capture was 
calculated at the thermal neutron fluence peak in tissue by subtracting the gamma-ray dose 
component from total radiation dose. The proton RBE then is the ratio of dose of the 
reference radiation quality (Fike et al. 1991) and this proton dose. 
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Figure 7. 2: Calculated total physical isodose contour plot in an axial plane for the skin and scalp reflected 
Labrador head model, positioned in the BMRR epithermal neutron beam. 100 % correspond to 2.2 
cGy MW-1 min of reactor power. Contours are plotted from 10 to 90 %. The contour interval is 10 %. 
The proton RBE was calculated for both endpoints, although, due to the limited number of 
animals a proton RBE for contrast enhancing lesions in MR could only be estimated. The 
fact that both dogs irradiated for 134 min (dog 2155 and dog 2143) showed no contrast 
enhancing lesion in MR implies that they received less than 12.8 equivalent Gy, whereas 
the two other dogs (dog 2158 and dog 0370) received more than this reference dose. For 
the calculation of the proton RBE for lethal white matter necrosis, the dogs irradiated for 
158 min were said to have received exactly the reference dose equivalent of 14.9 Gy (Fike 
et al. 1991) for this respective endpoint 
7.2.7 Boron dose Petten dogs 
The short range of the α− and lithium particles originating from the boron capture 
reaction make the microdistribution of critical importance in the evaluation of biological 
effectiveness. The observable biological effect of this reaction is dependent on the 
distribution of the particular boron compound.  
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Figure 7. 3: Calculated total physical dose contour plot with 50 µg g-1 10B in tissue in an axial plane for the 
Beagle head model, positioned in the HFR epithermal neutron beam. The 100 % contour corresponds to 
19.8 cGy min-1. The contour interval is 10 %. 
 
To include this geometric effect, the term compound factor has been used in order to 
distinguish from the term RBE. The compound factor, CF (Gavin et al. 1993) also named 
compound biological effectiveness (CBE) factor (Morris et al. 1994), is dependent on the 
microdistribution in the target tissue of a certain boron compound and the RBE of the 
B(n,α) reaction for that target tissue. The compound factor for BSH was calculated in a 
manner analogous to the calculation for the beam component RBE. Dogs that reached the 
MR change endpoint without neurologic symptoms were presumed to have received at 
least 12.8 Gy to a significant volume of brain (Fike et al. 1991). Similarly, a compound 
factor was calculated for dogs that reached the lethal necrosis endpoint assuming that the 
critical part of brain received at least 14.9 Gy (Fike et al. 1991). The dose applied with 
BNCT changes dramatically with depth in tissue (see fig. 7.3). With the Beagles irradiated 
at the HFR, the peak dose volume included part of the predisposition area of dorsal white 
matter for radiation necrosis as observed in this study.  
BNCT doses of the respective dogs were compared with X-ray controls reported by Fike et 
al. (1991) to calculate the CF for BSH. Animals showing MR contrast enhancement (n=10) 
without neurological symptoms were said to have received at least an equivalent dose of 
12.8 Gy-equivalent. Similarly, dogs that reached the endpoint of lethal necrosis (n=13) 
must have had a minimum of 14.9 Gy-equivalent to a significant volume of the brain. The 
proton RBE derived from the scalp reflected dogs for brain damage was used for the fast 
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neutron and nitrogen capture components of the dose. No dose modification factor was 
applied for the gamma-ray dose component. To obtain the CF, the non-boron dose 
components were subtracted from the respective reference dose and the remainder was 
divided by the physical 10B capture dose.  
7.3 RESULTS 
7.3.1 General observations 
Irradiation and follow-up procedures, including post-treatment MR and CT 
procedures, were generally well tolerated by all animals. During infusion of 50 mg 10B kg-1 
bw. of BSH vomiting occurred in some animals. Lower concentrations did not have any 
obvious side effect. No significant radiation related abnormalities were detected on gross 
or histopathologic examination at other sites than the brain and overlaying tissue. 
7.3.2 Brain response 
In general, cerebral white matter seemed to be damaged preferentially by ionizing 
radiation. With higher doses the lesions became larger and more serious, but still were 
almost exclusively found in dorsal white matter. Animals not showing changes on MR 
scans were histopathologically found to be normal or have just very limited diffuse 
demyelination of primarily the dorsal white matter horns accompanied with some chronic 
vascular changes (teleangiectasia) and minor glial reaction. Areas found abnormal in MR 
scans turned out to be necrosis and major demyelination. No areas of necrosis without 
severe vascular abnormalities were detected. Endothelial proliferation of some 
microvasculature and microscopic hemorrhages, mainly at the outer margins of the white 
matter, were observed. Diffuse glial proliferation as well as focal accumulations of glial 
and/or white blood cells around the vasculature were noted. There were increased cellular 
spaces consistent with edema. More areas of grossly detectable abnormalities were seen 
with histopathology than were appreciated on CT or MR scans obtained the day before 
euthanasia. Animals suffering from neurologic symptoms would change from normal to 
slightly ataxic and progress to inability to walk within one to two days. Usually application 
of corticosteroids would slow down the process for a few hours without any therapeutical 
effect. These animals were euthanized as soon as possible followed by gross pathology. 
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Table 7. 1: Doses in BNCT with BSH as boron carrier (Petten study). 
Dose group 
Mean blood 
10B conc. 
Irradiation 
time 
Equivalent doses 
proton RBE 2.7 CF 0.53 
[Gy-equiv.] 
mean ± SE 
76 min 11.68 ± 0.59 
86 min 14.34 ± 0.75 
96 min 15.18 ± 0.41 
50 µg g-1 
106 min 16.9 ± 1.43 
76 min 
9.3 ± 0.08 
96 min 11.85 ± 0.4 
108 min 13.13 ± 0.21 
120 min 14.93 ± 0.25 
25 µg g-1 
132 min 16.72 ± 0.44 
In the EU-Petten study, neurological changes visible on the MR scans first occurred at  
5 - 6 months post-irradiation in 23 dogs. Ten of these dogs were clinically normal but MR 
scans showed lesions in the white matter around the ventricles. Thirteen dogs developed 
clinical abnormalities requiring euthanasia due to radiation necrosis of the brain 
(Annex A). 
7.3.3 Proton RBE 
Table 7. 2: WSU beam only dog brain response study 
Dog 
no. 
Mean blood 
10B conc. 
[µg g-1] 
Irradiation 
time 
[min] 
Brain 
MR 
changes 
response 
lethal 
necrosis 
MCNP calculated 
physical doses at 
thermal n peak 
[Gy] 
equivalent doses  
proton RBE 2.7 
[Gy-equiv.] 
2155 0 134 0 0 8.7 12.5 
2143 0 134 0 0 8.7 12.5 
2158 0 158 + 0 10.3 14.8 
0370 0 158 + + 10.3 14.8 
 
Four labrador dogs underwent surgical reflection of the overlaying tissues prior to 
irradiation. These dogs were irradiated with the BMRR epithermal neutron beam only. 
Two of the dogs (dog 2158 and dog 0370) irradiated for 158 minutes at 3 MW reactor 
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power, showed brain changes (Table 7.2), the other two (dog 2155 and dog 2143 irradiated 
for 134 minutes) did not. In one dog (dog 2158) only MR changes were observed and the 
other developed lethal brain necrosis (dog 0370). 
Calculation of the proton RBE for the endpoint of MR contrast enhancing lesions was 
based upon the assumption that the two dogs not showing MR changes received less than 
12.8 equivalent Gy, and the two others, which both reached this respective endpoint, had 
more than these 12.8 equivalent Gy. The resulting RBE should be within the range of 
1.9 - 2.8. For the endpoint of lethal white matter necrosis, the two dogs irradiated for 
158 min (dog 2158 and dog 0370) were assumed to have had exactly 14.9 equivalent Gy, 
since one of them reached the endpoint of lethal white matter necrosis and the other one 
did not. A proton RBE of 2.7 for this endpoint was calculated at thermal neutron fluence 
peak by subtracting the gamma-ray dose from the reference dose of 14.9 Gy (Fike et al. 
1991) and dividing the remainder by the physical proton dose. Since no precise proton 
RBE could be assigned to the MR endpoint and the value of 2.7 is within the calculated 
range, a proton RBE of 2.7 was used with respect to both endpoints for further 
calculations. 
7.3.4 Compound factor 
The BSH compound factors were estimated as follows: dogs that showed MR 
changes (n=24) were conceived to have received at least 12.8 Gy (Fike et al. 1991) to a 
significant volume of brain. Similarly, the compound factor was calculated for the dogs 
that reached the lethal necrosis endpoint (n=13) with the critical volume of brain having 
received at least 14.9 Gy (Fike et al. 1991). The calculated compound factors are listed for 
the different endpoints in table 7.3. 
 
Table 7. 3: Compound factors* computed for BSH in animals that reached the respective endpoint. 
Endpoint CFBSH 
MR changes range: 0.54-0.36; n=10 
lethal necrosis range: 0.59-0.33; n=13 
*   Compound factor = Ref. X-ray dose  2.7*physical proton dose - physical gamma-ray dose  
     physical 10B capture dose 
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Table 7. 4: Compound factors calculated for two representative dose groups, RBEproton=2.7 
MR contrast enhancement 
Dog (response)                CF 
Lethal necrosis 
Dog (response)                CF 
637 (neg) 
480 (pos) 
773 (neg) 
180 (neg) 
644 (pos) 
0.56 
0.54 
0.54 
0.51 
0.51 
790 (neg) 
516 (pos) 
778 (neg) 
803 (neg) 
627 (pos) 
0.57 
0.55 
0.54 
0.51 
0.49 
Mean (σn-1): 0.53 (±0.02)  0.53 (±0.03) 
Selecting only dogs, which doses were just below or above the one causing the respective 
effect, a CF value of 0.53 results for both endpoints (table 7.4). The 25 µg g-1 10B/108 min 
dose group and the 50 µg g-1 10B/96 min dose group have been used to delimit the CF for 
MR contrast enhancement and lethal necrosis, respectively. These dose groups - each 
consisting of five animals - were chosen because they both had three non-responders and 
two individuals, which reached the endpoint. They are believed to be closest to the ED50. 
The derived compound factor was used in combination with a proton RBE of 2.7 to 
calculate equivalent dose for each individual dog (n=38) at thermal neutron peak (table 
7.1). Equivalent dose response curves were generated and are plotted in figure 7.4. The fits 
resulted in ED50 values of 13 Gy equiv. and 13.1 Gy equiv. for the MR contrast enhancing 
lesions at the 50 mg g-1 and the 25 µg g-1 mean blood boron level, respectively. For the 
lethal brain damage endpoints the fitted data resulted in an ED50 value of 15.2 Gy equiv. 
for the 50 µg g-1 group and a value of 14.8 for the group of animals that had been irradiated 
at the 25 µg g-1 mean blood boron level  (figure 7.4).  
7.4 DISCUSSION 
For safe BNCT of brain tumors in patients, normal tissue tolerance will actually be 
the crucial point rather than the dose to the tumor. Therefore, the ability to predict the 
radiation dose to normal brain surrounding the tumor is required prior to actual treatment. 
The experiments in this study confine the combined biological effect of the various BNCT 
dose components on normal brain. Irradiations were performed at the epithermal neutron 
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ports of either the Brookhaven Medical Research Reactor or the High Flux Reactor in 
Petten. As biological endpoints contrast enhancing changes in MR scans and lethal brain 
necrosis were chosen. Dogs showed either neurological signs and/or MR changes. 
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Figure 7. 4: dog brain response to BNCT irradiation at the Petten HB11 epithermal neutron beam. 
Equivalent doses were calculated using a combined RBE of 2.7for the fast neutron component and the N(n,p) 
reaction, a BSH compound factor of 0.53 (see table 7.4) for both endpoints, and for all gamma radiation and 
others a factor of 1.0. Open markers (O ∆) are contrast enhancing brain lesions in MR scans. The solid 
markers (! #) stand for clinical symptoms due to white matter necrosis. Circles represent the 50 µg g-1 and 
triangles the 25 µg g-1 group, respectively. Mean doses per group with 1 standard deviation as error are 
plotted. Points were fitted with a sigmoidal response function. 
 
Neurological signs were observed with acceptable levels of skin damage (Philipp et al. 
1996), i.e. dry desquamation indicating that skin is not the dose limiting tissue with either 
compound after BNCT. Transfer of the results observed in dogs to treatment planning 
schemes for patients requires translation from physical into equivalent dose (Nigg, 1994). 
To do so, each physical dose component has to be multiplied by its RBE or compound 
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factor. However, the size of the dog, tissue boron concentration and neutron beam 
characteristics influence the depth of the peak radiation dose. Due to the complexity and 
number of factors involved, it should be emphasized that the totality of factors involved 
appear to be predictive. But a change in any individual factor would necessitate changes in 
the other components. By combining the proton RBE we tried to assess one of these 
components as accurate as possible. However, the number of overlaying tissue reflected 
dogs was very limited, and the setup of the Petten BSH study did unfortunately not allow a 
dose escalation study with the epithermal neutron beam in absence of boron.  
Much of the work presented is compared to X-ray data from hemibrain irradiations in 
dogs. It is assumed that MR contrast enhancing lesions without clinical symptoms are 
equivalent to the low density changes observed in CT with an ED50 of 12.8 Gy of X-rays. 
However, the histopathologic changes of the doses used in the generation of the 
ED50=12.8 Gy were minimal and in some cases the tissue looked normal (Fike et al.1988). 
In contrast, the MR changes said to be equivalent to 12.8 Gy, included contrast enhancing 
lesions that histopathologically appeared to be major vascular changes, necrosis and 
demyelination. In the X-ray data no significant contrast enhancement, necrosis or 
demyelination was noted at doses below 15 Gy. This discrepancy is recognized. Yet, any 
comparison of more severe radiation damage to less serious impairment will result in an 
overestimation of the doses involved. Therefore, an RBE estimation based on this will lead 
to a dose description on the safe side. However, in this study no proton RBE could be 
assigned to the endpoint of MR contrast enhancing lesions. The two dogs irradiated for 134 
minutes did not show any brain response thus limiting the proton RBE between 1.9 and 
2.8. The proton RBE of 2.7 was finally estimated on the reaction of two dogs irradiated to 
the same dose. One suffered lethal white matter necrosis, the other one did not. It is 
therefore assumed that this respective dose should correspond to the LD50 of 14.9 Gy 
reported by Fike. As stated in 7.3.3, the proton RBE was calculated at thermal neutron 
fluence peak, which lies exactly within the area of interest: the white matter dorsal of the 
ventricles. Histopathologic evaluation revealed in virtually the same observations: the 
damage was largely restricted to white matter and consisted of variable size foci of 
coagulation necrosis within which were ghost outlines of vessels, swollen axons, and 
mineralization. Adjacent white matter had varying degrees of edema, axonal degeneration, 
and demyelination, with vascular proliferation and inflammation. It is recognized that the 
number of animals included in the estimation of proton RBE is far too small. Nevertheless, 
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ethical considerations have made it impossible to add more scalp reflected dogs in the 
BMRR beam only study.  
With BNCT the gamma-ray dose rate is usually low suggesting less efficacy. For 
irradiations of the duration used here, the application of a gamma-ray dose rate factor 
(DRF) could be discussed for both beams (Fu, 1991). However, these dose rates occur in a 
mixed field of low and high LET radiation of various energies. This additional high LET 
radiation in the form of charged particles or fast neutrons may inhibit the effects of DNA 
repair at low gamma-ray dose rates. In our calculations it appeared that there is no 
dependence of the value for the CF on a DRF for gamma radiation. This is not surprising, 
since in the absence of boron, a change in DRF must lead to a compensating change in 
proton RBE.  
There are limitations to the use of the proton RBE since the fast neutron spectrum will 
change with depth in tissue and thus its RBE (Hall, 1975, Menzel et al. 1990). However, 
damage was in all cases restricted to white matter with a preference for the dorsal white 
matter. In addition, the energy of protons originating from the N(n,p) reaction will not 
change with depth. Using a combined RBE for recoil protons originating from the N(n,p) 
reaction and incident fast neutrons in combination with roughly the same irradiated brain 
volume including the predisposition area for comparison, will result in an averaged recoil 
proton RBE for that target volume at depth. The RBE of 2.7 of this evaluation is the same 
as the RBE reported for the N(n,p) reaction for late radiation effects in pig skin driven by 
vascular impairment (Archambeau 1989). This would suggest that either the proton recoil 
RBE is within the same range, or, that at depth, the thermal neutron component and thus 
the N(n,p) reaction predominates. Yet, MCNP calculations resulted in a more than two fold 
higher physical dose from fast neutrons at depth than emerges from the N(n,p) reaction. 
Archambeau also reported an RBE for the same endpoint after irradiation with higher 
energy fission neutrons of 3.6. Fukuda summarizes in his review in vitro data on the RBE 
of thermal neutrons (Fukuda et al. 1989). He concludes that an RBE between two and three 
would be a realistic estimate for reactor based thermal neutrons. The main dose component 
with thermal neutron irradiation in the absence of boron results from the N(n,p) capture 
reaction, although reactor based neutron beams usually are contaminated with some higher 
energy neutrons. Coderre and his coworkers derived an RBE of 3.2 for both radiation 
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qualities in a rat glioma model (Coderre et al. 1993). Hornsey showed in her review of 
clinical and experimental data on clinically used fast neutron beams that the RBE for CNS 
usually is high (Hornsey 1991). These studies further show that low energy fast neutrons 
are more effective than high energy fast neutrons. With the epithermal neutron beams used 
in this study, the available information with respect to the fast neutron component is rather 
limited. Alpen and Frankel reviewed the available experimental and clinical data to 
estimate the neutron RBE for neutron energies ranging from 5 keV to 5 MeV (Alpen and 
Frankel 1993). Their results show an increase in neutron RBE from 1.8 to 3.5 when 
neutron energies decrease from 1 MeV to 100 keV. The estimation of a fast neutron RBE 
for brain damage is further complicated by the thermalization of neutrons in tissue 
resulting in a progressive nitrogen capture with depth. Thus, combining the recoil protons 
and protons from the N(n,p) reaction is a very much simplified but pragmatic approach. 
Over the years a number of authors have addressed the question of volume effects, and 
there has been considerable argument as to whether or not there is a relation between the 
area or volume irradiated and the incidence of clinically relevant or experimentally 
detectable tissue injury. Phillips states in his review on early and late effect of radiation on 
normal tissue that in the CNS, volume will be extremely important. It is not the percentage 
of the organ irradiated but the absolute volume that is related to injury (Phillips 1991). Fike 
reported a restriction of radiation damage to white matter after X-irradiation of dog brain 
(Fike et al. 1988). A similar damage pattern has been observed with the BNCT irradiated 
dogs with a preference to the dorsal white matter. This area (or volume) was considered to 
be the most sensitive with respect to dose response, and therefore included in the volumes 
selected for equivalent dose description. 
With BNCT a compound factor is used to describe the biological effectiveness of the α 
particles generated in tissue in relation to the microdistribution of the boron capture agent 
in this tissue. Once the proton RBE was attained, compound factors for BSH could be 
computed. CFs were calculated for both endpoints with the use of a proton RBE of 2.7. 
The CF for MR contrast enhancing lesion and lethal necrosis with BSH after BNCT was 
equal to 0.53. This value fits very well in the range of values (0.49-0.55) reported for 
spinal cord damage in rats after BNCT with BSH using thermal neutron irradiation (Morris 
et al. 1996). However, the lower CF value for BSH of 0.38 for the BMRR BNCT-
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irradiated dogs (data not shown) is virtually the same as the value of 0.37 obtained for the 
lethal necrosis endpoint by the analysis of the HFR irradiated Beagles in chapter 6. In this 
analysis, CF and proton RBE were treated as independent variables and obtained from the 
same data set. It is concluded that the CF for BSH is about 0.37  0.38. The different 
outcome for HFR irradiated animals here in chapter 7 strongly indicates that dose 
modification factors such as CF and RBE may only be used in the respective set and 
cannot be used as input for analysis of a different experimental set up.  
The CF for BSH is much lower than the RBE for high LET charged particles. Due to the 
small diameter (5 - 7 µm) of the microvasculature in the brain, the endothelial nucleus 
receives considerably less boron neutron capture dose than the blood boron dose would 
suggest. This geometry effect or vascular sparing phenomenon decreases with increasing 
vessel diameter (Gavin et al. 1993 and 1994, Kitao 1975, and Rydin et al. 1976). 
The compound factor (CF) for a particular boron compound includes the RBE of the 
capture products, the distribution pattern of the compound and geometric effects like 
vascular sparing, and is therefore dependent on the compound used. Based on computer 
modeling, a CF value for normal brain tissue of 0.40 has been predicted for BSH (Gavin et 
al. 1993 and 1994).  
In summary the RBE and compound factors derived in this study are in good agreement 
with the results reported in the literature obtained by using different approaches or 
different systems. The results would need validation in other beams with different quality, 
to enable greater confidence in the individual component RBEs and or dose rate effects. 
The dose-response curves are steep, as was reported for brain damage in dogs after 
conventional X-ray irradiations (Fike et al. 1991). Steep dose response curves for CNS tissue 
irradiated with single dose have been reported for other systems (Rodriguez et al. 1991) 
implying that a high level of accuracy is required for dose delivery. 
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8.1 HEALTHY TISSUE TOLERANCE STUDIES 
Normal tissue tolerance establishes the dose limitations for any form of radiation 
therapy. In therapeutic treatments that involve the normal central nervous system (CNS), 
the risk of development of late radiation necrosis to regions of white matter is of concern. 
Boron neutron capture therapy (BNCT) offers the theoretical prospect of locally targeted 
radiotherapy for tumors such as glioblastoma. However, with presently available thermal 
and epithermal sources and currently used capture agents, the radiation tolerance of normal 
CNS still needs to be considered. The complexity of the mixed radiation field with BNCT 
makes it difficult to predict normal tissue tolerance. Hence, large animal healthy tissue 
tolerance studies were initiated at Petten using the epithermal neutron beam (HB11) of the 
High Flux Reactor (HFR). Experiments were designed to establish approximate tolerance 
doses for normal brain and skin to boron neutron capture irradiation as a prerequisite for 
clinical trials in human brain tumor patients.  
Skin was regarded as possible critical normal tissue or even tissue at risk, since neutron 
irradiation takes place as an external exposure and the irradiated skin area is relatively 
large with BNCT. Gavin and his group reported clinically significant skin effects in dogs 
after beam only irradiation using the epithermal neutron beam of the Brookhaven National 
Laboratory reactor (BMRR) (Gavin et al. 1994, 1993). The same group also investigated 
skin reactions to BNCT after systemic application of boroncaptatesodium (BSH). Dermal 
necrosis occurred only at doses significantly above those required to obtain brain necrosis. 
In the present study no aggravating skin reaction to BNCT was observed. The most severe 
effects were minor cases of dry desquamation along with almost complete hairloss in the 
irradiation field at radiation doses far exceeding those required to induce white matter 
necrosis. These changes were considered an acceptable normal tissue reaction. With 
respect to the radiation doses applied to the skin one would expect more severe reactions 
than observed in the HFR and BMRR irradiated animals. Gavin et al. (1992) reported a CF 
for BSH in skin of 0.5. However, computer modeling of CF on the base of a homogeneous 
boron distribution resulted in about four times higher values (Gavin et al. 1993). There is 
obviously also a dose sparing effect in skin with BSH. The sparing is little smaller (larger 
CF values) than in brain tissue but still significant. Whether this effect is related to the 
compound distribution or not stays to be examined.  
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The skin reactions gave evidence that the tissue at risk is not the skin but normal brain. 
Histopathologic examination of irradiated brain tissue revealed a dose dependent pattern of 
damage. After high doses that caused clinical symptoms in the dogs, large confluent areas 
of coagulation necrosis with variable degrees of fresh hemorrhage were found. At 
somewhat lower doses, not causing clinical signs but MR detectable brain damage, well 
defined focal areas of necrosis were observed with a spongiotic border and usually few 
reactive changes. The low dose groups showed histopathologically no changes or different 
degrees of demyelination, in some cases along with teleangiectasia. Two biological 
endpoints for brain tissue were chosen: detectable lesions in magnetic resonance (MR) 
imaging and clinical symptoms due to severe white matter necrosis. ED50 values could be 
assigned to both endpoints (chapter 3, table 8.1). The values are quite different for each 
endpoint demonstrating the need of physical dose translation into biologically effective 
equivalent dose. At the 25 µg g-1 mean blood 10B level, the dose due to the 10B(n,α)7Li 
reaction amounts to about 56% of total dose. At the 50 µg g-1 mean blood 10B level the 
portion is as high as 72%.  
 
Table 8. 1: ED50 values (Gy) gained for the respective endpoints (see chapter 3) 
 MR contrast enhancement Lethal necrosis 
ED50 25 µg g-1 mean blood 10B 13.6 15.2 
ED50 50 µg g-1 mean blood 10B 16.8 18.8 
Provided that late radiation damage to brain tissue in general and certainly with BNCT 
using a capture agent that in normal brain is restrained to the vascular lumen, is driven by 
the extent of vascular impairment, the two endpoints considered in this study should be a 
result of the same pathophysiologic mechanism. However, different ED50 values could be 
as to the different endpoints. The endpoint of MR contrast enhancement appears to be not 
qualitatively different from the endpoint of lethal brain necrosis. Morris et al. (1996) 
reported that there is no change in effectivity of variable doses of BSH in rats treated with 
BNCT. The variation in compound biological effectiveness factor values was not 
significant, indicating a constant relationship for at least the endpoint of neurological 
symptoms from CNS radiation damage. If MR detectable brain damage is driven by the 
same factors as the lethal necrosis endpoint, the dose increment needed to be added to the 
ED50 for MR detectable damage to reach the ED50 for clinical symptoms should be the 
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same for 25 µg g-1 mean blood 10B as for the 50 µg g-1 group. This is virtually the case 
with the presented data (table 8.1). Also the histopathologic findings of MR positive dogs 
resemble very much the ones, which suffered lethal white matter necrosis. However, the 
fact that in most analyses usually different biological weighting factors came up for the 
two endpoints might indicate a difference in quality rather than just quantity.  
Much of the work presented in this thesis is compared to historical X-ray data from 
hemibrain irradiations in dogs. It is assumed that MR contrast enhancing lesions without 
clinical symptoms are equivalent to the low density changes seen after X-irradiation (Fike 
et al.1988). At the time when these early X-ray studies were conducted magnetic resonance 
imaging was virtually not available and it appears that areas of low density detected in 
computer tomography do not compare to MR contrast enhancing brain lesions. The 
histopathologic changes of the doses used in the generation of the ED50=12.8 Gy were 
minimal and in some cases the tissue looked normal (Fike et al.1988). In contrast, in the 
present study MR changes said to be equivalent to 12.8 Gy, included contrast enhancing 
lesions that histopathologically appeared to be major vascular changes, necrosis and 
demyelination. In the X-ray data set no significant contrast enhancement, necrosis or 
demyelination was noted at doses below 15 Gy. This discrepancy is recognized. Yet, any 
comparison of more severe radiation damage to less serious impairment will result in an 
overestimation of the doses involved. Therefore, an RBE estimation based on this will lead 
to a dose description on the safe side. On the other hand, a span in ED50 of about 2 Gy was 
observed (table 8.1). The relative contribution of the different dose components do not 
change within this group of animals. If, as the data of Fike suggest, both endpoints chosen 
were related to virtually the same reference ED50 of about 15 Gy, they should not be 
distinguishable.  
Fike et al. (1988) prescribed the dose at the 95 % isodose and not at the 100 % isodose as 
was the case with all analyses in this thesis. This implements that the ED50 values used as 
reference doses are equivalent to 13.5 Gy and 15.7 Gy for low density in CT and lethal 
brain necrosis, respectively. Relating for example the data of chapter 7 to these slightly 
higher reference doses resulted in an 0.5 % increase in CF values (data not shown). In 
recent studies, Benczik (2000) performed whole brain irradiations on Beagle dogs using 6 
MV photons. She found an ED50 of 13 Gy and 13.4 Gy for CT and MR contrast enhancing 
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lesions, respectively. Fike (1988) reported 2/5 animals with contrast enhancing lesions in 
CT after a dose of 13.5 Gy and no responders after 14.3 Gy. The ED50 of 12.8 Gy for 1-
5 % low density areas on CT within the irradiated volume (100 % level: 13.5 Gy), which 
was used in this study as reference dose, corresponds to the 13.4 Gy reported by Benczik 
for contrast enhancing lesions in T1 weighted MR. Benczik also reported a strong 
correlation of MR contrast enhancement with histological lesions. On the other hand, two 
out of five dogs that received 16 Gy of photons displayed clinical symptoms corresponding 
to the endpoint called lethal necrosis in this study. The marked difference of about 3 Gy is 
even larger than the one of 2 Gy reported by Fike and observed in this study (see table 8.1).  
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Figure 8. 1: ED50 values for both endpoints at different mean blood 10B concentrations (zero-boron values 
epithermal neutron beam see Benczik 2000 and chapter 7, table 7.2). 
There is a phenomenon, which is not understood. The results of chapter 6 suggested that 
there might be lethal damage without MR contrast enhancement at low boron doses 
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(considerably lower fast neutron RBE for MR detectable changes (2.33) than for lethal 
necrosis (3.93)).  
However, this is not realistic. Benczik (2000) established an ED50 for MR contrast 
enhancement after epithermal neutron beam only irradiation. She did not find any animal 
showing clinical symptoms related to lethal necrosis within the dose range of 9.4  
11.5 Gy.  
Using ED50 value of Gavin for lethal necrosis (see table 7.2) and plotting it together with 
the values of our study suggests a linear correlation for at least the lethal white mater 
endpoint within the regarded interval (figure 8.1). Assuming that the relationship for MR 
detectable brain lesions would also follow a linear dependence with a similar slope results 
in an ED50 value at zero boron level of about 9.4 Gy. This is in agreement with the WSU 
beam only irradiated dogs 2155 and 2143, which received 8.7 Gy. These dogs did not show 
any contrast enhancing lesions on MR scans. However, the ED50 for contrast enhancing 
lesions Benczik found in her study (Benczik 2000) amounts to 12.6 Gy (11.34 (±0.55) at 
the 90% dose level).  
In the past, there have been two theories to explain the development of white matter 
necrosis after therapeutic irradiation: one is that the effect results from a slow loss of glial 
cells or their progenitors. Alternatively, this late event may be the result of a cascade of 
changes initially involving the microcirculation. In recent years, animal studies have 
tended to provide support for a vascular driven pathogenesis. Direct evidence of vascular 
changes prior to the development of necrosis has been found in rat brain (Calvo et al. 1988, 
Reinhold et al. 1990). The gross vascular changes were associated with a reduction in the 
number of endothelial cells but not in the number of oligodendrocytes. In the present study 
no necrotic area was found without major vascular changes. And in animals of the lower 
dose groups surviving at least one year, degenerative changes of the vasculature like 
teleangiectasia were observed. Studies in the rat spinal cord (Siegal et al. 1994) have 
demonstrated an increase in the ratio of thromboxane to prostacyclin in the latent period. 
These changes, a measure of endothelial cell function, indicate prothrombotic activation. In 
other studies, indirect evidence of vascular involvement was shown by the use of vascular 
mediated prophylactic treatment. The application of vasoactive drugs (Hornsey et al. 1990) 
or unsaturated lipid acids (Hopewell et al. 1994, El-Agamawi et al. 1996) after irradiation 
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was found to both reduce and delay the incidence of paralysis due to white matter necrosis. 
Van der Kogel and his coworkers demonstrated the lack of involvement of glial 
progenitors in radiation necrosis (Van der Kogel et al. 1995). The studies have involved 
BNCT type irradiation exposures with neutron capture agents that do or do not cross the 
blood brain barrier. In their experiments, all performed at dose levels isoeffective for 
induction of white matter necrosis, large differences in glial progenitor survival were 
observed which were directly related to differences in boron distribution in the 
parenchymal tissue. Hopewell and van der Kogel (1999) also came to the conclusion that 
there is both direct and indirect evidence that the vasculature is the primary target, damage 
to which results in a cascade of changes leading to the development of white matter 
necrosis. They suggest to make use of the protective intervention after irradiation for a safe 
escalation of the radiation dose with the potential for an improvement in the therapeutic 
ratio for radiation treatment (Hopewell and van der Kogel 1999). Within the scope of this it 
should be mentioned that modern radiation therapy of brain tissue always includes the 
application of corticosteroids as vasoprotective substance. It has been empirically proved 
to considerably reduce acute edema and should therefore forestall the cascade of edema 
and ischemia ultimately leading to white matter necrosis. 
Hopewell and van der Kogel (1999) also reported a longer latent period for development of 
paralysis in rats receiving uniform irradiation of the parenchyma and vasculature (beam-
only exposure) as compared to BSH-mediated BNCT, when the dose differential was 
greatest. They suggest an impairment of the reactive cascade by the higher radiation dose 
to the parenchyma (Hopewell and van der Kogel 1999). Comparing the latent period 
observed in the present study with epithermal neutron beam alone data of Benczik (2000) 
results in a very different pattern: Benczik found a mean latent period for the incidence of 
contrast enhancing lesions in T1-weighted MR of 55.8 (±19.0) weeks, whereas the mean 
latency period for the same endpoint in dogs irradiated at the 50 µg g-1 10B level in the 
present study was 30.3 (±9.1) weeks (Annex A, animals showing lethal necrosis excluded 
for comparison). Including the animals that reached the endpoint of lethal necrosis, the 
mean latency period is even shorter (28.9 ±8.1 weeks). There is a clear tendency towards a 
shorter latency period with BSH-BNCT treated animals as compared to epithermal beam 
only irradiated dogs. However, the difference is not significant. Comparing the latency 
periods for the endpoint of lethal necrosis, no difference can be noted between BPA-BNCT 
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treated animals (27 ± 1.8 weeks, Benczik 2000) and animals that were BSH-BNCT treated 
at the 50 µg g-1 10B level (25.5 ± 3.8 weeks, this thesis). 
Despite the targeting of tumors with boron capture agents, the tolerance of the normal CNS 
tissue remains of concern in BNCT with systematically applied boron carrier drugs. The 
underlying mechanisms are related to vascular damage leading via a cascade of events to 
disturbance of the microperfusion and finally to necrosis. This problem could be 
circumvented by the use of an optimized compound, which is strictly restrained to the 
tumor tissue, or the local application of a boron carrier. 
 
8.2 FRACTIONATION WITH BNCT 
Normal tissue tolerance will be approached with BNCT for brain tumors. 
Therefore, any physical or biological method to enhance the safety margin and the 
differential effects between tumor and normal tissue should be exploited. Selective 
incorporation of boron in the tumor is essential for successful BNCT. However, until a 
quantum leap in selective boron delivery occurs, fractionation deserves evaluation. It may 
not only increase the probability of delivering adequate amounts of boron to the tumor, but 
may also provide safety margins for normal tissue damage. On the other hand, BNCT in 
the foreseeable future will be available only in a few remote centers. Delivering BNCT in 
multiple fractions will be inconvenient to the patient and decrease the throughput of the 
facility, thereby restricting access for other patients. Each fraction also multiplies the costs 
of this therapy. There must therefore be a significant benefit to justify fractionated BNCT. 
The radiation dose with BNCT is a mixture of low and high linear energy transfer (LET) 
radiation. Fractionation of low LET radiation produces, in most cases, better tumor control 
for a given level of normal tissue toxicity than a single large dose. Dividing a dose into a 
number of fractions in general spares normal and to some extent also tumor tissue because 
of repair of sublethal damage between dose fractions and repopulation of cells if the 
overall treatment time is sufficiently long. At the same time, fractionation increases 
damage to the tumor because of reoxygenation and reassortment of cells into radiosensitive 
phases of the cycle (higher reproduction rate of tumor cells). With low LET radiation, the 
therapeutic gain is reduced if large doses per fraction are applied, especially with late 
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responding tissues such as CNS. The contribution of low LET radiation is significant with 
BNCT and may reach 50% of physical dose at depth due primarily to the capture of 
thermal neutrons by hydrogen and the release of a gamma-ray from the 1H(n,γ)2H reaction. 
However, the dose rate of this component is in the order of about 0.03 Gy h-1. 
Fractionation of high LET radiation hardly affects late normal tissue tolerance. With high 
LET radiation almost no repair of sublethal damage occurs and the effects of reassortment 
and reoxygenation are minimal. However, with BNCT the retargeting of the capture agent 
in the tumor with multiple application holds some attraction (Haritz et al. 1994). 
Fractionation also could be expected to be of benefit in allowing for the repair of photon-
induced sub-lethal damage as well as allowing for re-population of rapidly growing normal 
tissues in the treatment field such as mucosa or skin. Plus, that use could be made of 
multiple field irradiation with a fractionated irradiation scheme to further spare these 
rapidly growing tissues. 
Effects of fractionating BSH-based BNC irradiation have been evaluated in a limited 
number of dogs at the 25 µg g-1 mean blood 10B level (chapter 4). This study has been 
performed to detect possible changes in normal tissue tolerance after an irradiation scheme 
of four fractions separated by one day. MCNP calculated peak physical doses at 1.75 cm 
depth were 13.8 (± 0.3) Gy and 13.6 (± 0.3) Gy for the fractionated and the single dose 
groups, respectively. This dose level represented the ED50 for MR contrast enhancing 
lesions after single exposure. Though the groups were rather small (five animals per 
group), the fractionation study performed at the HFR in Petten suggests that fractionation 
was beneficial in that fewer changes were observed in the fractionated dogs versus 
approximately the same dose given in one large single dose. A sparing effect of 
fractionation could be observed in both skin and brain tissue (see chapter 4). Morris and 
coworkers reported a dose increment in rat spinal cord of ~17% as compared with single 
dose BNC irradiation using BSH as the capture agent (Morris et al. 1997). ED50 values for 
myeloparesis (limb paralysis) of 27.2 ± 0.9 Gy, 32 ± 1.4 Gy and 31.5 ± 0.4 Gy were found 
following irradiation with thermal neutrons in the presence of BSH given as a single dose 
or two or four equal fractions, respectively. The proportion of low LET radiation inherent 
in the irradiation of the rat spinal cord with thermal neutrons in the presence of BSH is 
considerably lower than that likely to be encountered at depth in the brain during clinical 
BNCT. It could therefore be argued that the findings from this experimental study were 
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likely to underestimate the effects of dose fractionation in clinical BNCT. The authors 
simulated the clinical conditions and found a sparing effect of only ~14% with 
fractionation. The effect was less than would be expected if the low-LET component of the 
dose had been fully repaired. It is concluded that fractionation is likely to be of limited 
benefit in the amelioration of normal CNS damage during clinical BNCT. The split dose 
regime holds some advantage, but no additional advantage is expected in moving to a four 
fraction protocol. Gavin and his coworkers investigated the effects of fractionation with 
BNC irradiation after infusion of BSH in Labrador dogs (Gavin et al. 1997). The split dose 
studies and four fraction studies performed at the BMRR epithermal neutron port indicated 
no demonstrable normal tissue sparing. This indicates that there would probably be no 
practical advantage, in terms of normal CNS sparing, in moving to a fractionation BNCT 
protocol and that fractionating BNCT should not focus on sparing of normal tissue but on 
re-targeting of the boron compound.  
In modeling a simplified treatment plan with two opposed beams for the BNL facility, 
Gupta and coworkers evaluated the maximum dose at midline that could be delivered 
without exceeding CNS normal tissue tolerance at any point in the brain (Gupta et al. 
1994). Over the whole spectrum of boron concentration ratios analyzed, significantly 
higher doses would appear to be tolerated if the treatment was fractionated. The 14  17 % 
increase in ED50 values by fractionation observed by Morris et al. (1997) is not very 
impressing at first sight. The sparing documented in chapter 4 is estimated to be within the 
same order of magnitude representing about 1.5 Gy. However, with the extremely steep 
dose-response relation generally found for CNS radiation damage, a sparing of more than 
one Gy usually means that one moves from 100% responders to no response in normal 
tissue. Regarding BNCT effects on brain tumors, re-targeting of boron should add 
additional benefit. This re-targeting is similar in concept to the repeated administration of 
chemotherapeutic drugs that accesses cells not previously affected due to the dependence 
of the dose distribution from the 10B(n,α)7Li reaction on the distribution of a particular 
boron compound at the cellular and subcellular level.  
8.3 DOSE DESCRIPTION 
The general aim of dosimetry and treatment planning is to provide data in order to 
predict the biological response of irradiated tissue. The relative biological effectiveness 
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(RBE) values of the various dose components, therefore, have to be taken into account 
when considering accuracy requirements concerning dosimetry and treatment planning for 
BNCT. With all analyses performed to date, it is assumed that doses resulting from the 
different radiation components behave additively.  
Another factor to take into consideration is the uncertainty in the dose calculation using 
MCNP and the comparison with actual measurements. Based on Raaymakers et al. (1996, 
1997), the uncertainty in the boron dose amounts to 5%, in the fast neutron dose to 18% 
and in the gamma-ray dose to 5%. The overall uncertainty in the reported physical dose 
would be 5 % at the 50 µg g-1 10B level as well as in the absence of boron. However, these 
extrapolations have limitations since the irradiation set-up of the dogs was very different 
from the actual measurements intended for the patient irradiation performed by 
Raaymakers et. al (1996, 1997). The differences are:  
i. 15*15*15 cm3 cubic water phantom versus polyethylene dog head;  
ii. differences in assumed divergence of the beam during calculations (dogs: 10 degrees, 
patients 2 degrees); 
iii. beam aperture to skin distance 0 cm (dogs) and 30 cm (patients) 
iv. different source description 
Dose description in BNCT is very complicated and nonintuitive. It requires insight in all 
aspects of the modality: physics, pharmaceutics, radiobiology, and the clinic. In 
conventional radiotherapy, dose is delivered as only one type of radiation. In contrast, for 
BNCT the dose components are numerous and differ in their relative contributions. The 
composition varies depending on the neutron beam used, the depth of the tumor, the boron 
compound used and the fractionation scheme, to name just a few variables. For the dose 
resulting from the boron neutron capture reaction (boron dose), the biological response 
depends not only on the radiation quality but also on the microdistribution of the boron 
compound. Due to the short pathlength of the α- and lithium- particles, which is 
comparable to the diameter of a cell, the probability of hitting the cell nucleus depends on 
the subcellular location of the boron. Since the microdistribution of boron largely depends 
on the boron carrier molecule used, radiobiological weighting factors are considered to be 
characteristic for each boron compound (and each tissue). Consequently, socalled 
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compound factors have been introduced to weight the boron dose with respect to the other 
dose components. This compound factor is the product of the RBE value for the high LET 
α− and lithium particles for a given biological effect and a geometrical boron distribution 
factor in the tissue considered. 
The recoil protons from a spectrum of fast neutron collisions with hydrogen and protons 
resulting from the nitrogen capture reaction have different energies. Hence, the fast neutron 
dose and the dose resulting from the 14N(n,p) reaction (nitrogen dose) might have different 
RBE values (Hall et al. 1975, Alpen et al. 1993, Blomquist et al. 1993, Blue et al. 1993). 
However, equal RBE values are often assumed for both dose components in experimental 
radiobiological studies in order to facilitate the analysis. 
The best estimates of the radiobiological weighting factors for the clinical situation with 
epithermal neutron beam BNCT are obtained from large animal studies. Using the boron 
compound BSH, such studies have been performed using Labradors and Beagles at the 
BMRR and the HFR in Petten, respectively. A comparison of these studies yielded that for 
similar blood 10B concentrations an equal response was obtained for an approximately two 
times higher total physical dose at the BMRR compared to the HFR (data not shown). This 
example demonstrates that total physical dose alone is not an adequate description of 
irradiation effects in tissue. Other parameters have to be included for safe treatment 
planning. 
A compound factor for BSH of 0.37 ± 0.06 was calculated in chapter 6, and an RBE value 
for the fast neutron and nitrogen dose component of 3.9 ± 0,4 for neurological symptoms 
due to white matter necrosis from the Petten healthy tissue tolerance study. In chapter 7, a 
compound factor for BSH of 0.53 for was derived. However, a combined RBE for the fast 
neutron and nitrogen dose of 2.7 was used. The latter was obtained from the brain tissue 
reaction of two dogs irradiated with the BMRR epithermal neutron beam in the absence of 
boron. Its value is low compared to the data of Benczik (2000). Benczik found an RBE for 
the high LET component of the FiR1 epithermal neutron beam of 3.3-4.3. This is in better 
agreement with the proton RBE calculated in chapter 6. It has already been stated in 
chapter 7 that the combination of the BMRR beam derived proton RBE probably can not 
be used for the HFR epithermal beam. However, using the BSH CF calculated for the 
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BMRR irradiated animals of 0.38 (data not shown) for the Petten data set results in a 
proton RBE of slightly below 4, which again fits the data of Benczik as well as the 
calculation of chapter 6. Calculation of a BSH compound factor in chapter 5 was based on 
an even higher fast neutron RBE of 4.9 deducted from skin effects of BMRR epithermal 
neutron beam only irradiated dogs, and an RBE for the nitrogen capture reaction of 2.7. A 
compound factor of 0.31 was derived for the endpoint of lethal white matter necrosis. In a 
computer model for the capillary endothelial dose a compound factor of 0.4 was obtained 
for BSH in dog brain (Gavin et al. 1994). 
These factors indicate that, while these boron capture fragments should have a high RBE 
based on LET, the geometric considerations have a large effect, resulting in an apparent 
relative biological effectiveness of less than 1. The relatively small weighting factor for the 
boron dose in brain tissue is believed to result from the exclusive localization of BSH in 
the vascular lumen and is consistent with microdosimetric calculations. These calculations 
indicate that, when boron is excluded from the parenchyma, the capillary wall receives 
only a small fraction of the dose resulting from the 10B(n,α)7Li reaction. This sparing is 
thought to be due to a lack of charged particle equilibrium and the upstream, downstream 
energy depositions not contributing to the capillary endothelial nuclear dose (Gavin et al. 
1993, 1994, Kitao 1975, Rydin et al. 1976). In other tissues such as the tumor or skin, BSH 
is not restricted to the vasculature by a blood brain barrier. Therefore, less sparing effects 
are expected and a higher compound factor is anticipated for these tissues. It is predicted 
that this difference in effectiveness between tumor and surrounding normal brain tissue 
results in a higher biologically effective dose to the tumor than to normal brain. For dog 
skin a BSH compound factor of 0.52 has been reported for the endpoint of radiation 
induced dermal necrosis (Gavin et al. 1992). This is still low as compared to values of 
slightly below two, predicted from computer modeling of the boron compound factor in 
skin (Gavin et al. 1994). Computer modeling was based on a homogeneous distribution of 
BSH in tissue. The discrepancy between the biological situation and the computer modeled 
compound factor for BSH in dog skin indicates that boron probably was not uniformly 
distributed in relation to the dermal vasculature. However, in high grade astrocytomas and 
glioblastomas the blood brain barrier is disrupted allowing BSH to extravasate, approach 
an almost uniform distribution within the tumor and therefore a CF close to the RBE of the 
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10B(n,α)7Li reaction, which should be considerably in extent of 1 because of its high LET 
(e.g. Gabel et al. 1984). 
There is a considerable variation in BSH compound factors obtained for different 
experimental setups and by different analytical methods. For the brain the computer 
modeled compound factor was 0.4 using the BMRR epithermal beam parameters. The 
capillary model with a distribution similar to BSH of 25 µg g-1 boron in the lumen and 
1 µg g-1 boron in the endothelial cytoplasm and surrounding parenchyma resulted in a 
capillary endothelial nuclear dose of 9.62 Gy with a peak physical dose of 20 Gy. The RBE 
values used for the nitrogen capture reaction, the 10B(n,α)7Li products and the fast neutron 
component were 2.7, 2.3 and 4.5, respectively. The first two values were taken from 
literature, the fast neutron RBE was estimated from skin reactions of BMRR epithermal 
neutron beam only irradiated Labradors (Gavin et al. 1994). A similar value for the BSH 
compound factor of 0.37 (endpoint: lethal white matter necrosis) was obtained in chapter 6 
with the Petten healthy tissue tolerance studies. This method used a simultaneous best fit of 
the proton RBE and the compound factor to all experimental data. The proton RBE (effects 
of the fast neutron component and protons resulting from the nitrogen capture reaction) for 
induction of severe neurological symptoms was found to be 3.93 ± 0.43. In chapter 5, a 
compound factor of 0.31 was calculated on the bases of a fast neutron RBE derived from 
skin effects in BMRR epithermal neutron beam only irradiated Labradors, since no beam-
only data were available for the Petten situation. The fast neutron RBE was estimated to be 
4.9 in these studies and it was applied to the Beagles irradiated at the HFR epithermal port 
in the presence of boron. This type of analysis raises two major questions: a) the BMRR 
epithermal neutron beam differs in geometry and probably in radiation quality from the 
HFR epithermal beam, and b) the fast neutron RBE was estimated for late radiation 
necrosis in skin not brain. In chapter 7, a combined proton RBE was obtained in brain 
tissue but for BMRR irradiated Labradors. The value has been used for subsequent 
calculation of a compound factor for BSH with the two different setups. When only the 
BMRR irradiated animals were included in the analysis, this yielded in a compound factor 
of 0.38 for lethal white matter necrosis, well in agreement with the compound factors 
above. Analysis of the Petten data resulted in a considerably higher CF value of 0.53. It is 
concluded that the BMRR beam geometry and experimental setup are not readily 
transferable to the Petten situation. With regard to this, the above data analyses confine the 
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range of values for the BSH compound factor with lethal white matter necrosis as endpoint 
to 0.4 or slightly less. Results need to be validated for different experimental setups. 
Consequently, these values can only be used for an estimation of the photon equivalent 
dose when the treatment conditions are similar to those for which the sets of factors were 
derived. 
 
Table 8. 2: Dose values for a mean blood 10B concentration of 50 µg g-1and an irradiation time of 60 minutes 
at 1.75 cm depth in a dog head. 
 
Dose component physical dose 
[Gy] 
weighting factor equivalent dose 
[Gy equiv.] 
10B(n,α)7Li 
14N(n,p)14C 
fast neutrons 
gamma-rays 
others 
8.66 (72%) 
0.30 (3%) 
0.71 (6%) 
2.13 (18%) 
0.17 (1%) 
0.4 
3.9 
3.9 
1.0 
1.0 
3.46 (36%) 
1.17 (12%) 
2.77 (29%) 
2.13 (22%) 
0.17 (2%) 
total 11.79 (100%)  9.7 (100%) 
An example of the influence of the radiobiological weighting factors on the proportion of 
the various dose components is given in table 8.2, where dose values at the position of 1.75 
cm depth in a dog head are listed. When radiobiological weighting factors are applied, the 
proportion of the various dose components changes considerably. The contribution of the 
boron capture dose to total dose in this example, decreases from 72% for the physical dose 
to 36% for the weighted dose, while the contribution of the fast neutron dose component 
increases from 6% to 29%. This example emphasizes the importance of an accurate 
determination of physical doses and their respective radiobiological weighting factors in 
view of the required accuracy in dosimetry for the clinical application of BNCT. 
With BNCT the gamma-ray dose rate is usually low, suggesting less efficacy of this dose 
component. However, additional high LET radiation in the form of charged particles or 
fast neutrons may reduce the probability of low LET radiation repair. Maruyama reported 
that with different dose rates of photons used in conjunction with Cf-252 irradiation there 
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was little or no additional contribution to the effectiveness of mixed radiation if neutrons 
contributed 35% or more to the dose. Moreover, the Cf-252 (65% neutrons) appeared to 
exert as much effects as pure neutron beams. As more gamma-ray radiation was added to 
the mixture, greater recovery occurred in the irradiated bone marrow or gut (Maruyama et 
al. 1993). Studies by McNally and coworkers showed that when high LET radiation, 
neutrons or α-particles, and low LET radiation were given together or in close proximity, 
interaction occured between the high and low LET components, resulting in more tissue 
damage than would have been expected if both radiations acted independently (McNally et 
al. 1984, 1988). However, when low LET radiation should be isoeffective in a mixed field, 
the interval between mixed irradiations should be sufficient for the sublethal damage 
induced by the first irradiation to disappear by repair. Or, in other words: no dose rate 
factor should be applied even for low dose rates of low LET radiation if a large enough 
portion of the dose applied consists of high LET radiation. Nevertheless, different dose rate 
factor scenarios were calculated for the data analysis of chapter 6 and chapter 7. There was 
no dependency of the value of compound factor on the dose rate factor for gamma-ray 
radiation. 
In the clinical study at the BMRR, physical radiation dose components are multiplied by 
experimentally determined RBE values or compound factors and then added. The resulting 
total dose is specified in photon equivalent Gy (Coderre et al. 1997). This approach is 
based on the assumption that the radiobiological weighting factors, determined in animal 
experiments, can be applied to the clinical situation. This assumption might be 
questionable since besides the unavoidable differences in biological systems, also the 
treatment parameters like number of fractions, field size or irradiated volume and thus the 
proportion of the various dose components in animal studies differ from those in the 
clinical situation. This is certainly the case if multiple field irradiations (for example 
irradiation of the head from opposite sites) are considered. Furthermore, dosimetric data 
for radiobiological studies are generally modeled using Monte Carlo techniques, for which 
extensive validation is still needed. 
Chapter 5 and 7 lack an accurate determination of the fast neutron RBE. With this every 
value of a compound factor (CF) becomes relative since in these two approaches the fast 
neutron RBE and CF are directly depending on each other. This is not the case for the 
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analysis of chapter 6 where RBE and CF were treated as two independent variables. 
However, in all three analyses the fast neutron RBE was coupled with the nitrogen capture 
reaction RBE and/or said to be a fix value independent from for example the depth in 
tissue. It is known that RBE changes with neutron energy and that recoil protons and 
capture protons differ in energy and thus in biological effectiveness. Moreover, neutrons 
are attenuated in tissue and therefore their energy changes dramatically with depth. This 
will impose another problem: the one of selecting the correct reference point or volume for 
dose specification, the one that is the most relevant to the observed biological effects. 
Using a fast neutron RBE of 4.9 and an RBE of 2.7 for the nitrogen capture reaction 
(chapter 5) for equivalent dose calculation results in an equivalent dose of 12.74 Gy at 1.75 
cm depth. This is very close to the ED50 value of Fike et al. (1988), which was used 
throughout this thesis as reference dose for MR contrast enhancing lesions. Besides the 
point that CT changes might not be comparable to MR contrast enhancing lesions, there is 
also the aspect that the physical dose distribution is not the same for photon irradiations 
and BNCT. In the calculation of RBE and CF values for the whole brain it is critical to use 
doses that can still be considered comparable for the effects observed. Benczik (2000) 
showed that after photon irradiation of the entire brain 60% of the total brain volume was 
within the 100% isodose, whereas 60% of the total brain volume was within the 90% 
isodose after epithermal neutron irradiation. The percentage of brain receiving 100% 
isodose is certainly lower with the hemibrain irradiations of Fike. The dose volume 
histograms of the Petten dogs showed that only about 17% of the brain received 100% of 
the dose, whereas about 40% of the total brain volume is within the 90% isodose. The 90% 
isodose also includes the predisposition area of dorsal white matter (figure 7.3). On this 
basis it might be appropriate to compare physical doses based on these two isodoses for 
calculations of radiobiological weighting factors. However, a dose escalation study at the 
zero boron level could not be performed at Petten to validate the proton RBE 
experimentally. Any change in RBE value will be followed by an adaptation of the 
corresponding CF. If physical doses were compared on the 90% isodose level the proton 
RBE might decrease followed by the respective increase in CF. Within the range of 2.7-3.9 
for the proton RBE, the CF would increase from 0.37-0.53 to approximately 0.40.7. 
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The analyses presented here are based on the concept that all dose components behave 
additively. However, no experimental evidence is available validating this crucial 
hypothesis. Another point is the translation of local physical proton dose into the 
macroscopically observable biological effects as discussed above. Also the concept of 
compound factors is questionable since it combines two different qualities: the 
microdistribution or geometry and the relative biological effectiveness of the ions 
emanating from the boron capture reaction. The latter would not be dependent on the boron 
compound used.  Therefore, it is suggested to separate these qualities and use the proper 
RBE for the 10B(n,α)7Li reaction plus a compound related geometrical factor. Unless there 
is more insight in the question of additivity and a more accurate fast neutron RBE 
description, dosimetry with BNCT remains problematic.  
8.4 CLINICAL STATUS OF BNCT AND FUTURE PROSPECTS 
In the view of the current dismal results obtained with conventional therapy in the 
treatment of glioblastoma multiforme, the focus of BNCT has been largely designed to 
treat CNS malignancies. The first objective is to determine whether BNCT has clinical 
efficacy with these therapeutically refractory tumors. Definite conclusions about the 
efficacy of BNCT using the currently available boron compounds can only be obtained by 
carefully designed clinical trials and objective comparison with the existing treatment 
modalities. 
BNCT has been used clinically in Japan, since 1968, by H. Hatanaka and Y. Nakagawa. A 
clinical trial using BPA and an epithermal neutron beam was initiated in 1994 at the 
Brookhaven National Laboratory and Massachusetts Institute of Technology (MIT) in the 
United States. At the MIT, BNCT using BPA is also applied to treat melanoma. 
Preliminary results for a group of ten glioblastoma multiforme patients in the BNL BMRR 
study showed no adverse effects on normal brain. Skin reactions were mild. Four patients 
developed recurrent tumor in the deeper regions of the target volume. The remaining 
patients had less than four months of postirradiation follow up (Coderre et al. 1997). 
Recently, Diaz et al. (2000) reviewed the phase I/II dose escalation studies on meanwhile 
fifty-three subjects with glioblastoma multiforme. Twenty-six subjects were treated using 
one field, 17 subjects were treated using two fields and ten subjects were treated using 
three fields. BPA-F related toxicity was not observed. Fifty of the 53 subjects have 
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progressed. The tumor progression was local in all cases. Functional brain tolerance was 
reached in the three-field group (n=10). All patients except one exhibit significant acute or 
subacute neurological toxicity. The incidence of neurologic toxicity in patients treated with 
one field (n=26) and two fields (n=17) was very low and the observed effects were 
transient. Diaz reported histological changes consistent with astrocytosis, gliosis and 
subacute edema outside the areas invaded by tumor. Also subacute demyelination was 
found in two subjects. One subject exhibited histologic changes consistent with 
Parkinsons disease and two patients had histologic changes consistent with Alzheimers 
disease. In Europe, an international project aiming at the treatment of glioblastoma using 
the boron compound BSH and the HFR epithermal neutron beam in Petten has advanced to 
first clinical trials in 1997. Preliminary results have recently been reported by Sauerwein et 
al. (2000). The authors conclude that the starting BNCT dose level was safe. They 
observed some adverse side effects that were related to BSH infusion. All ten patients of 
the first cohort suffered tumor recurrence. The authors reported the early and late radiation 
toxicity being slightly lower than with conventional radiotherapy. However, BNCT doses 
were obviously too low to be efficient in tumor control.  
From the results presented in this thesis, it can be concluded that patients can be treated 
with BNCT with a dosimetric background that meets clinical requirements. However, 
BNCT is a highly complex treatment modality. In conventional radiotherapy, dose 
escalation is used to attain an optimal balance of tumor control versus potential damage to 
normal tissue. In BNCT, this balance is in large part due to sufficient uptake of 10B in 
tumor and lack of uptake in normal tissue. Escalation of the radiation dose has little 
effectiveness in cells without boron. Maximization of the delivery of boron to the tumor is 
the most effective way to optimize BNCT. Increasing the neutron exposure will increase 
the non specific background dose to the normal tissues and produce no net gain in the 
therapeutic ratio. The clinical use of BNCT is at such a preliminary stage of development 
that it is necessary first to define the safe level of exposure of normal brain to the mixed 
radiation field and the high LET particles generated with the particular boron compounds 
involved. Clinical trials with BSH and BPA are in progress to assess their potential 
usefulness as capture agents for BNCT and to determine whether either of these 
compounds meets the minimum requirements for BNCT.  
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Since therapeutic success may require that a very significant percentage of tumor cells 
have adequate concentrations of boron, it seems highly unlikely that a single 
administration of a particular agent will achieve that objective. For several reasons, BNCT 
will be applied in fractions. Unless a very potent drug meeting all requirements for BNCT 
will come up, a case could be made for multiple administrations not only of a single drug, 
but also ultimately of a combination of various agents possessing differing mechanisms for 
achieving the targeting of tumor cells. For BNCT, a high tumor concentration and a long 
retention, high tumor-to-blood ratios with a rapid clearance from blood, and a high tumor-
to-normal tissue ratio are desirable, producing very substantial therapeutic ratios.  
The unusual porphyrin derivative, the tetrakis-carboanylcaboxylic acid ester of 2,4-(α,β-
dihydroxyl) deteroporphyrin (BOPP), has shown promise both in vitro and in vivo as a 
tumor selective agent. This compound was selectively localized to tumor at ratios as high 
as 400:1 relative to normal brain. It was shown that BOPP was localized within 
mitochondria and excluded from the nucleus (Hill et al. 1992). The intracellular 
localization of BOPP has been calculated to result in a 10-fold reduction in the amount of 
boron required to achieve tumor necrosis, since there is more efficient targeting of critical 
subcellular structures. While maximal BOPP uptake in tumor was observed 24 hours after 
administration, the optimum tumor-to-normal brain ratios were observed at 48 hours. This 
indicates that BOPP is not only selectively taken up by the tumor relative to the normal 
brain, but is also preferentially retained in tumor. A toxicology study in dogs revealed liver 
affection and cephalic vein thrombosis at doses up to 35 mg kg-1. In human dose escalation 
studies performed within the framework of photodynamic therapy for brain tumors, the 
maximal BOPP dose tolerated was about 4-8 mg kg-1. Main side effect was a higher 
incidence of thrombocytopenia in these subjects. In conclusion, BOPP seems to be toxic at 
dose levels far below the ones needed for BNCT when it would be used as the only boron 
carrying agent (Kahl 2000). BSH as one of the commercially available boron compounds 
already in clinical use has been shown to be strongly bound intracellularly in tumor cells. 
In healthy brain of glioma patients BSH is excluded from tissue and present only in the 
basement membrane of blood vessels (Otersen et al. 1997). The boron found in tumor 
tissue will therefore have a substantially increased biological effectiveness in relation to 
boron in the healthy tissue. This should, even for equal boron concentrations in tumor and 
blood, translate into a dose ratio significantly above unity for tumor over healthy brain 
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tissue. In addition, Masunaga and coworkers could demonstrate that BSH increased the 
sensitivity of quiescent cells to neutron irradiation as compared to BPA, although the 
average 10B concentration was almost the same for both compounds in the total tumor cell 
population (Masunaga et al. 1998). BPA on the other hand, because of its ability to cross 
the blood brain barrier, could accumulate in small clusters of tumor cells at a distance from 
the main tumor mass and tumor cells infiltrating the brain. It has very favorable tumor cell 
to blood and normal brain tissue ratios of about three to four in glioblastoma patients 
(Coderre et al. 1998). BPA is considered to distribute uniformly in both the nucleus and the 
cytoplasm and is therefore considered to be highly effective in tumor cell killing under 
neutron irradiation. All these different characteristics of boron carriers concerning access, 
accumulation and clearance of only three selected compounds suggest an multi-drug 
administration with BNCT. This approach is supported at least for the combination of BPA 
and BSH by data of Barth and coworkers (Barth et al. 2000). They infused F98 glioma 
bearing rats with BPA and BSH prior to thermal neutron irradiation and cured 25 % of the 
animals with minimal radiation induced brain damage. These results demonstrate that 
using a combination of boron agents and optimizing their delivery (e. g. blood brain barrier 
disruption and/or intracarotid infusion) can dramatically improve the efficacy of BNCT at 
least in rats. A possible proceeding would be to first infuse one or more times BOPP about 
two days before start of the fractionation scheme. Prior to each fraction a combination of 
BPA and BSH should be applied. However, further studies concerning eventual 
interactions of the drugs involved have to precede clinical trials before such an approach.  
The ultimate goal of BNCT, in combination with surgery, would be a complete cure of 
high grade brain tumors. More realistic, however, is the achievement of prolonged patient 
survival with concomitantly high quality of life. This would represent an important clinical 
advance. Carefully controlled clinical studies with BPA and BSH should provide an 
answer to the question of the efficacy of BNCT. Future development of more tumor 
selective boron carriers, optimization of adequate neutron beams, and the development of 
better treatment planning algorithms are realistic goals for the near future. 
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Figure 2: Series of transverse T2 weighted MR images of dog 627 7.5 months post irradiation about three 
weeks before onset of clinical symptoms. Massive changes in almost all white matter were observed (bright 
areas) indicating edema. 
 
 
Figure 3: Series of T1 weighted MR images of dog 627 after the application of contrast enhancing Gd-
DTPA (same day as fig.1). Large areas of increased signal intensity are seen in dorsal white matter consistent 
with blood brain barrier impairment and necrosis. 
 
 
Figure 4: Typical histological finding at the rim of white matter necrosis in dog 627 (killed the day clinical 
symptoms ocurred) from left to right: confluent area of coliquation necrosis (hyaline lagoon), extremely 
disperse tissue (massive edema), recent hemorrhages (white arrow) and vacuolisation (black arrow); HE. 
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Figure 5: Edema of plexus choroideus in dog 627, dilated blood vessels and lose connective tissue, HE. 
 
 
Figure 6: Excessive perivascular changes with vessel wall thickening and focal accumulation of small round 
cells (white arrow) and single cell necroses (black arrows) in close neighborhood to an older necrotic area, 
HE. 
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Figure 6: Diffuse glial reaction, HE. Figure 7: Old necrosis in dorsal white matter of dog  
614 with calcification, HE. 
 
  
Figure 8: Small glial scar in dorsolateral       Figure 9: Teleangiectasia dog 746. Vessels 
white matter of dog 746 killed one year       are widened and vessel walls are partially  
post irradiation: pigment deposition seen       atrophic, HE. 
as accumulation of brown spots, indi- 
cating an area of old hemorrhage and pro- 
nounced connective tissue, HE. 
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SUMMARY 
  
Boron neutron capture therapy (BNCT) is a bimodal treatment that is based upon 
the nuclear reaction of low energy (thermal) neutrons with 10B, a nontoxic, stable isotope 
of boron with a natural abundance of 20 %. The 10B nucleus has a large cross-section for 
capturing thermal neutrons compared to the nucleus of any element present in tissue. After 
capturing a thermal neutron, the resulting 11 B nucleus disintegrates into two charged 
particles with ranges in tissue comparable to the diameter of a cell. Neutron beams 
currently available for BNCT treatments are produced using nuclear reactors and often 
have a considerable contamination with gamma-rays and fast neutrons. These beam 
contaminants can cause considerable damage to normal tissue even if such tissues do not 
contain high 10B concentrations.  
The aim of this study was to estimate the tolerance of normal tissue to boron neutron 
capture irradiation and give a dose description model as a prerequisite for BNCT in brain 
tumor patients. Hence, large animal healthy tissue tolerance studies were initiated at Petten 
using the epithermal neutron beam (HB11) of the High Flux Reactor (HFR) and 
borocaptate sodium (BSH) as capture agent.  
Skin was regarded as possible critical normal tissue or even tissue at risk, since neutron 
irradiation takes place as an external exposure and the irradiated skin area is relatively 
large with BNCT. No aggravating skin reaction to BNCT with BSH was observed in the 
present study. The most severe effects were minor cases of dry desquamation along with 
almost complete hairloss in the irradiation field at radiation doses far exceeding those 
required to induce white matter necrosis. These changes were considered an acceptable 
normal tissue reaction. 
The skin reactions gave evidence that with BNCT using BSH the tissue at risk is not the 
skin but normal brain. Two biological endpoints for brain tissue were chosen: detectable 
lesions in magnetic resonance (MR) imaging and clinical symptoms due to severe white 
matter necrosis. ED50 values could be assigned to both endpoints: 13.6 Gy and 16.8 Gy for 
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MR contrast enhancing lesions and 15.2 Gy and 18.8 Gy for clinical symptoms due to 
white matter necrosis in animals irradiated at 25 µg g-1 and 50 µg g-1 10Boron blood levels, 
respectively (chapter 3). Histopathologic examination of irradiated brain tissue revealed a 
dose dependent pattern of damage. After high doses that caused clinical symptoms in the 
dogs, large confluent areas of coagulation necrosis with variable degrees of fresh 
hemorrhage were found. At somewhat lower doses, not causing clinical signs but MR 
detectable brain damage, well-defined focal areas of necrosis were observed with a 
spongiotic border and usually few reactive changes. The low dose groups showed 
histopathologically no changes or different degrees of demyelination, in some cases along 
with teleangiectasia.  
Effects of fractionating BSH-based BNC irradiation have been evaluated in a limited 
number of dogs (chapter 4). This study has been performed to detect possible changes in 
normal tissue tolerance after an irradiation scheme of four fractions separated by one day. 
MCNP calculated peak physical doses at 1.75 cm depth were 13.8 (± 0.3) Gy and 13.6 
(± 0.3) Gy for the fractionated irradiations and the single dose group, respectively. This 
dose level represented the ED50 for MR contrast enhancing lesions after single exposure. 
Though the groups were rather small (five animals per group), the fractionation study 
performed at the HFR in Petten suggests that fractionation was beneficial in that fewer 
changes were observed in the fractionated dogs versus approximately the same dose given 
in a single fraction. A sparing effect of fractionation could be observed in both skin and 
brain tissue. 
The general aim of dosimetry and treatment planning is to provide data in order to predict 
the biological response of irradiated tissue. The relative biological effectiveness (RBE) 
values of the various dose components, therefore, have to be taken into account when 
considering accuracy requirements concerning dosimetry and treatment planning for 
BNCT. The dose description models suggested in this thesis are based on the assumption 
that doses resulting from the different radiation components behave additively. For the 
dose resulting from the boron neutron capture reaction (boron dose), the biological 
response depends not only on the radiation quality but also on the microdistribution of the 
compound. Due to the short pathlength of the α- and Lithium- particles the probability of 
hitting the cell nucleus depends on the subcellular location of the boron. Since the 
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microdistribution of boron largely depends on the boron carrier molecule used, 
radiobiological weighting factors are considered to be characteristic for each boron 
compound. Consequently, so-called compound factors have been introduced to weight the 
boron dose with respect to the other dose components. This compound factor is the product 
of the RBE values for the high LET α− and Lithium particles for a given biological effect 
and a geometrical boron distribution factor in the tissue considered in relation to the 
observed blood boron concentrations. 
A compound factor for BSH of 0.37 ± 0.06 was calculated in chapter 6, and an RBE value 
for the fast neutron and nitrogen dose component of 3.9 ± 0.4 for neurological symptoms 
due to white matter necrosis from the Petten healthy tissue tolerance study. In chapter 7, a 
compound factor for BSH of 0.53 for was derived. However, a combined RBE for the fast 
neutron and nitrogen dose of 2.7 was used. The latter was obtained from the brain tissue 
reaction of two dogs irradiated with the BMRR epithermal neutron beam in the absence of 
boron. Calculation of a BSH compound factor in chapter 5 was based on a fast neutron 
RBE of 4.9 deducted from skin effects of BMRR epithermal neutron beam only irradiated 
dogs, and an RBE for the nitrogen capture reaction of 2.7. A compound factor of 0.31 was 
derived for the endpoint of lethal white matter necrosis. 
These factors indicate that, while these boron capture fragments should have a high RBE 
based on LET, the geometric considerations have a large effect, resulting in an apparent 
relative biological effectiveness of less than 1. The relatively small weighting factor for the 
boron dose in normal brain tissue is believed to result from the exclusive localization of 
BSH in the vascular lumen. There also is a considerable variation in BSH compound 
factors obtained for different experimental setups and by different analytical methods. It is 
concluded that one beam geometry and experimental setup is not easily transferable to 
others (chapter 8).  
For the clinical application of BNCT in brain tumors several possibilities of improvement 
are discussed in chapter 8: the combination of different drugs, time schedules for drug 
application, the fractionation scheme and aspects of dose calculation (volume vs. point).  
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SAMENVATTING 
 
Boron Neutron Capture Therapie (BNCT) is een vorm van radiotherapie die gebruik maakt 
van het feit dat het isotoop 10B, een niet-toxisch stabiel isotoop van borium met een natuurlijke 
abundantie van 20 %, met een hoge waarschijnlijkheid een vangstreactie aangaat met laag-
energetische (thermische)  neutronen. Deze waarschijnlijkheid is vele malen hoger dan die van de 
elementen waaruit het weefsel bestaat. Na de invangst van een thermisch neutron vervalt de 
resulterende 11B kern in twee geladen deeltjes die hun kinetische energie verliezen in weefsel over 
een afstand die vergelijkbaar is  met de diameter van één cel. De neutronenbundels die momenteel 
beschikbaar zijn voor BNCT worden geproduceerd in kernreactoren en hebben vaak aanzienlijke 
verontreinigingen met gammastraling en snelle (hoog energetische) neutronen die een niet 
verwaarloosbare dosis in weefsel geven en tot schade in het normale weefsel kunnen leiden. 
 
Het doel van deze studie was de bepaling van de tolerantiedosis van normal hersenweefsel na een 
boron neutron capture (BNC) bestraling als voorwaarde voordat BNCT kon worden uitgevoerd in  
patiënten met hersentumoren. Hiervoor werden normale weefseltolerantiestudies met honden als 
proefdier uitgevoerd  in Petten waarbij gebruik gemaakt werd van de epithermische 
neutronenbundel HB11 van de Hoge Flux Reactor (HFR) en het natriumborocaptaat (BSH) als 
vangst agens. 
 
De huid werd beschouwd als één van de mogelijke kritische weefsel waarin schade na bestraling 
kan optreden omdat de neutronenbestraling met een externe bundel plaatsvindt en het bestraalde 
huidoppervlak relatief groot is bij BNCT. Er werden echter geen dosislimiterende huidreacties 
waargenomen na BNC bestraling met BSH. Het meest ernstige effect dat kon worden 
waargenomen was een aantal gevallen van droge huidschilfering en compleet haarverlies in het 
bestralingsveld bij stralingsdoses die aanzienlijk hoger waren dan noodzakelijk om necrose in de 
witte substantie van de hersenen te veroorzaken. De huid veranderingen werden derhalve als 
acceptabele normale weefsel reacties beschouwd. 
 
De gevonden huidreacties geven aan dat het weefsel dat dosislimiterend is bij BNCT met BSH  niet 
de huid maar het gezonde hersenweefsel is. Om de schade in de hersenen na bestraling te kunnen 
kwantificeren werden twee biologische parameters gebruikt, te weten  met  Magentic Resonance 
Imaging (MRI ) aantoonbare laesies en klinische symptomen tengevolge van ernstige necrose in 
de witte substantie van de hersenen. De ED50 waarden  voor beide parameters konden worden 
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bepaald. De ED50 voor MRI  aantoonbare laesies was 13.6 Gy en 16.8 Gy  bij dieren die bestraald 
werden bij 10B bloed concentraties van respectievelijk 25 en 50 µg.g-1. De ED50 voor ernstige 
necrose  was 15.2 Gy en 18.8 Gy  bij dieren die bestraald werden bij 10B bloed concentraties van 
respectievelijk 25 en 50 µg.g-1 (zie Hoofdstuk 3). Histopathologische evaluatie  van de bestraalde 
hersenen  liet een dosisafhankelijk schade patroon zien. Na hoge doses straling die  klinische 
symptomen veroorzaken in de hond, werden uitgestrekte gebieden met coagulatie necrose 
gevonden waarin ook recente bloedingen zichtbaar waren. Bij lagere doses waarbij geen klinische 
verschijnselen optraden maar wel MRI afwijkingen gevonden werden,  konden goedgedefinieerde 
focale laesies met necrose waargenomen worden die een sponsachtig begrenzing hebben. De lage 
doses veroorzaakten geen veranderingen of slechts een geringe mate van demyelinisatie, soms 
gecombineerd met verwijding van de bloedcapillairen. 
 
De effecten van fractionering van BNC bestraling met BSH werden onderzocht met behulp van een 
gering aantal honden (Hoofdstuk 4). Deze studie werd uitgevoerd om na re gaan of fractionering  ( 
4 fracties; 24 uur interval) een sparend effect op de normale weefsel tolerantie zou hebben in 
vergelijking met een eenmalige acute dosis. De met MCNP berekende piek fysische dosis op 1.75 
cm diepte bedroeg 13.8 (± 0.3) Gy en  13.6 (± 0.3) Gy voor respectievelijk de gefractioneerde en 
eenmalig acute groep. Dit dosis niveau komt overeen met de ED50 voor MRI aantoonbare laesies na 
een eenmalige acute dosis. Hoewel het aantal dieren gering was ( 5 dieren per groep) bleek uit dit 
fractioneringsexperiment dat in vergelijking met een eenmalige acute dosis fractionering met BNC 
bestraling met BSH resulteerde in een geringer aantal MRI aantoonbare laesies. Dit sparende effect 
van fractionering kon zowel in de huid als in de hersenen worden waargenomen.  
 
De doelstelling van dosimetrie en de treatment-planning van een bestraling is om data te genereren 
die het mogelijk maken om de biologische response van het bestraalde weefsel te voorspellen. De 
relatieve biologische effectiviteit van de diverse dosiscomponenten dient daarom in beschouwing te 
worden genomen wanneer dosimetrie en treatment-planning voor BNCT gebruikt wordt. De 
modellen die in dit proefschrift gebruikt worden voor de beschrijving van de dosis zijn gebaseerd 
op de aanname dat alle dosiscomponenten zich additief gedragen. Voor de dosis afkomstig van de 
invangst van neutronen door borium ( boron dosis) geldt dat de biologische response niet alleen 
afhankelijk is van de RBE maar ook van de microdistributie van BSH in een cel. De 
waarschijnlijkheid voor een α of Li deeltje om de kern van een cel te raken is gezien de korte 
dracht van de deeltjes sterk afhankelijk van de lokalisatie van het borium in een cel. Gezien het feit 
dat de microdistributie van het borium grotendeels afhankelijk van de boriumcarrier die gebruikt 
wordt, zijn de radiobiologische weegfactoren borium carrier specifiek. Gezien het feit dat tijdens 
een bestraling alleen de bloed borium concentraties bekend zijn en geen directe informatie 
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beschikbaar is over microdistributie in weefsel is het begrip Compound factor geïntroduceerd om 
de fysische dosis te wegen voor biologische effectiviteit. Deze compound factor is het product van  
de RBE waarde voor een gegeven biologisch effect in een weefsel en een geometrische 
verdelingsfactor voor de boriumcarrier in dat weefsel. 
 
In Hoofdstuk 6 werd voor BSH een compound factor van 0.36 ± 0.06 en een RBE waarde voor de 
snelle neutronen dosis plus stikstof vangstdosis gelijk aan 3.9 ± 0.4 berekend voor klinische 
symptomen ten gevolge van necrose in de witte substantie van de hersenen. In Hoofdstuk 7 werd 
voor hetzelfde biologische effect een compound factor van 0.53 berekend waarbij een 
gecombineerde RBE voor de snelle neutronen en stikstof vangstdosis gelijk aan 2.7 werd gebruikt. 
Deze laatste waarde werd verkregen uit analyse van een experiment uitgevoerd bij de BMRR 
waarbij dieren zonder BSH werden bestraald.  De berekening van de compound factor in 
Hoofdstuk 5 was gebaseerd op een analyse van de snelle neutronen RBE voor huidreacties na 
bestraling van dieren zonder BSH met de BMRR waarbij een RBE van 2.7 voor de stikstof 
vangstreactie werd aangenomen. Deze methode resulteerde in een compound factor van 0.31 voor  
necrose in de witte substantie van de hersenen. 
 
Deze factoren geven aan dat ondanks het feit dat borium vangstfragmenten gebaseerd op hun hoog 
LET karakter een hoge RBE zouden moeten hebben, de geometrische factoren een groot effect 
hebben en resulteren in een ogenschijnlijke RBE die kleiner dan 1 is.. The relatief kleine 
wegingsfactor voor de borium dosis met BSH in normaal hersenweefsel wordt verondersteld een 
gevolg te zijn van de exclusieve lokalisatie van BSH in het vasculaire lumen. Er is een aanzienlijke 
variatie in de afgeleide waarden voor de compound factor voor BSH met de verschillende setups en 
verschillende beschreven analysemethoden. De conclusie is dat één bundelgeometrie en 
experimentele setup niet makkelijk overdraagbaar is naar een andere (Hoofdstuk 8). 
 
Voor de klinische toepassing van BNCT bij hersentumoren worden diverse mogelijkheden voor 
verbetering besproken in Hoofdstuk 8. Hierbij valt te denken aan combinatie van verschillende 
boroncarriers, doseringsschemas, fractioneringschemas en dosisberekeningen waarbij volume in 
plaats van puntdosis beschouwd worden. 
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ZUSAMMENFASSUNG 
 
Die Bor-Neutroneneinfangtherapie (engl. BNCT) ist eine bimodale Therapieform, 
die auf der Kernreaktion von niedrig-energetischen (thermischen) Neutronen mit B-10, 
einem stabilen Borisotop beruht. B-10 hat im Vergleich zu anderen im Gewebe 
vorkommenden Elementen einen großen Einfangsquerschnitt für Neutronen. Wird ein 
Neutron durch B-10 eingefangen, zerfällt der Kern in zwei geladene Teilchen mit einer 
Reichweite im Gewebe in der Größenordnung von etwa einem Zelldurchmesser. Die z. Z. 
zur Verfügung stehenden Neutronenquellen sind zum überwiegenden Teil 
reaktorgebunden, d. h. daß ein gemischtes Strahlenfeld mit einem weiten Spektrum von 
Neutronen verschiedenster Energien und gamma-Strahlung vorliegt. Dadurch kann im 
Normalgewebe auch dann erheblicher Schaden entstehen, wenn die Borkonzentration sehr 
niedrig ist. 
Das Ziel der vorliegenden Studie war es einerseits, die Normalgewebetoleranzdosis zu 
ermitteln, und andererseits Modelle zur Dosisbeschreibung für die spätere Verwendung in 
der Therapieplanung von Hirntumorpatienten zu entwickeln. Dazu wurden in Petten an 
dem epithermischen Neutronenstrahl HB11 des Hochflußreaktors HFR Hunde bestrahlt, 
denen zuvor verschieden hohe Konzentrationen der borhaltigen Substanz BSH appliziert 
worden waren (Kapitel 3). 
Wegen der äußeren Bestrahlung und der Größe des bei  BNCT von Hirntumoren 
betroffenen Hautareals hatte man vor Beginn der Studie angenommen, daß das Risiko 
starker Hautschäden hoch sei. Dies konnte in der vorliegenden Studie nicht bestätigt 
werden. Der massivste Effekt in der Haut war trockene Schuppung in Verbindung mit 
Haarausfall, und das nach Strahlendosen, die deutlich über denen lagen, die Hirnnekrosen 
verursachten.  
Dies macht deutlich, daß nicht die Schädigung der Haut, sondern die Strahlennekrose des 
normalen Hirngewebes der dosislimitierende Faktor ist. Die Köpfe der Tiere wurden bei 
B-10-Konzentrationen von 25 µg g-1 oder 50 µg g-1 im Blut mit verschiedenen 
238  Zusammenfassung 
Neutronendosen bestrahlt. Es wurden folgende Effekte (Endpunkte) untersucht: 
a) Schäden, die nach Kontrastmittelgabe im Kernspintomogramm 
(Magnetresonanztomographie, MRT) sichtbar wurden, und b) Schäden, in der Regel 
Nekrosen des Hirngewebes, die zu klinischen Ausfallserscheinungen führten. Es wurden 
nachstehende Werte für die Dosis, bei der die Hälfte der untersuchten Individuen den 
jeweiligen Effekt zeigte (ED50), gefunden: 13,6 Gy und 16,8 Gy für die im 
Kernspintomogramm zu erkennenden Schäden bzw. 15,2 Gy und 18,8 Gy für den 
Endpunkt der klinischen Ausfallserscheinungen, jeweils bei einem Borspiegel von 25 µg g-
1 oder 50 µg g-1 im Blut (Kapitel 3). Die Dosiswerte für die jeweiligen Endpunkte sind sehr 
unterschiedlich, was verdeutlicht, daß die physikalische Dosis allein eine nur 
unzureichende Beschreibung liefert. Um dem Kliniker eine Möglichkeit zur Abschätzung 
der Gewebereaktion an die Hand zu geben, ist die Übersetzung der physikalischen Dosis in 
eine biologisch effektive Äquivalentdosis erforderlich (Kapitel 5-7). 
Mittels der fraktionierten BNC-Bestrahlung einer kleinen Gruppe von Hunden konnten 
positive Fraktionierungseffekte festgestellt werden (Kapitel 4). Sowohl die Haut als auch 
das Hirngewebe wiesen deutlich weniger Schäden auf als in der Vergleichsgruppe 
beobachtet worden waren. Die Tiere erhielten die gleiche Gesamtdosis wie die 
Vergleichsgruppe, in der sich bei etwa der Hälfte der Tiere Veränderungen im 
Kernspintomogramm zeigten.  
Die Modelle zur Beschreibung der biologischen Äquivalentdosis, die in den Kapiteln 5 bis 
7 näher erläutert werden, beruhen allesamt auf der Annahme, daß sich die einzelnen 
Dosiskomponenten additiv verhalten. Hier sind insbesondere die Dosis aus der Bor-
Neutroneneinfangreaktion (kurz: Bordosis) und die Dosis, die aus den Rückstoßprotonen 
der hochenergetischen (schnellen) Neutronen resultiert, von Bedeutung. Bei der Wichtung 
der Bordosis relativ zu den anderen Dosiskomponenten muß nicht nur die Effektivität der 
Partikelstrahlung, sondern  wegen der kurzen Reichweite der Partikel  auch die 
Verteilung des Bors auf Zellniveau betrachtet werden. Da diese Verteilung stark von den 
Eigenschaften des verwendeten Trägermoleküls abhängt, sind entsprechende 
strahlenbiologische Wichtungsfaktoren mehr oder weniger charakteristisch für die 
jeweilige Substanz und werden engl. compound factor (CF) genannt. Dieser compound 
factor setzt sich zusammen aus der relativen biologischen Wirksamkeit (RBW, engl. RBE) 
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der Partikelstrahlung und einem Geometriefaktor, der die Verteilung des Bors im Gewebe 
beschreibt.  
In Kapitel 6 wurde ein compound factor für BSH von 0,37 ±0,06 und ein RBW-Wert für 
die Rückstoßprotonen und die Stickstoff-Neutroneneinfangreaktion von 3,9 ±0,4 für den 
Endpunkt neurologischer Ausfallserscheinungen berechnet. Das Model von Kapitel 7 
ergab einen compound factor von 0,53. In diesem Model wurde ein RBW-Wert für 
Rückstoßprotonen und die Stickstoff-Neutroneneinfangreaktion von 2,7 zugrunde gelegt, 
der aus der Reaktion des Hirngewebes von zwei Hunden ermittelt wurde, die ohne 
vorherige Bor-Infusion in Brookhaven am epithermischen Neutronenstrahl des BMRR 
bestrahlt worden waren. Die Berechnungen des compound factors für BSH in Kapitel 5 
basieren auf einem RBW-Wert für Rückstoßprotonen von 4,9 und einem Wert von 2,7 für 
die Stickstoff-Neutroneneinfangreaktion, hergeleitet aus Reaktionen der Haut in Tieren, 
die ebenfalls ohne Bor am epithermischen Neutronenstrahl des BMRR bestrahlt worden 
waren, und ergaben einen compound factor von 0,31. 
Diese niedrigen Werte für den BSH-compound factor veranschaulichen, daß die Verteilung 
des Bors im Gewebe einen großen Einfluß auf diesen Wichtungsfaktor für die Bor-
Neutroneneinfangreaktion hat. Obwohl die aus der Einfangreaktion resultierende 
Partikelstrahlung lokal eine sehr hohe RBW hat, ergibt das Produkt aus RBW und 
Geometriefaktor einen Wert, der deutlich kleiner 1 ist. Dies paßt gut zu der Annahme, daß 
BSH im normalen Hirngewebe auf die Gefäßlumina beschränkt ist und die intakte Blut-
Hirnschranke unter physiologischen Bedingungen nicht passiert. 
In Kapitel 8 werden u. a. einige Möglichkeiten diskutiert, wie BNCT evtl. für die klinische 
Anwendung verbessert werden könnte, z. B. die Kombination verschiedener Borträger, die 
Beachtung der aus Tierversuchen bekannten unterschiedlichen pharmakokinetischen 
Eigenschaften verschiedener Borträger für den Zeitpunkt der Applikation relativ zum 
Bestrahlungszeitpunkt, die fraktionierte Bestrahlung und Aspekte für die Dosisberechnung 
(punktuell oder auf ein bestimmtes Volumen bezogen). 
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NACHWORT 
Diese Arbeit wäre nicht das, was sie ist, ohne die breite Unterstützung durch die 
Menschen, die mich in der langen Zeit von nunmehr vierzehn Jahren begleitet und 
unterstützt haben. Jeder einzelne hat seinen Beitrag geliefert, sei es indem er mir den 
Rücken freihielt und mich auffing, wenn gar nichts mehr gehen wollte, sei es durch 
ständiges Nörgeln und Fragen, wann es denn endlich soweit ist, und last but not least vor 
allem durch die tatkräftige und fachliche Unterstützung bei der Planung und der 
Durchführung der Experimente oder  mindestens ebenso wichtig  durch konstruktive 
Kritik am Manuskript. 
Für letzteres möchte ich ganz besonders meinen Referenten Prof. Pat Gavin, Prof. John 
Fike, Prof. John Hopewell, Dr. Ben Mijnheer und Prof. Leer danken, deren Anregungen 
und Anmerkungen ganz erheblich dazu beigetragen haben, die Qualität der Arbeit zu 
verbessern. Dr. Ben Mijnheer danke ich dafür, daß er kurzfristig die Aufgabe des 
Referenten übernommen hat, und Prof. Hopewell und Prof. Fike für die psychische 
Unterstützung und den Ansporn weiter zu machen. 
Außerdem möchte ich mich bei meinem Promotor Prof. van der Kogel bedanken, der trotz 
der vielen Mißverständnisse und zeitweise schwierigen Kommunikation die Arbeit 
begleitet hat, und sich im Endspurt als sehr hilfreicher Mittler zwischen der Universität 
Nijmegen und mir als im Ausland ansässiger Doktorandin erwies. Besonderer Dank gilt 
auch meinem Betreuer Dr. René Huiskamp für seine nicht nur fachliche Unterstützung. 
Ihm verdanke ich meine wissenschaftliche Denkweise, die Erfahrungen, die ich auf den 
diversen internationalen Kongressen sammeln konnte, und eine besondere Sicht auf alles, 
was Deutsch ist. Auch hat er mir die nötigen Freiheiten für die Experimente eingeräumt 
und die Voraussetzungen für ein sinnvolles Arbeiten in Petten geschaffen. 
Die große Anzahl von Menschen, die mich während der praktischen Phase mit viel 
Engagement und Enthusiasmus unterstützt haben, ist eine schier endlose Liste. Ich möchte 
hier allen danken, die zum Zustandekommen dieser Arbeit beigetragen haben: Dr. Axel 
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Siefert und Juan Casado-Poblador für die vielen Stunden, die wir an Wochenenden und 
nachts mit den Hunden verbracht haben, Ray Moss für die Betreuung des Projektes von 
GCO Seite und Peter Watkins für die MCNP-Berechnungen. Els Winter, Sylvia Spanjer, 
Helene Philippo, Dr. Emmy Meijne, Esther van Bakkum, Reyer Bas, und Ron Groothuis 
möchte ich für die tatkräftige Unterstützung bei ECN danken, Finn Stecher-Rasmussen, 
Klaas Ravensberg und Geoff Constatine als HB11-Experten, die u. a. dafür sorgten, daß 
die Neutronen für die Bestrahlungen zur Verfügung standen und sich ebenfalls so manche 
Nacht im HFR mit uns um die Ohren geschlagen haben. Marc Konijnenberg und Niels 
Raaijmakers gilt mein Dank für die professionellen Messungen der Blutproben, ohne die 
der Zeitpunkt der Bestrahlungen nicht so akkurat hätte getimed werden können. Bei allen 
Kollegen, die ich im Laufe dieser Zeit kennen und schätzen gelernt habe, möchte ich mich 
vor allem für die freundliche Aufnahme und die angenehme Arbeitsatmosphäre bedanken, 
die die Arbeit in Petten so angenehm für mich gemacht hat. 
Besonderer Dank geht auch an die Mitarbeiter des AMC für die ausgesprochen 
aufmerksame Betreuung der Hunde, die weit über eine reine Versorgung hinausging, und 
die Unterstützung im handling der Tiere und bei den Sektionen. Desweiteren gilt mein 
Dank den Mitarbeitern des Bijvoet Centers in Utrecht, die uns in die hohe Kunst der 
Kernspintomographie eingewiesen haben, und zur Stelle waren, wenn Schwierigkeiten mit 
der Technik auftraten. 
Hermann Kröckel hat mich überhaupt erst auf die Möglichkeit aufmerksam gemacht, als 
Stipendiat der EU in Petten zu promovieren, und mich bei GCO eingeführt. Ihm und seiner 
Familie verdanke ich viele schöne Stunden, die Kenntnis des abendlichen borrels und 
eine Einführung in die holländische Lebensart. 
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